<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523419310748</prism:url><dc:identifier>doi:10.1016/j.ejmech.2019.111922</dc:identifier><eid>1-s2.0-S0223523419310748</eid><prism:doi>10.1016/j.ejmech.2019.111922</prism:doi><pii>S0223-5234(19)31074-8</pii><dc:title>Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go? </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>02235234</prism:issn><prism:volume>187</prism:volume><prism:startingPage>111922</prism:startingpage><prism:pageRange>111922</prism:pagerange><articleNumber>111922</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2020-02-01</prism:coverdate><prism:coverDisplayDate>1 February 2020</prism:coverdisplaydate><prism:copyright>© 2019 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Huang, Qiuyao</dc:creator><dc:creator>Zhong, Yan</dc:creator><dc:creator>Dong, Hui</dc:creator><dc:creator>Zheng, Qiyao</dc:creator><dc:creator>Shi, Shuo</dc:creator><dc:creator>Zhu, Kai</dc:creator><dc:creator>Qu, Xinming</dc:creator><dc:creator>Hu, Wenhao</dc:creator><dc:creator>Zhang, Xiaolei</dc:creator><dc:creator>Wang, Yuanxiang</dc:creator><dc:description>
                  As a transcription factor, STAT3 protein transduces extracellular signals to the nucleus and then activates transcription of target genes. STAT3 has been well validated as an attractive anticancer target due to its important roles in cancer initiation and progression. Identification of specific and potent STAT3 inhibitors has attracted much attention, while there has been no STAT3 targeted drug approved for clinical application. In this review, we will briefly introduce STAT3 protein and review its role in multiple aspects of cancer, and systematically summarize the recent advances in discovery of STAT3 inhibitors, especially the ones discovered in the past five years. In the last part of the review, we will discuss the possible new strategies to overcome the difficulties of developing potent and specific STAT3 inhibitors and hope to shed light on future drug design and inhibitor optimization.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>STAT3</dcterms:subject><dcterms:subject>Anticancer target</dcterms:subject><dcterms:subject>Small molecular inhibitor</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523419310748" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523419310748" rel="scidir"/></link></coredata><objects><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="667" height="160" size="25945">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="68" height="55" size="1169">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="131" height="56" size="1872">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="578" height="269" size="21476">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="43" height="26" size="668">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="734" height="143" size="27343">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="63" height="35" size="1254">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="689" height="334" size="80903">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="49" height="28" size="885">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="56" height="27" size="801">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx14.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="405" height="200" size="29627">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="311" height="118" size="7225">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="734" height="166" size="26878">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="102" height="111" size="2283">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx18.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="60" height="34" size="1202">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="54" height="27" size="858">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx13.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="54" height="20" size="754">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx15.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="667" height="343" size="53872">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="70" height="20" size="777">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx17.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="538" height="304" size="37989">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr10.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="727" height="135" size="19694">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="50" height="27" size="645">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx16.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="578" height="235" size="28639">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr11.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="117" height="71" size="2173">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx12.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="58" height="32" size="754">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx10.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="195" height="89" size="3398">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="58" height="20" size="780">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx11.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="533" height="274" size="41698">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="167" height="91" size="2843">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="53" size="2023">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="203" height="164" size="3768">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="93" size="2680">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="102" size="3455">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="fx9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="194" height="117" size="1963">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx9.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="43" size="2032">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="122" size="2701">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="106" size="13847">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="218" height="126" size="2425">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx8.sml?httpAccept=%2A%2F%2A</object><object ref="fx14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="106" size="2545">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx14.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="108" size="13460">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="83" size="2300">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="50" size="1819">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="fx18" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="151" height="164" size="2891">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx18.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="123" size="2830">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="fx13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="110" size="2962">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx13.sml?httpAccept=%2A%2F%2A</object><object ref="fx15" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="1796">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx15.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="113" size="4372">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="fx17" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="62" size="2332">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx17.sml?httpAccept=%2A%2F%2A</object><object ref="gr10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="124" size="4029">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr10.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="41" size="2627">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="fx16" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="119" size="2644">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx16.sml?httpAccept=%2A%2F%2A</object><object ref="gr11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="89" size="3097">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr11.sml?httpAccept=%2A%2F%2A</object><object ref="fx12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="132" size="2576">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx12.sml?httpAccept=%2A%2F%2A</object><object ref="fx10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="123" size="2724">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx10.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="100" size="2102">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="fx11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="74" size="2729">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx11.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="113" size="4571">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="119" size="2972">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2953" height="709" size="198375">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="302" height="244" size="8829">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="582" height="247" size="14147">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2559" height="1193" size="178717">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="194" height="117" size="3222">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3248" height="633" size="190859">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="281" height="157" size="6877">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3051" height="1480" size="759349">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="218" height="126" size="4355">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="249" height="121" size="3657">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1794" height="886" size="288785">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1378" height="523" size="59002">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3248" height="735" size="203960">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="454" height="493" size="18408">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx18_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="268" height="150" size="6516">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="240" height="121" size="4039">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="240" height="87" size="3865">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx15_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2953" height="1518" size="389800">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="312" height="88" size="4416">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx17_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2382" height="1348" size="285502">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3220" height="599" size="154787">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="223" height="121" size="3343">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx16_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2559" height="1041" size="216408">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="521" height="315" size="16348">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="261" height="146" size="4000">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="863" height="396" size="26457">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="261" height="88" size="4204">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2359" height="1213" size="303465">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="739" height="401" size="20447">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419310748-fx7_lrg.jpg?httpAccept=%2A%2F%2A</object></objects><scopus-id>85076217565</scopus-id><scopus-eid>2-s2.0-85076217565</scopus-eid><pubmed-id>31810784</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85076217565" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20191128">2019-11-28</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20191128">2019-11-28</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20200114">2020-01-14</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20200114">2020-01-14</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2020-01-14T19:18:34</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523419310748</xocs:eid>
      <xocs:pii-formatted>S0223-5234(19)31074-8</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523419310748</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2019.111922</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523419X00240</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20200114">2020-01-14T23:17:18.98366Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20200201</xocs:date-search-begin>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1574961789">2019-11-28T17:23:09.98781Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst orcid primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>187</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>187</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 187</xocs:vol-iss-suppl-text>
      <xocs:sort-order>12</xocs:sort-order>
      <xocs:first-fp>111922</xocs:first-fp>
      <xocs:article-number>111922</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>111922</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20200201</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>1 February 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-02-01</xocs:cover-date-start>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Review Papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>© 2019 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>REVISITINGSIGNALTRANSDUCERACTIVATORTRANSCRIPTION3STAT3ANTICANCERTARGETINHIBITORDISCOVERYGO</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>HUANG</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>Q</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>STAT3 structure and signaling pathway</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Constitutive STAT3 activation in human cancers</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>STAT3 and immunotherapy</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>5</xocs:item-toc-label>
            <xocs:item-toc-section-title>STAT3 inhibitors</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>5.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Noncovalent STAT3 inhibitors</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>5.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Noncovalent STAT3 inhibitors targeting SH2 domain</xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>5.1.1.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Phosphate analogues</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>5.1.1.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Salicylic acid analogues</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>5.1.1.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>1, 4-Naphthoquinone analogues</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>5.1.1.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Phenylsulfonamide analogues</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>5.1.1.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Aminotetrazole analogues</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>5.1.1.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Quinoline analogues</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>5.1.1.7</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Carboxylic ester analogues</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>5.1.1.8</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Carboxylic acid analogues</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>5.1.1.9</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Bicyclic aromatic analogues</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>5.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Noncovalent STAT3 inhibitors targeting DNA-binding domain</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>5.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Other noncovalent STAT3 inhibitors</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>5.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Covalent STAT3 inhibitors</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>6</xocs:item-toc-label>
            <xocs:item-toc-section-title>Perspective</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Declaration of competing interestCOI</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgements</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-section-title>Abbreviations</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>HILLMER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>15</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>KUJAWSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>3367</xocs:ref-first-fp>
            <xocs:ref-last-lp>3377</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>MIKLOSSY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>611</xocs:ref-first-fp>
            <xocs:ref-last-lp>629</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>BANERJEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2570</xocs:ref-first-fp>
            <xocs:ref-last-lp>2578</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>WALDMANN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>66</xocs:ref-first-fp>
            <xocs:ref-last-lp>70</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>JOHNSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>234</xocs:ref-first-fp>
            <xocs:ref-last-lp>248</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>97</xocs:ref-first-fp>
            <xocs:ref-last-lp>105</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>DARNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>740</xocs:ref-first-fp>
            <xocs:ref-last-lp>749</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>798</xocs:ref-first-fp>
            <xocs:ref-last-lp>809</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>VILLARINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>21</xocs:ref-first-fp>
            <xocs:ref-last-lp>27</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>736</xocs:ref-first-fp>
            <xocs:ref-last-lp>746</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>PILATI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>499</xocs:ref-first-fp>
            <xocs:ref-last-lp>506</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>SHAHMARVAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>926</xocs:ref-first-fp>
            <xocs:ref-last-lp>933</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>AIGNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>33576</xocs:ref-first-fp>
            <xocs:ref-last-lp>33581</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>LERNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>2564</xocs:ref-first-fp>
            <xocs:ref-last-lp>2577</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>586</xocs:ref-first-fp>
            <xocs:ref-last-lp>599</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>DESIMONE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>3493</xocs:ref-first-fp>
            <xocs:ref-last-lp>3503</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>16975</xocs:ref-first-fp>
            <xocs:ref-last-lp>16980</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>COPPO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>4102</xocs:ref-first-fp>
            <xocs:ref-last-lp>4110</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>GARCIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>2499</xocs:ref-first-fp>
            <xocs:ref-last-lp>2513</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>BRAUNSTEIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>34133</xocs:ref-first-fp>
            <xocs:ref-last-lp>34140</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>YUAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>269</xocs:ref-first-fp>
            <xocs:ref-last-lp>273</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>DELGOFFE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-article-number>e23060</xocs:ref-article-number>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>7765</xocs:ref-first-fp>
            <xocs:ref-last-lp>7769</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>WINGELHOFER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1713</xocs:ref-first-fp>
            <xocs:ref-last-lp>1726</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>532</xocs:ref-first-fp>
            <xocs:ref-last-lp>544</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>BELDIFERCHIOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-article-number>e0174835</xocs:ref-article-number>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>WATSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>840</xocs:ref-first-fp>
            <xocs:ref-last-lp>844</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>MCDANIEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>8226</xocs:ref-first-fp>
            <xocs:ref-last-lp>8238</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>GARCIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>2499</xocs:ref-first-fp>
            <xocs:ref-last-lp>2513</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>ZHUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>416</xocs:ref-first-fp>
            <xocs:ref-last-lp>426</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>NIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>2000</xocs:ref-first-fp>
            <xocs:ref-last-lp>2008</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>MASUDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>3351</xocs:ref-first-fp>
            <xocs:ref-last-lp>3355</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>SRIURANPONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>2948</xocs:ref-first-fp>
            <xocs:ref-last-lp>2956</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>DONDONCOW</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>313</xocs:ref-first-fp>
            <xocs:ref-last-lp>316</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>ISHII</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>849</xocs:ref-first-fp>
            <xocs:ref-last-lp>856</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>NATESH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>225</xocs:ref-first-fp>
            <xocs:ref-last-lp>237</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>ARORA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>327</xocs:ref-first-fp>
            <xocs:ref-last-lp>343</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>XIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>3173</xocs:ref-first-fp>
            <xocs:ref-last-lp>3180</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>WATANABE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>608</xocs:ref-first-fp>
            <xocs:ref-last-lp>609</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>XIONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>926</xocs:ref-first-fp>
            <xocs:ref-last-lp>957</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>CHAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>86</xocs:ref-first-fp>
            <xocs:ref-last-lp>97</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>VILLALVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>826</xocs:ref-first-fp>
            <xocs:ref-last-lp>838</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>MAROTTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2723</xocs:ref-first-fp>
            <xocs:ref-last-lp>2735</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>KOSKELA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1905</xocs:ref-first-fp>
            <xocs:ref-last-lp>1913</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>ANDERSSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1204</xocs:ref-first-fp>
            <xocs:ref-last-lp>1208</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>COURONNE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1748</xocs:ref-first-fp>
            <xocs:ref-last-lp>1752</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>DUTTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>911</xocs:ref-first-fp>
            <xocs:ref-last-lp>915</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>OHGAMI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>105</xocs:ref-first-fp>
            <xocs:ref-last-lp>107</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>TAKEDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>39</xocs:ref-first-fp>
            <xocs:ref-last-lp>49</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>KORTYLEWSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1314</xocs:ref-first-fp>
            <xocs:ref-last-lp>1321</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>CONSTANTINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>798</xocs:ref-first-fp>
            <xocs:ref-last-lp>810</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>48</xocs:ref-first-fp>
            <xocs:ref-last-lp>54</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>YUE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>864</xocs:ref-first-fp>
            <xocs:ref-last-lp>870</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>SONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1146</xocs:ref-first-fp>
            <xocs:ref-last-lp>1158</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>ATSAVES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1633</xocs:ref-first-fp>
            <xocs:ref-last-lp>1637</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>MARZEC</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>20852</xocs:ref-first-fp>
            <xocs:ref-last-lp>20857</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>FANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>12189</xocs:ref-first-fp>
            <xocs:ref-last-lp>12202</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>LITZENBURGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1038</xocs:ref-first-fp>
            <xocs:ref-last-lp>1051</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>ZERDES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-normalized-surname>DEBNATH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>6645</xocs:ref-first-fp>
            <xocs:ref-last-lp>6668</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>FURTEK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>308</xocs:ref-first-fp>
            <xocs:ref-last-lp>318</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref64">
            <xocs:ref-normalized-surname>MANDAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>6126</xocs:ref-first-fp>
            <xocs:ref-last-lp>6141</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref65">
            <xocs:ref-normalized-surname>COLEMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>6661</xocs:ref-first-fp>
            <xocs:ref-last-lp>6670</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref66">
            <xocs:ref-normalized-surname>MANDAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>2429</xocs:ref-first-fp>
            <xocs:ref-last-lp>2442</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref67">
            <xocs:ref-normalized-surname>MANDAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>3549</xocs:ref-first-fp>
            <xocs:ref-last-lp>3563</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref68">
            <xocs:ref-normalized-surname>MANDAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>8970</xocs:ref-first-fp>
            <xocs:ref-last-lp>8984</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref69">
            <xocs:ref-normalized-surname>GOMEZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1733</xocs:ref-first-fp>
            <xocs:ref-last-lp>1736</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref70">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>85</xocs:ref-first-fp>
            <xocs:ref-last-lp>89</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref71">
            <xocs:ref-normalized-surname>MIKLOSSY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>611</xocs:ref-first-fp>
            <xocs:ref-last-lp>629</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref72">
            <xocs:ref-normalized-surname>TURKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>45443</xocs:ref-first-fp>
            <xocs:ref-last-lp>45455</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref73">
            <xocs:ref-normalized-surname>TURKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>261</xocs:ref-first-fp>
            <xocs:ref-last-lp>269</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref74">
            <xocs:ref-normalized-surname>GUNNING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>2800</xocs:ref-first-fp>
            <xocs:ref-last-lp>2803</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref75">
            <xocs:ref-normalized-surname>SIDDIQUEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>7391</xocs:ref-first-fp>
            <xocs:ref-last-lp>7396</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref76">
            <xocs:ref-normalized-surname>BALL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>20669</xocs:ref-first-fp>
            <xocs:ref-last-lp>20679</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref77">
            <xocs:ref-normalized-surname>FLETCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1959</xocs:ref-first-fp>
            <xocs:ref-last-lp>1964</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref78">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1398</xocs:ref-first-fp>
            <xocs:ref-last-lp>1409</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref79">
            <xocs:ref-normalized-surname>PAGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>5605</xocs:ref-first-fp>
            <xocs:ref-last-lp>5609</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref80">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>9623</xocs:ref-first-fp>
            <xocs:ref-last-lp>9628</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref81">
            <xocs:ref-normalized-surname>HAFTCHENARY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1102</xocs:ref-first-fp>
            <xocs:ref-last-lp>1107</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref82">
            <xocs:ref-normalized-surname>YUE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>652</xocs:ref-first-fp>
            <xocs:ref-last-lp>663</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref83">
            <xocs:ref-normalized-surname>PAGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1047</xocs:ref-first-fp>
            <xocs:ref-last-lp>1055</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref84">
            <xocs:ref-normalized-surname>PAGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>7190</xocs:ref-first-fp>
            <xocs:ref-last-lp>7200</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref85">
            <xocs:ref-normalized-surname>LOPEZTAPIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>250</xocs:ref-first-fp>
            <xocs:ref-last-lp>255</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref86">
            <xocs:ref-normalized-surname>SONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>4700</xocs:ref-first-fp>
            <xocs:ref-last-lp>4705</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref87">
            <xocs:ref-normalized-surname>BHASIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>391</xocs:ref-first-fp>
            <xocs:ref-last-lp>395</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref88">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>39</xocs:ref-first-fp>
            <xocs:ref-last-lp>50</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref89">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>4402</xocs:ref-first-fp>
            <xocs:ref-last-lp>4412</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref90">
            <xocs:ref-normalized-surname>SCHUST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>114</xocs:ref-first-fp>
            <xocs:ref-last-lp>118</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref91">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2718</xocs:ref-first-fp>
            <xocs:ref-last-lp>2731</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref92">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1251</xocs:ref-first-fp>
            <xocs:ref-last-lp>1258</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref93">
            <xocs:ref-normalized-surname>HUBBARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1091</xocs:ref-first-fp>
            <xocs:ref-last-lp>1103</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref94">
            <xocs:ref-normalized-surname>THAKUR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>10194</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref95">
            <xocs:ref-normalized-surname>QIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>74</xocs:ref-first-fp>
            <xocs:ref-last-lp>86</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref96">
            <xocs:ref-normalized-surname>FOWLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>6</xocs:ref-first-fp>
            <xocs:ref-last-lp>17</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref97">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>5592</xocs:ref-first-fp>
            <xocs:ref-last-lp>5596</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref98">
            <xocs:ref-normalized-surname>GUO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>752</xocs:ref-first-fp>
            <xocs:ref-last-lp>764</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref99">
            <xocs:ref-normalized-surname>PALLANDRE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>163</xocs:ref-first-fp>
            <xocs:ref-last-lp>174</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref100">
            <xocs:ref-normalized-surname>MATSUNO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>371</xocs:ref-first-fp>
            <xocs:ref-last-lp>375</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref101">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1381</xocs:ref-first-fp>
            <xocs:ref-last-lp>1387</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref102">
            <xocs:ref-normalized-surname>DAKA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1348</xocs:ref-first-fp>
            <xocs:ref-last-lp>1355</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref103">
            <xocs:ref-normalized-surname>SHAHANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>79</xocs:ref-first-fp>
            <xocs:ref-last-lp>84</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref104">
            <xocs:ref-normalized-surname>XU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>4783</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref105">
            <xocs:ref-normalized-surname>BHARADWAJ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>26307</xocs:ref-first-fp>
            <xocs:ref-last-lp>26330</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref106">
            <xocs:ref-normalized-surname>REDELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref107">
            <xocs:ref-normalized-surname>BRAMBILLA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1194</xocs:ref-first-fp>
            <xocs:ref-last-lp>1206</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref108">
            <xocs:ref-normalized-surname>REN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>454</xocs:ref-first-fp>
            <xocs:ref-last-lp>459</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref109">
            <xocs:ref-normalized-surname>FURTEK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>77998</xocs:ref-first-fp>
            <xocs:ref-last-lp>78008</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref110">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>180</xocs:ref-first-fp>
            <xocs:ref-last-lp>185</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref111">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>578</xocs:ref-first-fp>
            <xocs:ref-last-lp>590</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref112">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>699</xocs:ref-first-fp>
            <xocs:ref-last-lp>713</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref113">
            <xocs:ref-normalized-surname>JIANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>6857</xocs:ref-first-fp>
            <xocs:ref-last-lp>6867</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref114">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1188</xocs:ref-first-fp>
            <xocs:ref-last-lp>1196</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref115">
            <xocs:ref-normalized-surname>SHIH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>32690</xocs:ref-first-fp>
            <xocs:ref-last-lp>32701</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref116">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>802</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref117">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>887</xocs:ref-first-fp>
            <xocs:ref-last-lp>897</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref118">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>301</xocs:ref-first-fp>
            <xocs:ref-last-lp>310</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref119">
            <xocs:ref-normalized-surname>GAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2549</xocs:ref-first-fp>
            <xocs:ref-last-lp>2558</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref120">
            <xocs:ref-normalized-surname>SCHUST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1235</xocs:ref-first-fp>
            <xocs:ref-last-lp>1242</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref121">
            <xocs:ref-normalized-surname>BUETTNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>432</xocs:ref-first-fp>
            <xocs:ref-last-lp>443</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref122">
            <xocs:ref-normalized-surname>HEIDELBERGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>4719</xocs:ref-first-fp>
            <xocs:ref-last-lp>4722</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref123">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>498</xocs:ref-first-fp>
            <xocs:ref-last-lp>507</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref124">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>195</xocs:ref-first-fp>
            <xocs:ref-last-lp>203</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref125">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>538</xocs:ref-first-fp>
            <xocs:ref-last-lp>550</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref126">
            <xocs:ref-normalized-surname>JI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1010</xocs:ref-first-fp>
            <xocs:ref-last-lp>1014</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref127">
            <xocs:ref-normalized-surname>WEIDLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>6</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref128">
            <xocs:ref-normalized-surname>HELLSTEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>269</xocs:ref-first-fp>
            <xocs:ref-last-lp>280</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref129">
            <xocs:ref-normalized-surname>DONDONCOW</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>15969</xocs:ref-first-fp>
            <xocs:ref-last-lp>15978</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref130">
            <xocs:ref-normalized-surname>BUETTNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>432</xocs:ref-first-fp>
            <xocs:ref-last-lp>443</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref131">
            <xocs:ref-normalized-surname>WEISSENBERGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5781</xocs:ref-first-fp>
            <xocs:ref-last-lp>5795</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref132">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>217</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref133">
            <xocs:ref-normalized-surname>SELVENDIRAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1169</xocs:ref-first-fp>
            <xocs:ref-last-lp>1179</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref134">
            <xocs:ref-normalized-surname>SELVENDIRAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>837</xocs:ref-first-fp>
            <xocs:ref-last-lp>845</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref135">
            <xocs:ref-normalized-surname>HAHN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>6409</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref136">
            <xocs:ref-normalized-surname>DAHLIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>2091</xocs:ref-first-fp>
            <xocs:ref-last-lp>2113</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref137">
            <xocs:ref-normalized-surname>NELSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1620</xocs:ref-first-fp>
            <xocs:ref-last-lp>1637</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref138">
            <xocs:ref-normalized-surname>WONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>883</xocs:ref-first-fp>
            <xocs:ref-last-lp>887</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref139">
            <xocs:ref-normalized-surname>BEEBE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>74</xocs:ref-first-fp>
            <xocs:ref-last-lp>91</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref140">
            <xocs:ref-normalized-surname>OGURA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>896</xocs:ref-first-fp>
            <xocs:ref-last-lp>901</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref141">
            <xocs:ref-normalized-surname>WAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>40</xocs:ref-first-fp>
            <xocs:ref-last-lp>46</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref142">
            <xocs:ref-normalized-surname>LONSDALE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>3816</xocs:ref-first-fp>
            <xocs:ref-last-lp>3830</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref143">
            <xocs:ref-normalized-surname>SINGH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>307</xocs:ref-first-fp>
            <xocs:ref-last-lp>317</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref144">
            <xocs:ref-normalized-surname>LAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>101</xocs:ref-first-fp>
            <xocs:ref-last-lp>114</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref145">
            <xocs:ref-normalized-surname>SCHIEDEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>482</xocs:ref-first-fp>
            <xocs:ref-last-lp>491</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref146">
            <xocs:ref-normalized-surname>HU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1420</xocs:ref-first-fp>
            <xocs:ref-last-lp>1442</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref147">
            <xocs:ref-normalized-surname>HAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>941</xocs:ref-first-fp>
            <xocs:ref-last-lp>964</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref148">
            <xocs:ref-normalized-surname>CHURCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>444</xocs:ref-first-fp>
            <xocs:ref-last-lp>452</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref149">
            <xocs:ref-normalized-surname>QIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>6685</xocs:ref-first-fp>
            <xocs:ref-last-lp>6704</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref150">
            <xocs:ref-normalized-surname>ZHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>462</xocs:ref-first-fp>
            <xocs:ref-last-lp>481</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref151">
            <xocs:ref-normalized-surname>WURZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>445</xocs:ref-first-fp>
            <xocs:ref-last-lp>447</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref152">
            <xocs:ref-normalized-surname>WURZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>453</xocs:ref-first-fp>
            <xocs:ref-last-lp>461</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref153">
            <xocs:ref-normalized-surname>ZOPPI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>699</xocs:ref-first-fp>
            <xocs:ref-last-lp>726</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref154">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>448</xocs:ref-first-fp>
            <xocs:ref-last-lp>466</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref155">
            <xocs:ref-normalized-surname>CREW</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>583</xocs:ref-first-fp>
            <xocs:ref-last-lp>598</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref156">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1354</xocs:ref-first-fp>
            <xocs:ref-last-lp>1356</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref157">
            <xocs:ref-normalized-surname>MURASE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>20151</xocs:ref-first-fp>
            <xocs:ref-last-lp>20161</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref158">
            <xocs:ref-normalized-surname>BAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>498</xocs:ref-first-fp>
            <xocs:ref-last-lp>511</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>HUANGX2020X111922</xocs:refkey3>
         <xocs:refkey4ai>HUANGX2020X111922XQ</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2022-01-14T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-01-14T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2019 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2019-12-02T08:16:23.602Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>GDSTC</xocs:funding-agency-acronym>
            <xocs:funding-agency>Guangdong Science and Technology Department</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100007162</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-acronym>SYSU</xocs:funding-agency-acronym>
            <xocs:funding-agency>Sun Yat-sen University</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100002402</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-acronym>NSFC</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Natural Science Foundation of China</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100001809</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency>National Major Science and Technology Projects of China</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100013076</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(19)31074-8</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523419310748</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523419310748</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2019.111922</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2020-01-14T22:42:13.816392Z</xocs:timestamp>
         <xocs:cover-date-start>2020-02-01</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/MAIN/application/pdf/24043d9da73590b68e1bd5de01eb00cc/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2459599</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>20</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523419310748-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/PREVIEW/image/png/6923b2a9bba9f6aa74ca99c1313c12c1/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>41652</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr6/DOWNSAMPLED/image/jpeg/822f04987919be86dcf347ce916f1bb6/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>25945</xocs:filesize>
               <xocs:pixel-height>160</xocs:pixel-height>
               <xocs:pixel-width>667</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx5/DOWNSAMPLED/image/jpeg/b154a15c8212370c1e3e01bfb8839a71/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1169</xocs:filesize>
               <xocs:pixel-height>55</xocs:pixel-height>
               <xocs:pixel-width>68</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx2/DOWNSAMPLED/image/jpeg/43c979d3b0cd6e3a6b3f89f3d127c306/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1872</xocs:filesize>
               <xocs:pixel-height>56</xocs:pixel-height>
               <xocs:pixel-width>131</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr9/DOWNSAMPLED/image/jpeg/c177c4d74c97865c66ff59f625c7e291/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>21476</xocs:filesize>
               <xocs:pixel-height>269</xocs:pixel-height>
               <xocs:pixel-width>578</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx9/DOWNSAMPLED/image/jpeg/35ec7e8be04a1e23b6a1a5126e627d40/fx9.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>668</xocs:filesize>
               <xocs:pixel-height>26</xocs:pixel-height>
               <xocs:pixel-width>43</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr2/DOWNSAMPLED/image/jpeg/1d941604bc131f1f51d002ecc67a1139/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>27343</xocs:filesize>
               <xocs:pixel-height>143</xocs:pixel-height>
               <xocs:pixel-width>734</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx3/DOWNSAMPLED/image/jpeg/8fcd2bb05e420981ba425938e995a05d/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1254</xocs:filesize>
               <xocs:pixel-height>35</xocs:pixel-height>
               <xocs:pixel-width>63</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr1/DOWNSAMPLED/image/jpeg/89ef69db431b8c8ad5bfb656765dba93/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>80903</xocs:filesize>
               <xocs:pixel-height>334</xocs:pixel-height>
               <xocs:pixel-width>689</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx8/DOWNSAMPLED/image/jpeg/2e7b967f926f11534d40654c0237d9b2/fx8.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>885</xocs:filesize>
               <xocs:pixel-height>28</xocs:pixel-height>
               <xocs:pixel-width>49</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx14/DOWNSAMPLED/image/jpeg/8a3d91bfb858befab36e41d80bd0942d/fx14.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>801</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>56</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx1/DOWNSAMPLED/image/jpeg/6d6c44c0d79f92bbec89adfe8474f7d6/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>29627</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>405</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr7/DOWNSAMPLED/image/jpeg/ec9872699800a337ed21044ac7218f92/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>7225</xocs:filesize>
               <xocs:pixel-height>118</xocs:pixel-height>
               <xocs:pixel-width>311</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr3/DOWNSAMPLED/image/jpeg/275c1b4551117a3d589573363ca0b4d3/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>26878</xocs:filesize>
               <xocs:pixel-height>166</xocs:pixel-height>
               <xocs:pixel-width>734</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx18.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx18/DOWNSAMPLED/image/jpeg/46a057739392edfdc5caf6cd65af9276/fx18.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2283</xocs:filesize>
               <xocs:pixel-height>111</xocs:pixel-height>
               <xocs:pixel-width>102</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx4/DOWNSAMPLED/image/jpeg/04a87139c19e28302b9a02ac6a97f49f/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1202</xocs:filesize>
               <xocs:pixel-height>34</xocs:pixel-height>
               <xocs:pixel-width>60</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx13/DOWNSAMPLED/image/jpeg/3cfab4d30691e376085c903930591460/fx13.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>858</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>54</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx15.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx15/DOWNSAMPLED/image/jpeg/b115a301e9e52a4ab787a58f471d58b4/fx15.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>754</xocs:filesize>
               <xocs:pixel-height>20</xocs:pixel-height>
               <xocs:pixel-width>54</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr4/DOWNSAMPLED/image/jpeg/6246037cf9c9186b0e98892721aefb22/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>53872</xocs:filesize>
               <xocs:pixel-height>343</xocs:pixel-height>
               <xocs:pixel-width>667</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx17.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx17/DOWNSAMPLED/image/jpeg/dc96be037ce431c77ffc8d62ca107831/fx17.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>777</xocs:filesize>
               <xocs:pixel-height>20</xocs:pixel-height>
               <xocs:pixel-width>70</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr10/DOWNSAMPLED/image/jpeg/fe4a791d500bbac1d1fc42f7dc1d2d3f/gr10.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37989</xocs:filesize>
               <xocs:pixel-height>304</xocs:pixel-height>
               <xocs:pixel-width>538</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr8/DOWNSAMPLED/image/jpeg/3f0ce13740371ea8832e84b229d43e65/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>19694</xocs:filesize>
               <xocs:pixel-height>135</xocs:pixel-height>
               <xocs:pixel-width>727</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx16.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx16/DOWNSAMPLED/image/jpeg/20f7abc0378fcd32270000fc73e3e32c/fx16.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>645</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>50</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr11/DOWNSAMPLED/image/jpeg/fc69f6372d69d5a696312ebdf7b6557d/gr11.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>28639</xocs:filesize>
               <xocs:pixel-height>235</xocs:pixel-height>
               <xocs:pixel-width>578</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx12/DOWNSAMPLED/image/jpeg/cb3ed217b7aa12dd0f31a66443dca753/fx12.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2173</xocs:filesize>
               <xocs:pixel-height>71</xocs:pixel-height>
               <xocs:pixel-width>117</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx10/DOWNSAMPLED/image/jpeg/5b32f0fa609be5c11afee864499c64e0/fx10.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>754</xocs:filesize>
               <xocs:pixel-height>32</xocs:pixel-height>
               <xocs:pixel-width>58</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx6/DOWNSAMPLED/image/jpeg/238781ffc7a7ac79abe6230cff8a27c7/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3398</xocs:filesize>
               <xocs:pixel-height>89</xocs:pixel-height>
               <xocs:pixel-width>195</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx11/DOWNSAMPLED/image/jpeg/f529a75dd20f6f679781009217ab06f5/fx11.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>780</xocs:filesize>
               <xocs:pixel-height>20</xocs:pixel-height>
               <xocs:pixel-width>58</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr5/DOWNSAMPLED/image/jpeg/dfb4ae7c73dc483751633e3c0873c2b5/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>41698</xocs:filesize>
               <xocs:pixel-height>274</xocs:pixel-height>
               <xocs:pixel-width>533</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx7/DOWNSAMPLED/image/jpeg/c2621287616f603d1d14e25b46dd21dd/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2843</xocs:filesize>
               <xocs:pixel-height>91</xocs:pixel-height>
               <xocs:pixel-width>167</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr6/THUMBNAIL/image/gif/f50e29323884190f9aab2d64d8c4e9cb/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2023</xocs:filesize>
               <xocs:pixel-height>53</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx5/THUMBNAIL/image/gif/17845c323c497a9e28b63f372796aec8/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3768</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>203</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx2/THUMBNAIL/image/gif/3dc78f9761277f866aeffd7914279e15/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2680</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr9/THUMBNAIL/image/gif/65849a4c4b152bdc35e6f775a910721d/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3455</xocs:filesize>
               <xocs:pixel-height>102</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx9/THUMBNAIL/image/gif/449f6263dd7b2285c114ab9665318c8e/fx9.sml</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1963</xocs:filesize>
               <xocs:pixel-height>117</xocs:pixel-height>
               <xocs:pixel-width>194</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr2/THUMBNAIL/image/gif/59b29389f8413bdd0023e80aef2b4506/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2032</xocs:filesize>
               <xocs:pixel-height>43</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx3/THUMBNAIL/image/gif/b97f5e271bea0b345ddae7daf2847eb8/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2701</xocs:filesize>
               <xocs:pixel-height>122</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr1/THUMBNAIL/image/gif/6cdc99a68f2494be19c7926b1f2daa7f/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13847</xocs:filesize>
               <xocs:pixel-height>106</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx8/THUMBNAIL/image/gif/26da313381480b375c9fea8743982bea/fx8.sml</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2425</xocs:filesize>
               <xocs:pixel-height>126</xocs:pixel-height>
               <xocs:pixel-width>218</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx14/THUMBNAIL/image/gif/26c7ca89d762baea54dd2e949019aa2b/fx14.sml</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2545</xocs:filesize>
               <xocs:pixel-height>106</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx1/THUMBNAIL/image/gif/a1ee43257419b7735314f4618c18fa62/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13460</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr7/THUMBNAIL/image/gif/643e67e818de85ccc52e39d36de70fa1/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2300</xocs:filesize>
               <xocs:pixel-height>83</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr3/THUMBNAIL/image/gif/295c15ed9c12244e5c4315da706b9f5d/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1819</xocs:filesize>
               <xocs:pixel-height>50</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx18.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx18/THUMBNAIL/image/gif/519bd145c9ad30f8a92660679c1a0251/fx18.sml</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2891</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>151</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx4/THUMBNAIL/image/gif/26847eb59531c20f66002f6a6209e0e1/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2830</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx13/THUMBNAIL/image/gif/04d5701e6ec492bef408232d3618ec49/fx13.sml</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2962</xocs:filesize>
               <xocs:pixel-height>110</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx15.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx15/THUMBNAIL/image/gif/9da783e9dc83ce047cab5797110fd3b1/fx15.sml</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1796</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr4/THUMBNAIL/image/gif/a8b0a7d6f18b04dec7a142e1dd16d4eb/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4372</xocs:filesize>
               <xocs:pixel-height>113</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx17.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx17/THUMBNAIL/image/gif/f137dd0251939433d26f26ff9c77377e/fx17.sml</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2332</xocs:filesize>
               <xocs:pixel-height>62</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr10/THUMBNAIL/image/gif/73897cdbad677fd257cf3540fbb24928/gr10.sml</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4029</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr8/THUMBNAIL/image/gif/2870ea25413453742ca123237fff8ed4/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2627</xocs:filesize>
               <xocs:pixel-height>41</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx16.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx16/THUMBNAIL/image/gif/33886bd30806fa4af52e2c0dd468d332/fx16.sml</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2644</xocs:filesize>
               <xocs:pixel-height>119</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr11/THUMBNAIL/image/gif/b48e5ee87542390d9cda9ef17f750315/gr11.sml</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3097</xocs:filesize>
               <xocs:pixel-height>89</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx12/THUMBNAIL/image/gif/a1d675484a7a9ee264529769a69b6edb/fx12.sml</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2576</xocs:filesize>
               <xocs:pixel-height>132</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx10/THUMBNAIL/image/gif/04698e16291299d0abce25b4532ffff3/fx10.sml</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2724</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx6/THUMBNAIL/image/gif/5b78921dc761a5c1831e8d283a28eceb/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2102</xocs:filesize>
               <xocs:pixel-height>100</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx11/THUMBNAIL/image/gif/c65fb3221ad6df6154b8fe59911501b5/fx11.sml</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2729</xocs:filesize>
               <xocs:pixel-height>74</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr5/THUMBNAIL/image/gif/be6bdebfba8f99871166b51d32b2f5b8/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4571</xocs:filesize>
               <xocs:pixel-height>113</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx7/THUMBNAIL/image/gif/828eba10f089fc470165ce22279fd042/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2972</xocs:filesize>
               <xocs:pixel-height>119</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr6/HIGHRES/image/jpeg/1f7c4ad889b5eddc25bc054d24260ab0/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>198375</xocs:filesize>
               <xocs:pixel-height>709</xocs:pixel-height>
               <xocs:pixel-width>2953</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx5/HIGHRES/image/jpeg/1b72f4d83fc388c5d61a9b441c8d2e1a/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>8829</xocs:filesize>
               <xocs:pixel-height>244</xocs:pixel-height>
               <xocs:pixel-width>302</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx2/HIGHRES/image/jpeg/8a8762ad756ff0dc4325cfb3318812af/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>14147</xocs:filesize>
               <xocs:pixel-height>247</xocs:pixel-height>
               <xocs:pixel-width>582</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr9/HIGHRES/image/jpeg/7cca7ee2bafa8fefe08bac5f776c74d0/gr9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>178717</xocs:filesize>
               <xocs:pixel-height>1193</xocs:pixel-height>
               <xocs:pixel-width>2559</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx9/HIGHRES/image/jpeg/b8bb750c8cc1c4899156e8f171e7ad3a/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3222</xocs:filesize>
               <xocs:pixel-height>117</xocs:pixel-height>
               <xocs:pixel-width>194</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr2/HIGHRES/image/jpeg/02b39e7a31de536aab1e6ab873f0f1ce/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>190859</xocs:filesize>
               <xocs:pixel-height>633</xocs:pixel-height>
               <xocs:pixel-width>3248</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx3/HIGHRES/image/jpeg/8fabfe4ca23e58d8a79dbe2c50efa56f/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6877</xocs:filesize>
               <xocs:pixel-height>157</xocs:pixel-height>
               <xocs:pixel-width>281</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr1/HIGHRES/image/jpeg/5fe8dfd2084ef08c1d6419de66590a6a/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>759349</xocs:filesize>
               <xocs:pixel-height>1480</xocs:pixel-height>
               <xocs:pixel-width>3051</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx8/HIGHRES/image/jpeg/7fd1581679a50ece877235d22b89aa4c/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4355</xocs:filesize>
               <xocs:pixel-height>126</xocs:pixel-height>
               <xocs:pixel-width>218</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx14/HIGHRES/image/jpeg/b879893179ebe2eff3fbcc062609d206/fx14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3657</xocs:filesize>
               <xocs:pixel-height>121</xocs:pixel-height>
               <xocs:pixel-width>249</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx1/HIGHRES/image/jpeg/fbc0e09bda161ae45cdcaa1ad9ebe45d/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>288785</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>1794</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr7/HIGHRES/image/jpeg/4eff4a561f73082841b871a3b0d83f6f/gr7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>59002</xocs:filesize>
               <xocs:pixel-height>523</xocs:pixel-height>
               <xocs:pixel-width>1378</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr3/HIGHRES/image/jpeg/6e3db549fc94cdb09f2fac32b4873eff/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>203960</xocs:filesize>
               <xocs:pixel-height>735</xocs:pixel-height>
               <xocs:pixel-width>3248</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx18_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx18/HIGHRES/image/jpeg/60615ec24db030c1d9a3c820dabd76f8/fx18_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>18408</xocs:filesize>
               <xocs:pixel-height>493</xocs:pixel-height>
               <xocs:pixel-width>454</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx4/HIGHRES/image/jpeg/b51d5d319093fd33f7a4f86114faa94f/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6516</xocs:filesize>
               <xocs:pixel-height>150</xocs:pixel-height>
               <xocs:pixel-width>268</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx13/HIGHRES/image/jpeg/928f9a0206223755a0de28b4b04cf823/fx13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4039</xocs:filesize>
               <xocs:pixel-height>121</xocs:pixel-height>
               <xocs:pixel-width>240</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx15_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx15/HIGHRES/image/jpeg/512c89051c655b3fffcd7e8c4551f8ed/fx15_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3865</xocs:filesize>
               <xocs:pixel-height>87</xocs:pixel-height>
               <xocs:pixel-width>240</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr4/HIGHRES/image/jpeg/c371d61cd39d8e1153d4e8c2909aa95d/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>389800</xocs:filesize>
               <xocs:pixel-height>1518</xocs:pixel-height>
               <xocs:pixel-width>2953</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx17_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx17/HIGHRES/image/jpeg/10246642ca47609122488521c86656c0/fx17_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4416</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>312</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr10/HIGHRES/image/jpeg/a3bd410455b9623aa61a32ae0e6f1283/gr10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>285502</xocs:filesize>
               <xocs:pixel-height>1348</xocs:pixel-height>
               <xocs:pixel-width>2382</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr8/HIGHRES/image/jpeg/e15c5185e3ad1df36dc7030bf3b8fcd0/gr8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>154787</xocs:filesize>
               <xocs:pixel-height>599</xocs:pixel-height>
               <xocs:pixel-width>3220</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx16_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx16/HIGHRES/image/jpeg/5a71281a0901e790501454a5f9a56563/fx16_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3343</xocs:filesize>
               <xocs:pixel-height>121</xocs:pixel-height>
               <xocs:pixel-width>223</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr11/HIGHRES/image/jpeg/7b574c99166d612e3e7cfcff13e9cf3b/gr11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>216408</xocs:filesize>
               <xocs:pixel-height>1041</xocs:pixel-height>
               <xocs:pixel-width>2559</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx12/HIGHRES/image/jpeg/7cde4546e2dcecb962f759142e9c1c8f/fx12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>16348</xocs:filesize>
               <xocs:pixel-height>315</xocs:pixel-height>
               <xocs:pixel-width>521</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx10/HIGHRES/image/jpeg/e7a8c21bd3e6b3e1e8e6ea4039380bc0/fx10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4000</xocs:filesize>
               <xocs:pixel-height>146</xocs:pixel-height>
               <xocs:pixel-width>261</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx6/HIGHRES/image/jpeg/225bbadb4a8c335cefa80ebd629f6588/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>26457</xocs:filesize>
               <xocs:pixel-height>396</xocs:pixel-height>
               <xocs:pixel-width>863</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx11/HIGHRES/image/jpeg/2dda654e06fcc2995647d82b95698251/fx11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4204</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>261</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/gr5/HIGHRES/image/jpeg/f7e96cc6655eabede87e311a4bab394e/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>303465</xocs:filesize>
               <xocs:pixel-height>1213</xocs:pixel-height>
               <xocs:pixel-width>2359</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419310748-fx7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419310748/fx7/HIGHRES/image/jpeg/74ec1ce46eb5c468f304af7f1808610e/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>20447</xocs:filesize>
               <xocs:pixel-height>401</xocs:pixel-height>
               <xocs:pixel-width>739</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="rev" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>111922</aid>
            <ce:article-number>111922</ce:article-number>
            <ce:pii>S0223-5234(19)31074-8</ce:pii>
            <ce:doi>10.1016/j.ejmech.2019.111922</ce:doi>
            <ce:copyright type="full-transfer" year="2019">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">STAT3 structure and signaling pathway. (A) STAT3 domains; (B) SH2 domain characteristics of STAT3 in which red color represents areas of positive charge and yellow color represents negative charge; (C) STAT3 signaling pathway. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0015" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523419310748/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Structures of compounds <ce:bold>1</ce:bold>–<ce:bold>4</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523419310748/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Structures of compounds <ce:bold>5</ce:bold>–<ce:bold>8</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523419310748/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Structures of compounds <ce:bold>9</ce:bold>–<ce:bold>21</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523419310748/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">Structures of compounds <ce:bold>22</ce:bold>–<ce:bold>30</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523419310748/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Structures of compounds <ce:bold>31</ce:bold>–<ce:bold>34</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:href="pii:S0223523419310748/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Structures of compounds <ce:bold>42</ce:bold>–<ce:bold>43</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:href="pii:S0223523419310748/gr7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Structures of compound <ce:bold>53</ce:bold>–<ce:bold>55</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:href="pii:S0223523419310748/gr8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Fig. 9</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">Structures of compounds <ce:bold>62</ce:bold>–<ce:bold>66</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Fig. 9</ce:alt-text>
               <ce:link locator="gr9" xlink:href="pii:S0223523419310748/gr9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig10">
               <ce:label>Fig. 10</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">Structures of compounds <ce:bold>73</ce:bold>–<ce:bold>79</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Fig. 10</ce:alt-text>
               <ce:link locator="gr10" xlink:href="pii:S0223523419310748/gr10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig11">
               <ce:label>Fig. 11</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Structures of compounds <ce:bold>80</ce:bold>–<ce:bold>85</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0065" role="short">Fig. 11</ce:alt-text>
               <ce:link locator="gr11" xlink:href="pii:S0223523419310748/gr11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="tspara0010" view="all">Luciferase reporter activity of aminotetrazole analogues at 50 μM.<ce:inline-figure baseline="0.0">
                        <ce:link locator="fx2" xlink:href="pii:S0223523419310748/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        <ce:alt-text id="alttext0070" role="short">Image 2</ce:alt-text>
                     </ce:inline-figure>
                  </ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0075" role="short">Table 1</ce:alt-text>
               <tgroup cols="5">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R<inf loc="post">1</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HeLa/STAT3-Luc cells (%)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HeLa/STAT1-Luc cells (%)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>35</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx3" xlink:href="pii:S0223523419310748/fx3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0080" role="short">Image 3</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">53.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11.1</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>36</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523419310748/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0085" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">70.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.7</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>37</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx5" xlink:href="pii:S0223523419310748/fx5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0090" role="short">Image 5</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">95.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">44.5</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>38</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-NHCH<inf loc="post">2</inf>CO<inf loc="post">2</inf>H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.1</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>39</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-CHO</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">66.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">62.3</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>40</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-CH<inf loc="post">2</inf>OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">66.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">43.6</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>41</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NO<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">-NCN</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">91.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">48.8</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl2" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="tspara0015" view="all">Cytotoxic activity (IC<ce:inf loc="post">50</ce:inf>) of carboxylic ester analogues on different cell lines.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0095" role="short">Table 2</ce:alt-text>
               <ce:link locator="fx6" xlink:href="pii:S0223523419310748/fx6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="7">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">1</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="colgroup" namest="col4" nameend="col7">IC<inf loc="post">50</inf> (μM)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">PANC-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HPAC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">SW1990</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>44</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>i-</italic>Pro</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.9</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>45</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>i-</italic>Pro</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>100</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>46</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <italic>i-</italic>But</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.1</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>47</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">t-But</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.5</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>48</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Me</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Bn</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">16.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.8</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl3" rowsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0075">
                  <ce:simple-para id="tspara0020" view="all">Inhibitory activity IC<ce:inf loc="post">50</ce:inf> (μM) of carboxylic acid analogues on different cell lines.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0100" role="short">Table 3</ce:alt-text>
               <ce:link locator="fx7" xlink:href="pii:S0223523419310748/fx7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="7">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">SPR<br/></br>K<inf loc="post">D</inf> (μM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">EMSA<br/></br>IC<inf loc="post">50</inf> (μM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">DU145 IC<inf loc="post">50</inf> (μM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">NIH3T3/v-Src IC<inf loc="post">50</inf> (μM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">NIH3T3 IC<inf loc="post">50</inf> (μM)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>49</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx8" xlink:href="pii:S0223523419310748/fx8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0105" role="short">Image 8</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">57.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">68.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">100.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>500</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>50</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx9" xlink:href="pii:S0223523419310748/fx9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0110" role="short">Image 9</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">53.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">65.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">41.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>500</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>51</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx10" xlink:href="pii:S0223523419310748/fx10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0115" role="short">Image 10</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">80.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">45.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>500</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>52</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx11" xlink:href="pii:S0223523419310748/fx11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0120" role="short">Image 11</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">83.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">65.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">62.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">420</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl4" rowsep="0">
               <ce:label>Table 4</ce:label>
               <ce:caption id="cap0080">
                  <ce:simple-para id="tspara0025" view="all">Effects of compounds <ce:bold>56</ce:bold>–<ce:bold>61</ce:bold> on proliferation of human breast and pancreatic cancer cell lines.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0125" role="short">Table 4</ce:alt-text>
               <ce:link locator="fx12" xlink:href="pii:S0223523419310748/fx12" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="6">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">1</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="colgroup" namest="col3" nameend="col6">IC<inf loc="post">50</inf> (μM)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MCF-7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">AsPC1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Panc-1</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>56</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.79</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.47</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.73</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>57</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx13" xlink:href="pii:S0223523419310748/fx13" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0130" role="short">Image 13</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.76</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.54</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>58</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx14" xlink:href="pii:S0223523419310748/fx14" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0135" role="short">Image 14</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.69</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>59</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx15" xlink:href="pii:S0223523419310748/fx15" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0140" role="short">Image 15</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.91</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>60</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx16" xlink:href="pii:S0223523419310748/fx16" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0145" role="short">Image 16</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>61</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx17" xlink:href="pii:S0223523419310748/fx17" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0150" role="short">Image 17</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.61</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.11</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl5" rowsep="0">
               <ce:label>Table 5</ce:label>
               <ce:caption id="cap0085">
                  <ce:simple-para id="tspara0030" view="all">Inhibitory activity on STAT3 transcription and human breast cancer cell lines of compounds <ce:bold>67</ce:bold>–<ce:bold>72</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0155" role="short">Table 5</ce:alt-text>
               <ce:link locator="fx18" xlink:href="pii:S0223523419310748/fx18" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <tgroup cols="5">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">1</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="colgroup" namest="col4" nameend="col5">Inhibitory activity IC<inf loc="post">50</inf> (μM)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">IL-6/STAT3 pathway</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-468</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>67</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26.68</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">18.83</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>68</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.71</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.61</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>69</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.38</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19.70</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>70</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">11.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">57.25</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>71</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5-Br</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">168.40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.85</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>72</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SO<inf loc="post">2</inf>NH<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">35.67</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24.34</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl6" rowsep="0">
               <ce:label>Table 6</ce:label>
               <ce:caption id="cap0090">
                  <ce:simple-para id="tspara0035" view="all">Effects of compounds <ce:bold>73</ce:bold>–<ce:bold>77</ce:bold> on proliferation of human breast and pancreatic cancer cell lines.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0160" role="short">Table 6</ce:alt-text>
               <tgroup cols="5">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="colgroup" namest="col2" nameend="col5">IC<inf loc="post">50</inf> (μM)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MCF-7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">AsPC1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Panc-1</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>73</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.60</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.89</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.77</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>75</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.26</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>76</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.91</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.92</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.34</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>77</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.76</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.97</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.88</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl7" rowsep="0">
               <ce:label>Table 7</ce:label>
               <ce:caption id="cap0095">
                  <ce:simple-para id="tspara0040" view="all">Small-molecule inhibitors of STAT3.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0165" role="short">Table 7</ce:alt-text>
               <tgroup cols="6">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Target domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Proposed MOA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cancer cell line tested</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Tumor model</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Refs</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ISS610 (<bold>3</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2 domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting dimerization</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NIH3T3/vSrc,<br/></br>MDA-MB-231,<br/></br>MDA-MB-435</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">n/d</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1190" refid="bib73">73</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">S3I-M2001 (<bold>7</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2 domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting dimerization</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NIH3T3/vSrc,<br/></br>MDA-MB-231,<br/></br>MDA-MB-435,<br/></br>Panc-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1195" refid="bib74">74</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SF-1-066 (<bold>15</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2 domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting dimerization</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-231,<br/></br>MDA-MB-468,<br/></br>Panc-1, DU145,<br/></br>OCI-AML-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1200" refid="bib78">78</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BP-1-102 (<bold>16</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2 domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting dimerization</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NIH3T3/v-Src, MDA-MB-231, Panc-1, DU145, A549</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-231<br/></br>A549</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1205" refid="bib79">79</cross-ref>]<br/></br>[<cross-ref id="crosref1210" refid="bib80">80</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH4-54 (<bold>17</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2 domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting dimerization</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">U251MG,<br/></br>MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">U251MG</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1215" refid="bib81">81</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">STA-21 (<bold>22</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2 domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting dimerization</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-231, MDA-MB-435s, MDA-MB-468</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">n/d</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1220" refid="bib86">86</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">LLL-3 (<bold>23</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2 domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting dimerization</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">U87, DU145,<br/></br>PC3, LNCaP,<br/></br>MCF-7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">U87</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1225" refid="bib87">87</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">LLL-12 (<bold>24</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2 domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting dimerization</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-231,<br/></br>U87, HAPC, U373,<br/></br>PANC-1, SK-BR-3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-231,<br/></br>U87</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1230" refid="bib88">88</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">STX-0119 (<bold>42</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2 domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting dimerization</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HEK293, GDM-1,<br/></br>HL-60, KG-1,<br/></br>THP-1, K562<br/></br>MDA-MB-468</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SCC-3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1235" refid="bib100">100</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">C188-9 (<bold>54</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2 domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting dimerization</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Kasumi-1,<br/></br>KG-1, GDM-1, Kasumi-1, NB-4,<br/></br>UM-SCC-17B</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">UM-SCC-17B</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1240" refid="bib105">105</cross-ref>]<br/></br>[<cross-ref id="crosref1245" refid="bib106">106</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HJC0152 (<bold>59</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">DNA-binding domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting STAT3 DNA binding</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-231,<br/></br>MCF-7, Panc-1,<br/></br>AsPC1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1250" refid="bib110">110</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">InS3-54 (<bold>62</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">DNA-binding domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting STAT3 DNA binding</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A549, H1299, MDA-MB-231, MDAMB-468</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">n/d</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1255" refid="bib114">114</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A18 (<bold>63</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">DNA-binding domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting STAT3 DNA binding</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A549, MCF10A1, MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A549</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1260" refid="bib116">116</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">LC-28 (<bold>64</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">DNA-binding domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting STAT3 DNA binding</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">H1299, SKOV3,<br/></br>SKOV3/DDP</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">n/d</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1265" refid="bib117">117</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Static (<bold>73</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2 domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting dimerization</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-231, MDA-MB-435, HepG2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">n/d</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1270" refid="bib120">120</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HJC0123 (<bold>75</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2 domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting dimerization</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-231,<br/></br>MCF-7, Panc-1,<br/></br>AsPC1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1275" refid="bib123">123</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Galiellalactone (<bold>80</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">DNA-binding domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting STAT3 DNA binding</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HepG2, DU145, PC3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">DU145</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1280" refid="bib127">127</cross-ref>]<br/></br>[<cross-ref id="crosref1285" refid="bib128">128</cross-ref>]</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">C48 (<bold>81</bold>)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">DNA-binding domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Inhibiting STAT3 DNA binding</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-468,<br/></br>MDA-MB-231,<br/></br>LNCaP</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-468</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">[<cross-ref id="crosref1290" refid="bib130">130</cross-ref>]</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0045" view="all">Note: n/d = not determined.</ce:simple-para>
               </ce:legend>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl8" rowsep="0">
               <ce:label>Table 8</ce:label>
               <ce:caption id="cap0100">
                  <ce:simple-para id="tspara0050" view="all">STAT3 inhibitors in clinical trials.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0170" role="short">Table 8</ce:alt-text>
               <tgroup cols="6">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">target<br/></br>domain</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">study<br/></br>phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">trial status</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">tumor<br/></br>model</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">NCT<br/></br>Identifier</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">STA-21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">no objective responses</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">n/d</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inter-ref id="intref0010" xlink:href="ctgov:NCT01047943" xlink:type="simple">NCT01047943</inter-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OPB-31121</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">termined</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">advanced<br/></br>leukemias</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inter-ref id="intref0015" xlink:href="ctgov:NCT01029509" xlink:type="simple">NCT01029509</inter-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OPB-51602</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">termined</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">advanced nasopharyngeal carcinoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inter-ref id="intref0020" xlink:href="ctgov:NCT02058017" xlink:type="simple">NCT02058017</inter-ref>
                        </entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">C188-9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SH2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase I</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">recruiting</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">breast cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inter-ref id="intref0025" xlink:href="ctgov:NCT03195699" xlink:type="simple">NCT03195699</inter-ref>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:legend>
                  <ce:simple-para id="tspara0055" view="all">Note: n/d = not determined.</ce:simple-para>
               </ce:legend>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Review article</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523419310748-ad6dcc97e995f64fad756b46736b96ef">
                  <ce:given-name>Qiuyao</ce:given-name>
                  <ce:surname>Huang</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523419310748-43ce6d1d4a6b51adb34dee8ef2876748">
                  <ce:given-name>Yan</ce:given-name>
                  <ce:surname>Zhong</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0025" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523419310748-46612b4fc96932376acae709c45d44c2">
                  <ce:given-name>Hui</ce:given-name>
                  <ce:surname>Dong</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523419310748-cd61eeadc2c9c766ce30d299701035cf">
                  <ce:given-name>Qiyao</ce:given-name>
                  <ce:surname>Zheng</ce:surname>
                  <ce:cross-ref id="crosref0035" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523419310748-40f6aed47a8d178822d7b4b8d0d1aecf">
                  <ce:given-name>Shuo</ce:given-name>
                  <ce:surname>Shi</ce:surname>
                  <ce:cross-ref id="crosref0040" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523419310748-7ec86fef2ee338d0640997090d937330">
                  <ce:given-name>Kai</ce:given-name>
                  <ce:surname>Zhu</ce:surname>
                  <ce:cross-ref id="crosref0045" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523419310748-f9bce4104088fe95bb9a8275a7bda71d">
                  <ce:given-name>Xinming</ce:given-name>
                  <ce:surname>Qu</ce:surname>
                  <ce:cross-ref id="crosref0050" refid="aff3">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" orcid="0000-0003-1511-2614" author-id="S0223523419310748-6ec166574fb71482370fe3bb67afbb72">
                  <ce:given-name>Wenhao</ce:given-name>
                  <ce:surname>Hu</ce:surname>
                  <ce:cross-ref id="crosref0055" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au9" author-id="S0223523419310748-621f02de492ac727d20a4ff7daeb084c">
                  <ce:given-name>Xiaolei</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0060" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0065" refid="cor2">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au10" orcid="0000-0001-5650-4396" author-id="S0223523419310748-5b4c8c93ea521dfadd3c3468180e80bc">
                  <ce:given-name>Yuanxiang</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="crosref0070" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0075" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523419310748-ee0c5afe0c95bbae2700a7478b445051">
                  <ce:label>a</ce:label>
                  <ce:textfn>Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Guangdong Key Laboratory of Chiral Molecule and Drug Discovery</sa:organization>
                     <sa:organization>School of Pharmaceutical Sciences</sa:organization>
                     <sa:organization>Sun Yat-Sen University</sa:organization>
                     <sa:city>Guangzhou</sa:city>
                     <sa:postal-code>510006</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">Guangdong Key Laboratory of Chiral Molecule and Drug Discovery, Sun Yat-Sen University, Guangzhou, 510006, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523419310748-21b56bd54e49c36272e4aa770d66c8db">
                  <ce:label>b</ce:label>
                  <ce:textfn>Guangdong Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Guangdong Key Laboratory of New Drug Design and Evaluation</sa:organization>
                     <sa:organization>School of Pharmaceutical Sciences</sa:organization>
                     <sa:organization>Sun Yat-Sen University</sa:organization>
                     <sa:city>Guangzhou</sa:city>
                     <sa:postal-code>510006</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">Guangdong Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff3" affiliation-id="S0223523419310748-092beff6ae0ab3f8ca00a192a7213569">
                  <ce:label>c</ce:label>
                  <ce:textfn>Innovation Practice Center, Changchun University of Chinese Medicine, Changchun, 130117, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Innovation Practice Center</sa:organization>
                     <sa:organization>Changchun University of Chinese Medicine</sa:organization>
                     <sa:city>Changchun</sa:city>
                     <sa:postal-code>130117</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0020">Innovation Practice Center, Changchun University of Chinese medicine, Changchun, 130117, China</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">Q.H. and Y.Z. contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="2" month="11" year="2019"/></ce:date-received>
            <ce:date-revised day="27" month="11" year="2019"/></ce:date-revised>
            <ce:date-accepted day="27" month="11" year="2019"/></ce:date-accepted>
            <ce:abstract class="author" id="abs0010" xml:lang="en" view="all"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">As a transcription factor, STAT3 protein transduces extracellular signals to the nucleus and then activates transcription of target genes. STAT3 has been well validated as an attractive anticancer target due to its important roles in cancer initiation and progression. Identification of specific and potent STAT3 inhibitors has attracted much attention, while there has been no STAT3 targeted drug approved for clinical application. In this review, we will briefly introduce STAT3 protein and review its role in multiple aspects of cancer, and systematically summarize the recent advances in discovery of STAT3 inhibitors, especially the ones discovered in the past five years. In the last part of the review, we will discuss the possible new strategies to overcome the difficulties of developing potent and specific STAT3 inhibitors and hope to shed light on future drug design and inhibitor optimization.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523419310748/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords class="keyword" id="kwrds0010" xml:lang="en" view="all">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>STAT3</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Anticancer target</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Small molecular inhibitor</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0025" view="all">STAT3 is a dual-functional protein with ability of signal transduction and activation of gene transcription. Under physiological conditions, it mediates cell proliferation, differentiation, apoptosis, survival, immune function, angiogenesis and other important cellular processes in response to stimulation of a large number of cytokines and growth factors [<ce:cross-ref id="crosref0080" refid="bib1">1</ce:cross-ref>,<ce:cross-ref id="crosref0085" refid="bib2">2</ce:cross-ref>]. Normal STAT3 signaling is tightly controlled in standard cellular response. However, constitutive STAT3 activation occurs frequently in a variety of human cancers [<ce:cross-refs id="crosrefs0010" refid="bib3 bib4 bib5">3–5</ce:cross-refs>]. Overwhelming preclinical and clinical evidences demonstrate the pivotal involvement of STAT3 in promoting several hallmarks of cancer [<ce:cross-refs id="crosrefs0015" refid="bib6 bib7 bib8">6–8</ce:cross-refs>]. Furthermore, STAT3 is found persistently hyperactivated and associates with resistance to chemotherapy and poor prognosis [<ce:cross-refs id="crosrefs0020" refid="bib6 bib7 bib8">6–8</ce:cross-refs>]. Aberrant STAT3 activity is also observed in immune cells where it restrains anti-tumor immune response through upregulation of immunosuppressive factors and downregulation of immune activation factors [<ce:cross-ref id="crosref0090" refid="bib9">9</ce:cross-ref>,<ce:cross-ref id="crosref0095" refid="bib10">10</ce:cross-ref>]. On the other hand, although the persistent activation of STAT3 can be attributed to multiple mechanisms [<ce:cross-ref id="crosref0100" refid="bib11">11</ce:cross-ref>,<ce:cross-ref id="crosref0105" refid="bib12">12</ce:cross-ref>], the mutation of STAT3 itself has recently drawn wide attentions, owing to the fact that more and more mutations in key active sites have been found in cancer patients. The gain-of-function STAT3 mutations closely associate with the occurrence and progression of cancer [<ce:cross-ref id="crosref0110" refid="bib13">13</ce:cross-ref>]. Taken together, numerous studies have demonstrated the validation of STAT3 as an anticancer target and development of potent and specific STAT3 inhibitors is still an attracting approach for cancer therapy.</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">STAT3 structure and signaling pathway</ce:section-title>
                  <ce:para id="p0030" view="all">The STAT family is comprised of seven proteins including STAT1, STAT2, STAT3, STAT4, STAT5α, STAT5β and STAT6 [<ce:cross-ref id="crosref0115" refid="bib14">14</ce:cross-ref>] Among them, STAT3 was originally discovered as an acute-phase response factor (APRF) in IL-6 inflammatory response process [<ce:cross-ref id="crosref0120" refid="bib14">14</ce:cross-ref>]. It consists of about 770 amino acids with a relative molecular weight of 88 kDa. Four isoforms of STAT3 have been identified in mammals including STAT3α, STAT3β, STAT3γ and STAT3δ. They usually contain six structural domains (<ce:cross-ref id="crosref0125" refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>A), including the N-terminal domain, coiled-coil domain, DNA-binding domain, linker domain, SH2 domain and transactivation domain, each of which play different roles in the process of signal transduction and activation of gene transcription. In addition, STAT3 has two important phosphorylation sites, Tyr705 and Ser727(<ce:cross-ref id="crosref0130" refid="fig1">Fig. 1</ce:cross-ref>). The N-terminal domain performs important functions for STAT3 dimers nuclear translocation and subsequently cooperative DNA binding [<ce:cross-refs id="crosrefs0025" refid="bib15 bib16 bib17">15–17</ce:cross-refs>]. The coiled-coil domain mediates the interaction of STAT3 with other proteins. The DNA binding domain recognizes specific DNA sequence and then forms the STAT3-DNA complexes. The linker domain is involved in the interaction with cellular transcriptional system. The SH2 domain is crucial for STAT3 binding to the phosphotyrosine residues on the kinase receptors, resulting in the following phosphorylation of STAT3 by tyrosine kinase. The SH2 domain is also critical for STAT3 dimerization via reciprocal interactions between the phosphorylated Tyr705 within one monomer and the SH2 domain within the other monomer. There are three important solvent-accessible sub-pockets in the SH2 domain which can be targeted by small-molecule inhibitors (<ce:cross-ref id="crosref0135" refid="fig1">Fig. 1</ce:cross-ref>B), and will be discussed detailly in section <ce:cross-ref id="crosref0140" refid="sec5">5</ce:cross-ref>. The critical phosphorylation sites, Tyr705 and Ser727 are essential for STAT3 activation and subsequent dimerization.</ce:para>
                  <ce:para id="p0035" view="all">STAT3 can be activated by the binding of a variety of cytokines, hormones and growth factors to their cell surface receptors (<ce:cross-ref id="crosref0145" refid="fig1">Fig. 1</ce:cross-ref>C). In canonical Janus kinase (JAK)-STAT3 signaling pathway, ligands bind to the receptors on the cell membrane and lead to receptors dimerization [<ce:cross-ref id="crosref0150" refid="bib18">18</ce:cross-ref>,<ce:cross-ref id="crosref0155" refid="bib19">19</ce:cross-ref>]. Then, receptor dimers recruit and activate JAK kinase proteins in the cytoplasm. Activated JAKs phosphorylate the tyrosine residue of receptors where inactive STAT3 binds through the SH2 domain. Subsequently JAKs phosphorylate Tyr705 residue of STAT3 and activate STAT3. Nonreceptor tyrosine kinases, Src and Abl, are also able to activate STAT3 [<ce:cross-ref id="crosref0160" refid="bib20">20</ce:cross-ref>,<ce:cross-ref id="crosref0165" refid="bib21">21</ce:cross-ref>]. Activated STAT3 proteins form dimers and then translocate from the cytoplasm to the nucleus where the dimers bind to STAT3-specific DNA-response elements and regulate the expression of STAT3 target genes. The downstream genes may mediate cell proliferation, apoptosis, differentiation, survival, immune response, angiogenesis and other important physiological processes.</ce:para>
                  <ce:para id="p0040" view="all">Tyrosine phosphorylation and subsequent dimerization of STAT3 are critical steps in the canonical JAK-STAT3 signaling pathway. Although phosphorylation at Tyr705 is required for dimerization in most case, there are evidences that STAT3 enable to dimerize in the absence of phosphorylation of Tyr705 in the non-canonical STAT3 signaling pathway [<ce:cross-ref id="crosref0170" refid="bib22">22</ce:cross-ref>]. Specifically, acetylation at Lys685 of STAT3 is reported to stabilize STAT3 dimers and to be necessary for its full transcriptional activity [<ce:cross-ref id="crosref0175" refid="bib23">23</ce:cross-ref>]. Besides homodimerization, STAT3 can also form heterodimers with STAT1 and therefore translocate into the nucleus to regulate expression of target genes [<ce:cross-ref id="crosref0180" refid="bib24">24</ce:cross-ref>]. Apart from regulating gene expression as a transcription factor, STAT3 may also play functions through epigenetic regulation such as DNA methylation and chromatin modification [<ce:cross-ref id="crosref0185" refid="bib25">25</ce:cross-ref>,<ce:cross-ref id="crosref0190" refid="bib26">26</ce:cross-ref>]. In addition to the well-known cytoplasmic location, STAT3 is also detected in mitochondrial fractions and contributes to regulation of mitochondrial electron transport chain (ETC) [<ce:cross-ref id="crosref0195" refid="bib27">27</ce:cross-ref>]. Taken together, STAT3 signaling can be activated by distinct mechanisms and exerts multiple physiological functions in normal cells. Moreover, STAT3 signaling is tightly controlled by negative regulatory factors, such as the suppressors of cytokine signaling (SOCS) and the protein tyrosine phosphatases (PTPs), to maintain transient activation state under physiological conditions [<ce:cross-ref id="crosref0200" refid="bib28">28</ce:cross-ref>].</ce:para>
               </ce:section>
               <ce:section id="sec3" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0040">Constitutive STAT3 activation in human cancers</ce:section-title>
                  <ce:para id="p0045" view="all">Aberrant STAT3 activation occurs frequently in a variety of solid tumors and hematological malignancies. A large number of studies show the critical role of persistent STAT3 activation in the context of malignant transformation and tumorigenesis. In this section, we will briefly review its suggested roles in cancer and its potential as an anticancer target.</ce:para>
                  <ce:para id="p0050" view="all">Incidence of aberrant STAT3 signaling has been observed in solid tumors [<ce:cross-ref id="crosref0205" refid="bib7">7</ce:cross-ref>] including breast, melanoma, head and neck squamous cell carcinoma (HNSCC), prostate, colon, pancreatic, renal, ovarian, and lung. One of the first evidence of constitutive STAT3 activation was found in breast cancer model [<ce:cross-ref id="crosref0210" refid="bib29">29</ce:cross-ref>]. Hyper-active STAT3 signaling was subsequently detected in breast cancer cell lines, tumor models, and patient samples [<ce:cross-ref id="crosref0215" refid="bib30">30</ce:cross-ref>]. Aberrant STAT3 activation promotes proliferation and survival of breast cancer cell and enhances resistance to chemotherapy by upregulating Bcl-XL, Bcl-2 and surviving proteins [<ce:cross-ref id="crosref0220" refid="bib29">29</ce:cross-ref>,<ce:cross-ref id="crosref0225" refid="bib30">30</ce:cross-ref>]. Constitutive STAT3 activation also participates in maintenance of the melanoma phenotype and tumor metastasis and promotes cancer cell growth and survival by up-regulating of Bcl-XL and Mcl-1 [<ce:cross-ref id="crosref0230" refid="bib31">31</ce:cross-ref>,<ce:cross-ref id="crosref0235" refid="bib32">32</ce:cross-ref>]. In addition, persistent activated STAT3 could upregulate vascular endothelial growth factor (VEGF) and promotes the melanoma invasion and metastasis [<ce:cross-ref id="crosref0240" refid="bib33">33</ce:cross-ref>]. Abnormally active STAT3 is also detected in HNSCC and regulates downstream genes that control cell growth and survival of HNSCC, including cyclin D1, VEGF and Bcl-XL [<ce:cross-ref id="crosref0245" refid="bib34">34</ce:cross-ref>,<ce:cross-ref id="crosref0250" refid="bib35">35</ce:cross-ref>]. It is also reported that STAT3 is constitutively activated with a high frequency in prostate cancer cells [<ce:cross-ref id="crosref0255" refid="bib36">36</ce:cross-ref>]. Studies reveal that abnormal STAT3 activation upregulates the expression of antiapoptotic proteins, such as Bcl-XL and Mcl-1 in prostate cancer [<ce:cross-ref id="crosref0260" refid="bib36">36</ce:cross-ref>,<ce:cross-ref id="crosref0265" refid="bib37">37</ce:cross-ref>]. Persistent STAT3 activation is found to be promoted by IL-6 and VEGF and upregulates expression of downstream genes in brain cancer [<ce:cross-ref id="crosref0270" refid="bib38">38</ce:cross-ref>]. These studies indicate that targeting constitutively active STAT3 may be a feasible strategy for cancer therapy.</ce:para>
                  <ce:para id="p0055" view="all">In addition to the observation of hyperactive STAT3 in solid tumors, constitutive STAT3 activation is also found in a variety of hematological malignancies including multiple myeloma, anaplastic large T cell lymphoma (ALCL), EBV-related Burkitt’s lymphoma, herpes simplex virus saimiri-dependent T cell lymphoma, cutaneous T cell lymphomas and leukemias [<ce:cross-ref id="crosref0275" refid="bib39">39</ce:cross-ref>,<ce:cross-ref id="crosref0280" refid="bib40">40</ce:cross-ref>]. The aberrant STAT3 signaling is involved in multiple processes of hematopoietic cancer. STAT3 can also be activated by various cytokines to promote deterioration of blood cancers, such as IL-6 in multiple myeloma, IL-12 in cutaneous T cell lymphoma and erythropoietin (EPO) in erythroleukemia [<ce:cross-ref id="crosref0285" refid="bib10">10</ce:cross-ref>]. Moreover, deficiency of negative regulators in STAT3 signaling such as SOCS may also contribute to constitutive activation of STAT3 in these tumors [<ce:cross-ref id="crosref0290" refid="bib41">41</ce:cross-ref>]. Except for critical role in cancer progression, some studies suggest STAT3 is a positive contributor in the early phases of carcinogenesis and required for cancer stem cell status maintenance [<ce:cross-refs id="crosrefs0030" refid="bib42 bib43 bib44 bib45">42–45</ce:cross-refs>]. Therefore, inhibition of STAT3 may block carcinogenesis at early stage of cancer development and is beneficial for cancer prevention.</ce:para>
                  <ce:para id="p0060" view="all">Besides upregulation of upstream stimulation and lack of negative regulation leading to constitutive STAT3 activation, mutations of STAT3 itself also contribute to persistent activation of STAT3 signaling. With the application of next generation sequencing technology in clinic, more and more STAT3 mutations are figured out in human cancers [<ce:cross-ref id="crosref0295" refid="bib13">13</ce:cross-ref>]. Some studies have revealed the closed association between STAT3 mutants and hematopoietic cancer progression [<ce:cross-ref id="crosref0300" refid="bib46">46</ce:cross-ref>,<ce:cross-ref id="crosref0305" refid="bib47">47</ce:cross-ref>]. Several mutational hotspots of STAT3, including Y640F (17%), D661V (9%), D661Y (9%), N647I (4%) and D661H (1%), have been detected in T-cell large granular leukemia (T-LGL) patients and chronic lymphoproliferative disorders of NK cells (CLPD-NK) patients [<ce:cross-ref id="crosref0310" refid="bib46">46</ce:cross-ref>]. These mutations are located in SH2 domain that mediates the dimerization and activation of STAT3. Functional experiments <ce:italic>in vivo</ce:italic> and <ce:italic>in vitro</ce:italic> indicate that mutant STAT3 can continuously activate and regulate downstream target gene expression [<ce:cross-ref id="crosref0315" refid="bib46">46</ce:cross-ref>,<ce:cross-ref id="crosref0320" refid="bib47">47</ce:cross-ref>]. Compared with wild-type STAT3, STAT3 mutants induce higher expression of target genes and thereby promote cancer progression. Studies of mutant STAT3 in T-LGL reveals a positive relationship between STAT3 mutants and the stages of cancer development [<ce:cross-ref id="crosref0325" refid="bib46">46</ce:cross-ref>]. Two highly frequent mutants K658 N and Y640F are also found in inflammatory liver tumors [<ce:cross-ref id="crosref0330" refid="bib13">13</ce:cross-ref>]. Another study indicates that over-expression of STAT3 Y640F mutant in mouse bone marrow transplantation model can induce myeloid malignancies [<ce:cross-ref id="crosref0335" refid="bib48">48</ce:cross-ref>]. In addition, activating STAT3 mutations are also detected in the DNA binding domain and the coiled-coil domain，which is also associated with carcinogenesis and cancer progression, although the frequency of mutations is much lower [<ce:cross-ref id="crosref0340" refid="bib47">47</ce:cross-ref>]. For example, M206K mutation, which locates in the coiled-coil domain and promotes STAT3 signaling activity and cell proliferation, is identified in diffuse large B cell lymphoma (DLBCL). The frequency of mutation is higher in subset of DLBCLs with CD30 expression and associates with poor prognosis [<ce:cross-ref id="crosref0345" refid="bib49">49</ce:cross-ref>,<ce:cross-ref id="crosref0350" refid="bib50">50</ce:cross-ref>]. STAT3 is predominantly mutated in hematopoietic neoplasms, especially in T-LGL leukemia (30–40% mutation rate), but not significantly mutated in other cancers beyond T-LGL, CLPD-NK and DLBCL [<ce:cross-ref id="crosref0355" refid="bib10">10</ce:cross-ref>,<ce:cross-refs id="crosrefs0035" refid="bib46 bib47 bib48 bib49 bib50">46–50</ce:cross-refs>]. But given the closed relationship between activating STAT3 mutation and cancer progress, especially in relation to the poor prognosis, development of specific inhibitors targeting STAT3 mutants might benefit these hematopoietic cancer with higher rate of mutations.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0045">STAT3 and immunotherapy</ce:section-title>
                  <ce:para id="p0065" view="all">Immunotherapy has been considered a promising strategy for cancer treatment and has received significant progress over the last 30 years. On the other hand, besides pivotal roles in proliferation, invasion, angiogenesis and metastasis of human cancers, STAT3 is also reported to play critical functions in modulation of tumor microenvironment and immune response, and has been considered as a promising target to improve the efficacy of cancer immunotherapy.</ce:para>
                  <ce:para id="p0070" view="all">Takeda et al. firstly identified STAT3 as a negative regulator of T helper 1 (Th1) cell immune activity in 1999 [<ce:cross-ref id="crosref0360" refid="bib51">51</ce:cross-ref>]. Lack of STAT3 activity in macrophages and neutrophils enhances Th1 activity in mouse model. Many tumor-derived factors, such as IL-6, IL-10 and VEGF, which activate STAT3, also show hyper-activity in tumor-associated immune cells. Such positive feed-forward loop supports the constitutive activation of STAT3 in tumor environment, and then persistently activated STAT3 inhibits both innate and adaptive immunity. Moreover, STAT3 promotes Th17 maturation and differentiation by regulating IL-17 production [<ce:cross-ref id="crosref0365" refid="bib9">9</ce:cross-ref>,<ce:cross-ref id="crosref0370" refid="bib51">51</ce:cross-ref>]. Th17 cells can be converted into regulator T cells, thereby promoting tumor-associated immunosuppression. Hyper-activated STAT3 also promotes secretion of IL-10 and TGF-β in regulatory T cells, therefore inhibiting the function of CD8<ce:sup loc="post">+</ce:sup> T cells [<ce:cross-ref id="crosref0375" refid="bib52">52</ce:cross-ref>]. Moreover, STAT3 activation can globally suppress maturation of dendritic cells (DCs), a highly differentiated monocyte, which contributes to the antigen-presenting process in human immune system [<ce:cross-ref id="crosref0380" refid="bib53">53</ce:cross-ref>]. It has been demonstrated that tumor-induced immune related factors in the tumor microenvironment play a critical role for immune response. Highly overexpressed STAT3 also downregulates the expression of IFNβ, IFN-γ, IL-12, CD80, CD86, CC-chemokine ligand 5 (CCL5) and CXC-chemokine ligand 10 (CXCL-10) in tumor microenvironment to help tumor cells escape from immune system [<ce:cross-ref id="crosref0385" refid="bib52">52</ce:cross-ref>,<ce:cross-ref id="crosref0390" refid="bib54">54</ce:cross-ref>,<ce:cross-ref id="crosref0395" refid="bib55">55</ce:cross-ref>].</ce:para>
                  <ce:para id="p0075" view="all">The programmed death ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) axis is one of the most important checkpoint pathways in immune response system. It suppresses the effector functions of activated T cells and autoimmune responses through T-cell exhaustion. Targeted therapies using anti-PD-L1 and anti-PD-1 antibodies against components of this pathway have been shown promising outcomes to reduce tumor burden in cancer patients. A great number of studies indicate that multiple oncogenic signaling pathways including JAK/STAT3 strictly regulate the expression of PD-L1 in cancer cells [<ce:cross-refs id="crosrefs0040" refid="bib56 bib57 bib58 bib59">56–59</ce:cross-refs>]. It is also reported that STAT3 binds to the PD-L1 promoter and regulates its expression transcriptionally. For example, binding STAT3 to the gene promoter region is required for the PD-L1 gene expression, which was verified by gel electromobility shift and chromatin immunoprecipitation assays in T cell lymphoma cells [<ce:cross-ref id="crosref0400" refid="bib58">58</ce:cross-ref>]. STAT3 also upregulates expression of PD-L1 in nasopharyngeal carcinoma driven by Epstein-Barr virus [<ce:cross-ref id="crosref0405" refid="bib59">59</ce:cross-ref>]. Moreover, activating STAT3 mutations promote expression of PD-L1 in NKTL cells, while STAT3 inhibition and silencing decreases PD-L1 expression [<ce:cross-ref id="crosref0410" refid="bib56">56</ce:cross-ref>]. Given the role of STAT3 in immune activity and the correlation of PD-L1 and STAT3 signaling pathway, the combination of immunotherapy, especially PD-1/PD-L1 antibodies, and STAT3 specific inhibitors might be a promising therapeutic approach for cancer treatment. In summary, STAT3 signaling promotes cross-talking between tumor cells, dendritic cells, and diverse immune-cell subsets including tumor-associated regulatory T cells to form an immunosuppressive network. Multilevel interactions between STAT3, tumor cells and immune cells facilitate immunosuppression, tumorigenesis and cancer progression. STAT3 also contributes to immunosuppression through regulation expression of PD-L1, IDO1 and secretion of immunosuppressive factors [<ce:cross-refs id="crosrefs0045" refid="bib55 bib56 bib57">55–57</ce:cross-refs>,<ce:cross-ref id="crosref0415" refid="bib60">60</ce:cross-ref>,<ce:cross-ref id="crosref0420" refid="bib61">61</ce:cross-ref>]. Therefore, inhibition of STAT3 may overcome immunosuppression in the tumor microenvironment and enhance efficacy of cancer immunotherapy.</ce:para>
               </ce:section>
               <ce:section id="sec5" view="all">
                  <ce:label>5</ce:label>
                  <ce:section-title id="sectitle0050">STAT3 inhibitors</ce:section-title>
                  <ce:para id="p0080" view="all">As a transcription factor, STAT3 molecules transduce extracellular signals from the surface membrane to the nucleus where they bind to specific DNA substrate and promote the transcription of target genes. Therefore, two major distinct strategies have been employed to develop inhibitors to block STAT3 signaling and activity in the past two decades [<ce:cross-ref id="crosref0425" refid="bib62">62</ce:cross-ref>,<ce:cross-ref id="crosref0430" refid="bib63">63</ce:cross-ref>]. One is the development of inhibitors targeting upstream molecules, such as JAKs and Src; the other one focuses on directly targeting STAT3 protein. Since the upstream molecules are involved in intricate signaling pathways, their inhibitors may elicit rather broad spectrum of kinase inhibition and lack specificity for STAT3 signaling pathway, thereby resulting in off-target toxicities. On the other hand, the upstream kinases inhibitors of STAT3 signaling pathway have been reviewed in detail in the previous reviews [<ce:cross-ref id="crosref0435" refid="bib62">62</ce:cross-ref>,<ce:cross-ref id="crosref0440" refid="bib63">63</ce:cross-ref>], so this part will not be duplicated here.</ce:para>
                  <ce:para id="p0085" view="all">Direct STAT3 inhibitors can be classified into different categories in view of their distinct mechanisms of action, including inhibition of STAT3 phosphorylation, dimerization, nuclear translocation, and inhibition of STAT3 DNA-binding activity. In order to simplify the sum-up of these inhibitors and shed light on the future STAT3 inhibitor discovery, two groups will be classified based on their opposite binding modes of action: noncovalent STAT3 inhibitors and covalent ones. Noncovalent inhibitors block STAT3 signaling via noncovalent electrostatic interactions (such as hydrogen bond, van der Waals attraction, ionic bond, and hydrophobic effect) with STAT3, which can be rapidly dissociated. Whereas covalent inhibitors inactivate STAT3 by forming covalent bonds with nucleophilic residues (such as cysteine) within STAT3, and show longer residue time and stronger inhibitory activities than noncovalent ones.</ce:para>
                  <ce:section id="sec5.1" view="all">
                     <ce:label>5.1</ce:label>
                     <ce:section-title id="sectitle0055">Noncovalent STAT3 inhibitors</ce:section-title>
                     <ce:para id="p0090" view="all">Since STAT3 dimerization and subsequent DNA-binding are the critical steps in the whole signaling pathway, direct STAT3 inhibitors are mainly designed and developed to target the SH2 domain or the DNA binding domain. Based on the different binding sites, noncovalent STAT3 inhibitors can be classified into two categories: (1) noncovalent STAT3 inhibitors targeting the SH2 domain; (2) noncovalent STAT3 inhibitors targeting the DNA binding domain. In addition, there are also a large of researches involving development of potential STAT3 inhibitors, whose binding sites are not clarified so far, and we will combine them together as other noncovalent STAT3 inhibitor.</ce:para>
                     <ce:section id="sec5.1.1" view="all">
                        <ce:label>5.1.1</ce:label>
                        <ce:section-title id="sectitle0060">Noncovalent STAT3 inhibitors targeting SH2 domain</ce:section-title>
                        <ce:para id="p0095" view="all">As described in section <ce:cross-ref id="crosref0445" refid="sec2">2</ce:cross-ref>, the SH2 domain comprises of three sub-pockets that can be targeted by small molecule STAT3 inhibitors (<ce:cross-ref id="crosref0450" refid="fig1">Fig. 1</ce:cross-ref>B), including: (1) the phosphorylated tyrosine 705 (pTyr705)-recognition site (labeled as the pY sub-pocket); (2) a side-pocket (labeled as pY-X sub-pocket); (3) the Leu706-recognition site (labeled as pY+1 sub-pocket). The pY pocket is composed of Lys591, Ser611, Glu612, Ser613, and Arg609. In the process of STAT3 homodimerization, pTyr705 residue within one monomer forms hydrogen bonds and salt bridges with above residues within the other monomer, especially Arg609 and Ser611 among others. The pY+1 pocket that is surrounded by Thr620, Trp623, Lys626, Gln635, Val 637, Ile659, is mainly hydrophobic, as indicated by the lack of hydrogen bond formation in this region. The pY-X pocket is specific for STAT3 and associates with the selectivity of STAT3 inhibitors, which consists of typical hydrophobic residues deep inside the pocket, such as Glu594, Arg595, Ile597, Ile634. However, it is noteworthy that the interactions with these three sub-pockets do not contribute equally to the binding affinity of STAT3 inhibitors, of which a large portion of the binding energy arises from the interaction with the pY sub-pocket. So many research groups are striving to discover more potent and drug-like scaffolds to target this sub-pocket. Therefore, noncovalent STAT3 inhibitors targeting the SH2 domain will be assorted based on their different fragments binding to the pY sub-pocket.</ce:para>
                        <ce:section id="sec5.1.1.1" view="all">
                           <ce:label>5.1.1.1</ce:label>
                           <ce:section-title id="sectitle0065">Phosphate analogues</ce:section-title>
                           <ce:para id="p0100" view="all">The early identified STAT3 inhibitors targeting SH2 domain are peptides and peptidomimetics [<ce:cross-ref id="crosref0455" refid="bib62">62</ce:cross-ref>]. McMurray group [<ce:cross-refs id="crosrefs0050" refid="bib64 bib65 bib66 bib67 bib68">64–68</ce:cross-refs>], and Wang team [<ce:cross-ref id="crosref0460" refid="bib69">69</ce:cross-ref>,<ce:cross-ref id="crosref0465" refid="bib70">70</ce:cross-ref>] made significant advances on the discovery of potent peptidomimetic STAT3 inhibitors incorporating a phosphorylated tyrosine residue. Since these researches had been reviewed in the previous publications [<ce:cross-ref id="crosref0470" refid="bib62">62</ce:cross-ref>,<ce:cross-ref id="crosref0475" refid="bib71">71</ce:cross-ref>] at great length, they will not be included in this perspective. Compared with peptides or peptidomimetics, small molecules have the advantages of high cell permeability, good bioavailability and strong physicochemical stability. So small molecule STAT3 inhibitors were developed based on the phosphate group, which forms hydrogen bonds and salt interactions with the pY sub-pocket.</ce:para>
                           <ce:para id="p0105" view="all">Turkson et al. [<ce:cross-ref id="crosref0480" refid="bib72">72</ce:cross-ref>] initially identified a phosphopeptide with the sequence of PY*LKTK (Y* representing phosphorylated tyrosine), derived from the dimerization interface of STAT3, to disrupt STAT3 dimerization, whose IC<ce:inf loc="post">50</ce:inf> value for inhibition of STAT3 DNA-binding activity <ce:italic>in vitro</ce:italic> was determined to be 235 μM by an electrophoretic mobility shift assay (EMSA). Analysis of alanine scanning mutagenesis and deletion verified and simplified the active sequence to tripeptides [<ce:cross-ref id="crosref0485" refid="bib72">72</ce:cross-ref>], such as PY*L (compound <ce:bold>1</ce:bold>, <ce:cross-ref id="crosref0490" refid="fig2">Fig. 2</ce:cross-ref>
                              <ce:float-anchor refid="fig2"/></ce:float-anchor>) and AY*L (compound <ce:bold>2</ce:bold>, <ce:cross-ref id="crosref0495" refid="fig2">Fig. 2</ce:cross-ref>), with the IC<ce:inf loc="post">50</ce:inf> values of 182 and 217 μM respectively in inhibiting STAT3 DNA-binding activity <ce:italic>in vitro</ce:italic>. With the aim of reducing tripeptide characteristics and size, the leads were modified to produce a series of small molecules by replacing the proline or alanine with aromatic groups [<ce:cross-ref id="crosref0500" refid="bib73">73</ce:cross-ref>]. Substitution of proline with 4-cyanobenzoate afforded the representative compound <ce:bold>3</ce:bold> (ISS610, <ce:cross-ref id="crosref0505" refid="fig2">Fig. 2</ce:cross-ref>), which improved the inhibition of STAT3 DNA binding activity with the IC<ce:inf loc="post">50</ce:inf> of 42 μM. However, compound <ce:bold>4</ce:bold> (<ce:cross-ref id="crosref0510" refid="fig2">Fig. 2</ce:cross-ref>), the non-phosphorylated form of compound <ce:bold>3</ce:bold>, had no effect on STAT3 DNA-binding activity <ce:italic>in vitro</ce:italic>, demonstrating the importance of interactions between phosphate group and the pY sub-pocket.</ce:para>
                           <ce:para id="p0110" view="all">Molecule modeling studies on compound <ce:bold>3</ce:bold> showed that only two of the three sub-pockets within SH2 domain mentioned above were accessed (pY and pY-X), with the pY+1 sub-pocket unoccupied. In order to address this problem and improve its binding affinity with STAT3, trisubstituted oxazoles or thiazoles (compound <ce:bold>5</ce:bold>, <ce:cross-ref id="crosref0515" refid="fig3">Fig. 3</ce:cross-ref>
                              <ce:float-anchor refid="fig3"/></ce:float-anchor>) were designed with two hydrophobic substituents targeting the relatively hydrophobic sub-pockets (pY+1 and pY-X) and the phosphate group binding to the pY site with the help of flexible ligand-docking studies [<ce:cross-ref id="crosref0520" refid="bib74">74</ce:cross-ref>]. Comprehensive structure–activity relationship (SAR) study demonstrated that the oxazole derivatives showed more promising inhibitory activities than thiazoles, taking the examples of compound <ce:bold>6</ce:bold> and <ce:bold>7</ce:bold> (<ce:cross-ref id="crosref0525" refid="fig3">Fig. 3</ce:cross-ref>) with the IC<ce:inf loc="post">50</ce:inf> values of 33 and 58 μM respectively for the inhibition of STAT3 DNA-binding activity <ce:italic>in vitro</ce:italic>. Compound <ce:bold>6</ce:bold> also displayed cytotoxic activities against human breast cancer cell line (MDA-MB-231, EC<ce:inf loc="post">50</ce:inf> = 180 μM) and NIH-3T3/v-src cells (EC<ce:inf loc="post">50</ce:inf> = 120 μM), both of which harbor constitutively active STAT3, while compound <ce:bold>6</ce:bold> did not show cytotoxic activity in NIH-3T3 cells even at the concentration of 1000 μM. Coordination of the sizes of R<ce:inf loc="post">1</ce:inf> and R<ce:inf loc="post">2</ce:inf> in compound <ce:bold>5</ce:bold> attracted necessary attentions, since attaching two steric fragments to the central oxazole core was not well tolerated. Incorporation of cyclohexylphenyl in compound <ce:bold>6</ce:bold> and naphthyl in <ce:bold>7</ce:bold> into oxazole afforded compound <ce:bold>8</ce:bold> (<ce:cross-ref id="crosref0530" refid="fig3">Fig. 3</ce:cross-ref>), which displayed dramatically reduced STAT3 DNAbinding inhibitory activity with the IC<ce:inf loc="post">50</ce:inf> of 255 μM.</ce:para>
                        </ce:section>
                        <ce:section id="sec5.1.1.2" view="all">
                           <ce:label>5.1.1.2</ce:label>
                           <ce:section-title id="sectitle0070">Salicylic acid analogues</ce:section-title>
                           <ce:para id="p0115" view="all">Considering the inherent low cellular membrane permeability of phosphate derivatives, dramatic efforts were made to identify drug-like small molecule STAT3 inhibitors with enhanced cell permeability and metabolic stability. In the aid of in silico structure-based high throughput virtual screening, Turkson group identified a hit (compound <ce:bold>9</ce:bold>, <ce:cross-ref id="crosref0535" refid="fig4">Fig. 4</ce:cross-ref>
                              <ce:float-anchor refid="fig4"/></ce:float-anchor>) using an <ce:italic>in vitro</ce:italic> STAT3 DNA-binding assay and EMSA analysis [<ce:cross-ref id="crosref0540" refid="bib75">75</ce:cross-ref>]. Compound <ce:bold>9</ce:bold> is characterized by a salicylic acid moiety that is a known mimetic of phenylphosphate group. Compound <ce:bold>9</ce:bold> inhibited STAT3 DNA-binding activity <ce:italic>in vitro</ce:italic> with an IC<ce:inf loc="post">50</ce:inf> of 86 μM, and induced apoptosis in breast and hepatocellular cancer cells that contain constitutively activated STAT3. Since the O-tosyl group (OTs) of compound <ce:bold>9</ce:bold> is usually recognized as a good leaving group, it is proposed that the inhibitory activities demonstrated <ce:italic>in vivo</ce:italic> might be derived from its covalent modification of STAT3 protein. Therefore, researches on verifying this hypothesis were conducted by Gunning et al. [<ce:cross-ref id="crosref0545" refid="bib76">76</ce:cross-ref>], which will be discussed in the next section.</ce:para>
                           <ce:para id="p0120" view="all">Given the moderate inhibitory activity of compound <ce:bold>9</ce:bold> against STAT3, Gunning group launched a rational drug design and discovery program to modify and optimize this small molecule with the purpose of obtaining more potent and selective STAT3 inhibitors based on the salicylic acid scaffold [<ce:cross-ref id="crosref0550" refid="bib77">77</ce:cross-ref>]. Firstly, they replaced the oxygen atom of the OTs with a nitrogen atom to stabilize the tosyl group and obtained compound <ce:bold>10</ce:bold> (<ce:cross-ref id="crosref0555" refid="fig4">Fig. 4</ce:cross-ref>). Gold docking studies revealed that the resulting tosylamide moiety accessed to the pY-X site and salicylic acid group reasonably targeted to the pY sub-pocket. But the inhibitory activity of compound <ce:bold>10</ce:bold> to disrupt STAT3 DNA binding was reduced to a negligible level with the IC<ce:inf loc="post">50</ce:inf> value above 300 μM by EMSA. Incorporating a methyl to the NH of the tosylamide (compound <ce:bold>11</ce:bold>, IC<ce:inf loc="post">50</ce:inf> > 300 μM) was also unsuccessful. Owing to the fact that compound <ce:bold>11</ce:bold> only targeted two of the three sub-pockets (pY and pY-X) within the SH2 domain, making one more contact with the third pocket (pY+1) may improve the inhibitory potency. Therefore, modifications of the NH of the amide group by incorporating hydrophobic moieties were conducted in order to make hydrophobic interactions with the pY+1 sub-pocket. It was revealed that benzyl substituted compound <ce:bold>12</ce:bold> (<ce:cross-ref id="crosref0560" refid="fig4">Fig. 4</ce:cross-ref>) displayed some recovery in activity (IC<ce:inf loc="post">50</ce:inf> = 292 μM, EMSA). Replacement of the benzyl in compound <ce:bold>12</ce:bold> with para-(phenyl)benzyl furnished compound <ce:bold>13</ce:bold> (<ce:cross-ref id="crosref0565" refid="fig4">Fig. 4</ce:cross-ref>), which inhibited STAT3 DNA binding activity with the IC<ce:inf loc="post">50</ce:inf> value of 115 μM. This enhancement might be due to additional hydrophobic interaction with the pY+1 sub-pocket as expected. <ce:italic>Para</ce:italic>-(<ce:italic>tert</ce:italic>-butyl)benzylated compound <ce:bold>14</ce:bold> (<ce:cross-ref id="crosref0570" refid="fig4">Fig. 4</ce:cross-ref>) showed slight decrease in activity (IC<ce:inf loc="post">50</ce:inf> = 194 μM) compared to compound <ce:bold>13</ce:bold>. Substitution of <ce:italic>para</ce:italic>-(<ce:italic>tert</ce:italic>-butyl)benzyl with especially hydrophobic <ce:italic>para</ce:italic>-cyclohexylbenzyl afforded compound <ce:bold>15</ce:bold> (<ce:cross-ref id="crosref0575" refid="fig4">Fig. 4</ce:cross-ref>), and led to considerable improvement in activity (IC<ce:inf loc="post">50</ce:inf> = 35 μM, EMSA) [<ce:cross-ref id="crosref0580" refid="bib78">78</ce:cross-ref>]. Moreover, compound <ce:bold>15</ce:bold> exhibited no significant inhibition of STAT1:STAT1 complex at 50 μM and no effect on STAT5:STAT5 complex even up to the concentration of 300 μM, as determined by EMSA analysis. Taken together, these data validated the practicability of the approach that forming hydrophobic interactions with the pY+1 sub-pocket via incorporating additional groups to the amide NH of compound <ce:bold>10</ce:bold> enhanced its STAT3 inhibitory activity and selectivity.</ce:para>
                           <ce:para id="p0125" view="all">In the other aspect, Gold docking studies revealed that tosyl group of compound <ce:bold>15</ce:bold> occupied to the hydrophobic pY-X sub-pocket which associates with the selectivity of STAT3 inhibitors, and Gunning group optimized this moiety to discover more potent and selective salicylic acid based analogues of compound <ce:bold>15</ce:bold>. It was revealed that replacement of sulfonamide moiety of compound <ce:bold>15</ce:bold> with hydrophobic substituents afforded more potent inhibitors, and especially that incorporating a pentafluorophenyl sulfonamide substituent to the salicylic acid moiety resulted in the most active inhibitor (compound <ce:bold>16</ce:bold>, <ce:cross-ref id="crosref0585" refid="fig4">Fig. 4</ce:cross-ref>) [<ce:cross-ref id="crosref0590" refid="bib79">79</ce:cross-ref>]. Compound <ce:bold>16</ce:bold> directly bond to STAT3 protein with the binding affinity (K<ce:inf loc="post">D</ce:inf>) of 504 nM as determined by surface plasmon resonance (SPR) analysis, and inhibited STAT3 DNA binding activity with an IC<ce:inf loc="post">50</ce:inf> value of 6.8 μM by EMSA. Compound <ce:bold>16</ce:bold> selectively inhibited growth, survival, migration, and invasion of STAT3-dependent tumor cells, such as NIH3T3/v-Src, MDA-MB-231, Panc-1, DU145, and A549 cells, but lacked cellular inhibitory activity in a range of nontarget cells, including normal NIH3T3, TE-71, NIH 3T3/v-Ras or A2780S cells without aberrantly active STAT3. When administered via intravenous injection (3 mg/kg) or oral gavage (3 mg/kg), compound <ce:bold>16</ce:bold> significantly inhibited growth of human breast (MDA-MB-231) and non–small-cell lung (A549) tumors in xenograft models, without obvious signs of toxicity [<ce:cross-ref id="crosref0595" refid="bib80">80</ce:cross-ref>].</ce:para>
                           <ce:para id="p0130" view="all">Further efforts were also made by Gunning group to optimize the pharmacokinetics (PK) properties of compound <ce:bold>16</ce:bold> via optimizing its salicylic acid fragment [<ce:cross-refs id="crosrefs0055" refid="bib81 bib82 bib83 bib84">81–84</ce:cross-refs>]. It was revealed that removing the hydroxyl group of the salicylic acid in compound <ce:bold>16</ce:bold> was well tolerated and led to a more potent STAT3 inhibitor (compound <ce:bold>17</ce:bold>) [<ce:cross-ref id="crosref0600" refid="bib81">81</ce:cross-ref>]. Compound <ce:bold>17</ce:bold> displayed a strong interaction with STAT3 (K<ce:inf loc="post">D</ce:inf> = 300 nM) in the SPR assay and preferentially inhibited STAT3 DNA binding activity with the IC<ce:inf loc="post">50</ce:inf> of 3.9 μM in the EMSA analysis, and showed no effects against STAT1 and STAT5 DNA binding activities in the parallel assay. In addition, compound <ce:bold>17</ce:bold> potently inhibited cell viability of U251MG and MDA-MB-231 with the IC<ce:inf loc="post">50</ce:inf> values of 1.9 and 4.5 μM respectively, and inhibited growth of mouse xenografts of human glioma (U251MG) and breast (MDA-MB-231) tumors at 3 mg/kg.</ce:para>
                           <ce:para id="p0135" view="all">Recently, Turkson group took an iterative medicinal chemistry program to optimize the N-methylglycinamide linker of the lead compound <ce:bold>16</ce:bold> and <ce:bold>17</ce:bold> to further improve their inhibitory potency and physicochemical properties [<ce:cross-ref id="crosref0605" refid="bib85">85</ce:cross-ref>]. Substitution at the glycine methylene group of lead <ce:bold>16</ce:bold> with methyl afforded two enantiomers, and the R-configuration <ce:bold>18</ce:bold> (<ce:cross-ref id="crosref0610" refid="fig4">Fig. 4</ce:cross-ref>) improved the inhibitory activity against STAT3 DNA-binding <ce:italic>in vitro</ce:italic> moderately with the IC<ce:inf loc="post">50</ce:inf> of 3.0 μM, while the corresponding S-configuration <ce:bold>19</ce:bold> (<ce:cross-ref id="crosref0615" refid="fig4">Fig. 4</ce:cross-ref>) displayed somewhat lower potency (IC<ce:inf loc="post">50</ce:inf> = 5.0 μM) than <ce:bold>18</ce:bold>. In addition, compound <ce:bold>18</ce:bold> strongly inhibited the viability of human metastatic melanoma C8161, 1205LU, and C81-61 cell lines harboring constitutively active STAT3, while demonstrated relatively weaker potency against the immortalized human normal melanocyte AR7119. Further SAR exploration with different substitutions at the methylene position of <ce:bold>16</ce:bold> confirmed that R-configuration analogues consistently exhibited higher activity than the S-analogues. Based on this observation, further modification of the benzoic acid moiety of <ce:bold>18</ce:bold> was conducted to improve STAT3 inhibitory potency. It was revealed that a single fluorine substitution at the 3-position of benzoic acid group (compound <ce:bold>20,</ce:bold> 
                              <ce:cross-ref id="crosref0620" refid="fig4">Fig. 4</ce:cross-ref>) led to 2-times enhancement in inhibitory potency against STAT3 DNA binding activity <ce:italic>in vitro</ce:italic> with the IC<ce:inf loc="post">50</ce:inf> of 1.8 μM and inhibited the MDA-MB-231 cell growth with the IC<ce:inf loc="post">50</ce:inf> of 3.9 μM. Considering that the alanine residue based compounds are more prone to metabolic N-demethylation, a further modification to the alanine linker was performed by joining the two methyl groups of compound <ce:bold>20</ce:bold> to form a new Pro-linker. The representative analogue <ce:bold>21</ce:bold> (<ce:cross-ref id="crosref0625" refid="fig4">Fig. 4</ce:cross-ref>) showed equivalent STAT3 DNA-binding inhibitory activity <ce:italic>in vitro</ce:italic> (IC<ce:inf loc="post">50</ce:inf> = 2.4 μM) compared to <ce:bold>20</ce:bold>, but indeed displayed much improved microsomal metabolic stability.</ce:para>
                        </ce:section>
                        <ce:section id="sec5.1.1.3" view="all">
                           <ce:label>5.1.1.3</ce:label>
                           <ce:section-title id="sectitle0075">1, 4-Naphthoquinone analogues</ce:section-title>
                           <ce:para id="p0140" view="all">For this series of compounds, especially those ones (compounds <ce:bold>22</ce:bold>–<ce:bold>24,</ce:bold> 
                              <ce:cross-ref id="crosref0630" refid="fig5">Fig. 5</ce:cross-ref>
                              <ce:float-anchor refid="fig5"/></ce:float-anchor>) discovered in earlier stage have been summarized in the previous reviews with detailed biological activities [<ce:cross-ref id="crosref0635" refid="bib62">62</ce:cross-ref>,<ce:cross-ref id="crosref0640" refid="bib63">63</ce:cross-ref>], therefore we will briefly introduce their design proposal and make a focus on the latest progresses. In order to identify novel small molecular STAT3 inhibitors, Lin et al. performed structure-based virtual screening of nearly 430000 compounds and discovered a new SH2 domain inhibitor (compound <ce:bold>22</ce:bold>) [<ce:cross-ref id="crosref0645" refid="bib86">86</ce:cross-ref>]. Compound <ce:bold>22</ce:bold> inhibited STAT3 DNA binding activity, disrupted STAT3 dimerization, and demonstrated promising inhibitory activity on STAT3-induced luciferase activity in carcinoma cells with constitutive STAT3 signaling (Caov-3 cloned cells and MDA-MB-435s cloned cells stably transfected with pLucTKS3). In addition, <ce:bold>22</ce:bold> exhibited selective anti-proliferative activity against breast carcinoma cells (MDA-MB-231, MDA-MB-435s, and MDA-MB-468) with persistently STAT3 expression over those without STAT3 overexpression (MCF-7 and MDA-MB-453). Considering the structural complexity of compound <ce:bold>22</ce:bold>, it is a hard work to optimize its STAT3 inhibitory activity and to improve cell permeability. Therefore, Li and co-workers simplified <ce:bold>22</ce:bold> to generate <ce:bold>23</ce:bold> by retaining the anthraquinone moiety as a critical pharmacophore [<ce:cross-ref id="crosref0650" refid="bib87">87</ce:cross-ref>]. Molecular docking revealed that <ce:bold>23</ce:bold> bond to the STAT3 SH2 domain in a similar way as <ce:bold>22</ce:bold> and its 1-acetyl group served as a H-bond acceptor interacting with Arg609. Compound <ce:bold>23</ce:bold> displayed similar cytotoxic activity as compound <ce:bold>22</ce:bold> against prostate cancer cell lines with persistently active STAT3.</ce:para>
                           <ce:para id="p0145" view="all">Another analogue, compound <ce:bold>24</ce:bold> [<ce:cross-ref id="crosref0655" refid="bib88">88</ce:cross-ref>], was developed by displacing the acetyl group with sulfonamide and showed higher selectivity for STAT3 than compound <ce:bold>22</ce:bold> and <ce:bold>23</ce:bold>. Computer modeling and simulation showed that sulfonamide targeted to the pY sub-pocket and formed at least 3 hydrogen bonds with Arg609, Ser611, and Ser613, while compound <ce:bold>24</ce:bold> lacked interactions with pY-X site or pY+1 site. As we mentioned above that the pY-X site is unique to STAT3, thus recovery or optimization of the binding interactions with this site may enhance the selectivity for STAT3. In the meantime, the drug-like properties of compound <ce:bold>24</ce:bold> with poor bioavailability is still defective, which need further optimization. Based on the above two considerations, Li et al. [<ce:cross-ref id="crosref0660" refid="bib89">89</ce:cross-ref>] firstly simplified the anthraquinone moiety to 1,4-naphthoquinone with the aim of improving its bioavailability, while keeping sulfonamide group because of its multiple interactions with the pY sub-pocket. And then a second group was incorporated to the C6 position of 1,4-naphthoquinone, which was proposed to bind to the pY-X sub-pocket and improve selectivity for STAT3. With the help of in silico site-directed fragment-based drug design strategy and computer docking, compound <ce:bold>25</ce:bold> (<ce:cross-ref id="crosref0665" refid="fig5">Fig. 5</ce:cross-ref>) was designed and identified. Cell-based assay revealed that compound <ce:bold>25</ce:bold> reduced the cell viability of human sarcoma cell lines with low IC<ce:inf loc="post">50</ce:inf> (0.52 μM for U2OS; 0.55 μM for RH30; and 1.39 μM for RD2). Western blot assays showed that compound <ce:bold>25</ce:bold> inhibited STAT3 phosphorylation in a dose-dependent manner in both RH30 and EW8 cell lines. Fluorescence polarization (FP) assay [<ce:cross-ref id="crosref0670" refid="bib90">90</ce:cross-ref>] validated that compound <ce:bold>25</ce:bold> bond to STAT3 SH2 domain. Compound <ce:bold>25</ce:bold> also suppressed <ce:italic>in vivo</ce:italic> tumor growth in human breast cancer MDA-MB-231 mouse xenograft. Taking advantage of advanced multiple ligand simultaneous docking, Yu et al. also designed compound <ce:bold>26</ce:bold> (<ce:cross-ref id="crosref0675" refid="fig5">Fig. 5</ce:cross-ref>) [<ce:cross-ref id="crosref0680" refid="bib91">91</ce:cross-ref>], as an orally bioavailable STAT3 inhibitor, which presented superior drug-like properties and selectivity compared with the above analogues. Compound <ce:bold>26</ce:bold> directly and selectively targeted STAT3 SH2 domain with an affinity (K<ce:inf loc="post">i</ce:inf>) of 440 nM, as determined by the FP assay. In contrast, no direct binding between <ce:bold>26</ce:bold> and STAT1/5 proteins was observed. Compound <ce:bold>26</ce:bold> exhibited promising cytotoxic activity against human breast cancer cell line, MDA-MB-231, with the IC<ce:inf loc="post">50</ce:inf> of 0.7 μM, which is 184-fold lower than that for MCF-10A normal breast epithelial cells (IC<ce:inf loc="post">50</ce:inf> = 128.9 μM). Compound <ce:bold>26</ce:bold> had desirable aqueous solubility and its oral bioavailability was measured to be 44.7% by PK study. Following-up <ce:italic>in vivo</ce:italic> studies on the antitumor efficacy demonstrated that 60% of MDA-MB-231 tumor weight and 73% of S180 tumor weight were shrunk upon treatment with compound <ce:bold>26</ce:bold> at the dose of 5 mg/kg orally administrated for 21 days. In the meantime, no damage to major organs was observed and body weight increased normally after treatment of compound <ce:bold>26</ce:bold>.</ce:para>
                           <ce:para id="p0150" view="all">Compound <ce:bold>27</ce:bold> (Napabucasin, <ce:cross-ref id="crosref0685" refid="fig5">Fig. 5</ce:cross-ref>) is reported to be an orally available cancer cell stemness inhibitor and exhibits excellent anticancer activities against diverse solid and hematologic cancers [<ce:cross-ref id="crosref0690" refid="bib92">92</ce:cross-ref>]. Several clinical trials of compound <ce:bold>27</ce:bold> are performed to evaluate its promising efficacies in patients with varying cancer types, both as a monotherapy and combination therapy [<ce:cross-ref id="crosref0695" refid="bib93">93</ce:cross-ref>]. Even though the exact target of compound <ce:bold>27</ce:bold> has yet to be fully elucidated, it is revealed that the anticancer activities of compound <ce:bold>27</ce:bold> is closely associated with the inhibition of STAT3 signaling pathway. It potently inhibited STAT3 phosphorylation, blocked nuclear translocation and decreased STAT3-mediated gene transcription. Compound <ce:bold>27</ce:bold> can be recognized as a promising lead compound to generate novel STAT3 inhibitors and subsequent objective optimization on compound <ce:bold>27</ce:bold> may focus on the improvement of specificity for STAT3 to avoid the off-targets cytotoxicities. Another natural product, compound <ce:bold>28</ce:bold> (Shikonin, <ce:cross-ref id="crosref0700" refid="fig5">Fig. 5</ce:cross-ref>) [<ce:cross-ref id="crosref0705" refid="bib94">94</ce:cross-ref>], harboring a naphthoquinone scaffold, is also reported to exhibit STAT3 inhibitory potency, but inhibits Focal adhesion kinase (FAK) and Src activation at the same time. In order to optimize the selectivity for STAT3, Yang et al. [<ce:cross-ref id="crosref0710" refid="bib95">95</ce:cross-ref>] primarily explored the interaction mode of compound <ce:bold>28</ce:bold> with STAT3 by virtual simulation and discovered that it mainly occupied the pY-X and pY sub-pockets and made hydrogen bonds with Lys591, Glu594 and Ile634. The simulation results also suggested that modification of the hydroxyl group on the side chain may further enhance the binding affinity and selectivity toward STAT3. Therefore, a scaffold growth strategy was employed to generate a series of compound <ce:bold>28</ce:bold> analogues, taking the example of the lead compound <ce:bold>29</ce:bold> (<ce:cross-ref id="crosref0715" refid="fig5">Fig. 5</ce:cross-ref>) which formed more hydrogen bonds with Gln635 and Ser636. Further <ce:italic>in vitro</ce:italic> investigation furnished the more efficient compound <ce:bold>30</ce:bold> (<ce:cross-ref id="crosref0720" refid="fig5">Fig. 5</ce:cross-ref>), which showed high anti-proliferative activity for MDA-MB-231 cells with the IC<ce:inf loc="post">50</ce:inf> value of 1.81 μM and induced cell apoptosis in MDA-MB-231 cells dose dependently. In addition, compound <ce:bold>30</ce:bold> inhibited constitutive STAT3 activation, transcriptional activity, nuclear translocation and downstream target genes expression in MDA-MB-231 cells, with no inhibitory effect on activation of STAT1 and STAT5. Furthermore, <ce:italic>in vivo</ce:italic> studies demonstrated that compound <ce:bold>30</ce:bold> notably suppressed the MDA-MB-231 cells xenografted tumor growth without obvious side effects.</ce:para>
                           <ce:para id="p0155" view="all">Although naphthoquinone analogues are designed as potent STAT3 inhibitors and induce significant anticancer responses, the undesirable properties [<ce:cross-ref id="crosref0725" refid="bib96">96</ce:cross-ref>] of these naphthoquinone derivatives are less explored. Therefore, more detailed mechanistic studies and multiple evaluations of drug-like properties for these compounds are needed for further drug discovery.</ce:para>
                        </ce:section>
                        <ce:section id="sec5.1.1.4" view="all">
                           <ce:label>5.1.1.4</ce:label>
                           <ce:section-title id="sectitle0080">Phenylsulfonamide analogues</ce:section-title>
                           <ce:para id="p0160" view="all">The COX2 inhibitor, compound <ce:bold>31</ce:bold> (Celecoxib, <ce:cross-ref id="crosref0730" refid="fig6">Fig. 6</ce:cross-ref>
                              <ce:float-anchor refid="fig6"/></ce:float-anchor>), was identified by Li and coworkers as STAT3 inhibitor by performing virtual screening of compounds from FDA approved drugs library [<ce:cross-ref id="crosref0735" refid="bib97">97</ce:cross-ref>]. Compound <ce:bold>31</ce:bold> could inhibit STAT3 phosphorylation induced by IL-6, whereas displayed little effect on the phosphorylation of STAT1 induced by interferon-γ. Meanwhile, compound <ce:bold>31</ce:bold> inhibited the viability of human colon cancer cell (HCT-116) with the IC<ce:inf loc="post">50</ce:inf> value of 43.3 μM. However, docking studies showed that it only targeted two sub-pockets of the SH2 domain with the phenylsulfonamide group binding to the pY site and the tolyl moiety occupying the pY-X site. In order to improve the inhibitory activity of compound <ce:bold>31</ce:bold>, compound <ce:bold>32</ce:bold> and <ce:bold>33</ce:bold> (<ce:cross-ref id="crosref0740" refid="fig6">Fig. 6</ce:cross-ref>) were identified through fragment-based drug design, via introducing the third substituents targeting to the pY+1 sub-pocket. Docking models demonstrated improved binding affinities for compound <ce:bold>32</ce:bold> (−8.6 kcal/mol) and <ce:bold>33</ce:bold> (−9.2 kcal/mol) compared to that of compound <ce:bold>31</ce:bold> (−6.9 kcal/mol). In the meantime, more potent inhibition of HCT-116 viability was observed for compound <ce:bold>32</ce:bold> (IC<ce:inf loc="post">50</ce:inf> = 9.7 μM) and <ce:bold>33</ce:bold> (IC<ce:inf loc="post">50</ce:inf> = 10.1 μM).</ce:para>
                           <ce:para id="p0165" view="all">Given the above sulfamide analogues expressing high selectivity for STAT3, Kong group [<ce:cross-ref id="crosref0745" refid="bib98">98</ce:cross-ref>] also designed a series of tripedal phenylsulfonamide derivatives in order to identify STAT3 inhibitors with better selectivity and improved drug-like properties, represented by the most potent compound <ce:bold>34</ce:bold> (<ce:cross-ref id="crosref0750" refid="fig6">Fig. 6</ce:cross-ref>). Molecular docking studies revealed that the phenylsulfonamide fragment of compound <ce:bold>34</ce:bold> bond to pY sub-pocket via hydrogen bond interactions with Arg609 residue, while the perfluorophenyl group occupied pY-X sub-pocket and the isopropylphenyl fragment targeted to the pY+1 sub-pocket. Compound <ce:bold>34</ce:bold> inhibited the proliferation of HCT-116 cells with the IC<ce:inf loc="post">50</ce:inf> of 6.66 μM, and markedly suppressed STAT3 phosphorylation in a dose-dependent manner, with little influence on STAT1 and STAT5 phosphorylation. In addition, compound <ce:bold>34</ce:bold> inhibited the colony formation of HCT-116 cells and induced the apoptosis. Moreover, <ce:italic>in vivo</ce:italic> anticancer efficacy study showed that compound <ce:bold>34</ce:bold> effectively suppressed the tumor growth of HCT-116 xenograft, with no significant change in body weight at the dose of 20 mg/kg.</ce:para>
                        </ce:section>
                        <ce:section id="sec5.1.1.5" view="all">
                           <ce:label>5.1.1.5</ce:label>
                           <ce:section-title id="sectitle0085">Aminotetrazole analogues</ce:section-title>
                           <ce:para id="p0170" view="all">In order to identify selective STAT3 inhibitors over STAT1, a structure-based virtual screening of a commercially available compound library followed by a luciferase-containing promoter assay was performed by Pudlo et al. [<ce:cross-ref id="crosref0755" refid="bib99">99</ce:cross-ref>] and resulted in the identification of a prospectively selective STAT3 inhibitor, compound <ce:bold>35</ce:bold> (<ce:cross-ref id="crosref0760" refid="tbl1">Table 1</ce:cross-ref>
                              <ce:float-anchor refid="tbl1"/></ce:float-anchor>), which displayed 53.9% inhibitory effect at 50 μM on STAT3 transcriptional activity with 5-fold selectivity over STAT1. Molecular docking displayed that the aminotetrazole group occupied the pY sub-pocket and formed hydrogen bonds with residues forming the sub-pocket (such as Lys591, Arg609, Ser611 and Ser613), and in the meantime that the benzyl ether moiety bond to the pY+1 site. Optimization of the para-methyl on the phenyl moiety revealed that incorporation of nitro group in <ce:bold>36</ce:bold> increased activity on STAT3 and selectivity over STAT1. Compound <ce:bold>36</ce:bold> blocked STAT3 transcriptional activity with an IC<ce:inf loc="post">50</ce:inf> value of 25.7 μM, and decreased proliferation of B9 myeloma cell line and MDA-MB-231 in a dose dependent manner. Keeping the nitro group confirmed at the para-position of phenyl, bioisosteres of tetrazole were screened to optimize the inhibitory activity and selectivity toward STAT3. Replacing the tetrazole of <ce:bold>36</ce:bold> with a carboxy acid in <ce:bold>38</ce:bold> reduced both STAT3 and STAT1 inhibitory activity to a large extent. Interestingly, non-ionizable aldehyde (<ce:bold>39</ce:bold>) and alcohol (<ce:bold>40</ce:bold>) derivatives demonstrated the same range of inhibition as <ce:bold>36</ce:bold>, but lost selectivity over STAT1. The cyanamide analogue <ce:bold>41</ce:bold> and phthalimide analogue <ce:bold>37</ce:bold> showed enhanced STAT3 inhibitory activity, but unfortunately lacked selectivity over STAT1.</ce:para>
                        </ce:section>
                        <ce:section id="sec5.1.1.6" view="all">
                           <ce:label>5.1.1.6</ce:label>
                           <ce:section-title id="sectitle0090">Quinoline analogues</ce:section-title>
                           <ce:para id="p0175" view="all">Asai et al. identified compound <ce:bold>42</ce:bold> (<ce:cross-ref id="crosref0765" refid="fig7">Fig. 7</ce:cross-ref>
                              <ce:float-anchor refid="fig7"/></ce:float-anchor>) as a novel STAT3 SH2 domain inhibitor by virtual screening using DOCK program with the crystal structure of STAT3 [<ce:cross-ref id="crosref0770" refid="bib100">100</ce:cross-ref>]. STAT3-dependent luciferase reporter gene assay validated compound <ce:bold>42</ce:bold> as a STAT3 direct inhibitor with 99% inhibitory potency at 100 μM. Fluorescence resonance energy transfer (FRET) assay showed that incubation of the HEK293 cells with compound <ce:bold>42</ce:bold> prior to IL-6 stimulation suppressed FRET signals. Treatment MDA-MB-468 with compound <ce:bold>42</ce:bold> led to a reduction in amplification of the c-Myc promoter revealed by a chromatin immunoprecipitation (Chip) assay. In contrast, a truncated analogue removing the 2-phenyl, compound <ce:bold>43</ce:bold>, lacked these activities. Compound <ce:bold>42</ce:bold> selectively inhibited DNA-binding activity of STAT3, with no effect on DNA binding activity of other STAT subtypes. Furthermore, compound <ce:bold>42</ce:bold> effectively suppressed the growth of human lymphoma cells in a SCC-3 subcutaneous xenograft model without visible toxicity via oral administration. Docking model of compound <ce:bold>42</ce:bold> with STAT3-SH2 domain illustrated that the 1,3,4-oxadiazolyl occupied the pY+1 sub-pocket and that the 2-phenyl group accessed to the pY-X sub-pocket, which explains the abolished inhibitory activity of compound <ce:bold>43</ce:bold> (<ce:cross-ref id="crosref0775" refid="fig7">Fig. 7</ce:cross-ref>) toward STAT3. However, it is noteworthy that compound <ce:bold>42</ce:bold> still suffers from the lack of interactions with the pY sub-pocket, which contributes mainly to the inhibitory activity of STAT3 dimerization as well known. Therefore, incorporation of one more appropriate group into compound <ce:bold>42</ce:bold> to recover this interaction may further improve its inhibitory effect on STAT3.</ce:para>
                        </ce:section>
                        <ce:section id="sec5.1.1.7" view="all">
                           <ce:label>5.1.1.7</ce:label>
                           <ce:section-title id="sectitle0095">Carboxylic ester analogues</ce:section-title>
                           <ce:para id="p0180" view="all">Based on the structure characteristics of STAT3-SH2 domain, Lin et al. [<ce:cross-ref id="crosref0780" refid="bib101">101</ce:cross-ref>] designed a novel series of small molecule STAT3 inhibitors, taking the example of compound <ce:bold>44</ce:bold> (<ce:cross-ref id="crosref0785" refid="tbl2">Table 2</ce:cross-ref>
                              <ce:float-anchor refid="tbl2"/></ce:float-anchor>), with the carboxylate moiety as a mimetic of phosphate to access the pY sub-pocket and di-trifluoromethyl substituted benzene designed to form hydrophobic interactions with the pY-X sub-pocket. A combination of urea and peptidyl fragment was used to link the above two groups to capture hydrogen bonds with the residues (such as Lys591, Ser636, and Gln635) located in the space between pY and pY-X sub-pockets. It was revealed that compound <ce:bold>44</ce:bold> inhibited STAT3 phosphorylation in rhabdomyosarcoma cell lines (such as RD2, RH28 and RH30) harboring constitutive STAT3 and also prevented IL-6 induced STAT3 phosphorylation and nuclear translocation. It was also observed that compound <ce:bold>44</ce:bold> treatment remarkably reduced colony formation and migration ability of the three cancer cells. Compound <ce:bold>44</ce:bold> also displayed measurable inhibitory activity against human pancreatic (PANC-1, HPAC and SW1990) and breast (MDA-MB-231) cancer cell lines with the IC<ce:inf loc="post">50</ce:inf> values in the range of 17.4–24.7 μM. Hydrolysis the carboxylate ester of <ce:bold>44</ce:bold> to free carboxylic acid <ce:bold>45</ce:bold> resulted in IC<ce:inf loc="post">50</ce:inf> values greater than 100 μM unexpectedly [<ce:cross-ref id="crosref0790" refid="bib102">102</ce:cross-ref>]. Replacement of the isopropyl (R<ce:inf loc="post">2</ce:inf> group) in <ce:bold>44</ce:bold> with bulkier groups, such as isobutyl in <ce:bold>46</ce:bold> and tert-butyl in <ce:bold>47</ce:bold>, demonstrated much increased inhibitory activity across all tested cell lines. While an aromatic phenyl group as R<ce:inf loc="post">2</ce:inf> substituent (compound <ce:bold>48</ce:bold>) was well tolerated with increased inhibitory activity compared to <ce:bold>44</ce:bold>.</ce:para>
                        </ce:section>
                        <ce:section id="sec5.1.1.8" view="all">
                           <ce:label>5.1.1.8</ce:label>
                           <ce:section-title id="sectitle0100">Carboxylic acid analogues</ce:section-title>
                           <ce:para id="p0185" view="all">In order to facilitate the identification of potent STAT3 inhibitors that can be used in clinic, Turkson group prepared a 3D quantitative structure activity relationship (QSAR) pharmacophore model firstly, and subsequent computational docking analysis based on the QSAR model identified 2, 6, 9-trisubstituted purine scaffolds as a potential skeleton to occupy the pharmacophore plot [<ce:cross-ref id="crosref0795" refid="bib103">103</ce:cross-ref>]. Forty-seven 2, 6, 9-trisubstituted purine derivatives were prepared and SPR evaluation demonstrated over one-third of them showing high binding affinity to STAT3 (K<ce:inf loc="post">D</ce:inf> < 10 μM), including the representative compounds <ce:bold>49</ce:bold>–<ce:bold>52</ce:bold> (<ce:cross-ref id="crosref0800" refid="tbl3">Table 3</ce:cross-ref>
                              <ce:float-anchor refid="tbl3"/></ce:float-anchor>). GOLD docking model showed that various appendages at R and the cyclohexylbenzyl substituent accessed to two predominantly hydrophobic sub-pockets (pY-X and pY+1, respectively), and that the polar N9-carboxylic acid occupied the polar pY sub-pocket. Further evaluation in <ce:italic>in vitro</ce:italic> EMSA analysis revealed that these compounds inhibited STAT3 DNA binding activity with IC<ce:inf loc="post">50</ce:inf> values of 27–84 μM. Furthermore, compounds <ce:bold>49</ce:bold>–<ce:bold>52</ce:bold> selectively suppressed viability of human prostate (DU145), breast (MDA-MB-231) and pancreatic (Panc-1) cancer cells, and v-Src-transformed mouse fibroblasts (NIH3T3/v-Src) that harbor aberrant STAT3 activity, with no effect on NIH3T3 cells. It should be noted that the activity difference between SPR analysis and EMSA analysis for compounds <ce:bold>49</ce:bold>–<ce:bold>52</ce:bold> may be owe to the presence of off-targets in the nuclear extracts utilized in the EMSA assay.</ce:para>
                        </ce:section>
                        <ce:section id="sec5.1.1.9" view="all">
                           <ce:label>5.1.1.9</ce:label>
                           <ce:section-title id="sectitle0105">Bicyclic aromatic analogues</ce:section-title>
                           <ce:para id="p0190" view="all">Using a virtual screening approach by docking compounds to the three sub-pockets (pY, pY-X and pY+3 residue binding site) of the STAT3 SH2 domain, Tweardy group [<ce:cross-ref id="crosref0805" refid="bib104">104</ce:cross-ref>] discovered a lead compound <ce:bold>53</ce:bold> (C188, <ce:cross-ref id="crosref0810" refid="fig8">Fig. 8</ce:cross-ref>
                              <ce:float-anchor refid="fig8"/></ce:float-anchor>), which exhibited an IC<ce:inf loc="post">50</ce:inf> of 20 μM in a FP assay and inhibited IL-6-mediated phosphorylation of STAT3 with an IC<ce:inf loc="post">50</ce:inf> of 73 μM. Compound <ce:bold>53</ce:bold> also abrogated activated STAT3 nuclear translocation with an IC<ce:inf loc="post">50</ce:inf> of 39 μM, and induced apoptosis of MDA-B-468 with EC<ce:inf loc="post">50</ce:inf> of 0.73 μM. Computational docking studies revealed that the (carboxymethyl)thio moiety of compound <ce:bold>53</ce:bold> bond to the pY site and formed hydrogen bonds with Arg609, Glu612 and Ser611, while the hydroxyl-oxygen of the benzoic acid moiety formed a hydrogen bond with the amide-hydrogen of Glu638, an important residue which locates in the pY+3 binding site. Based on the chemical scaffold of <ce:bold>53</ce:bold>, Tweardy et al. conducted similarity screening and identified a more potent compound <ce:bold>54</ce:bold> (C188-9, <ce:cross-ref id="crosref0815" refid="fig8">Fig. 8</ce:cross-ref>), which bond to STAT3 with the K<ce:inf loc="post">D</ce:inf> of 4.7 nM determined by the MicroScale Thermophoresis (MST) experiment [<ce:cross-ref id="crosref0820" refid="bib105">105</ce:cross-ref>,<ce:cross-ref id="crosref0825" refid="bib106">106</ce:cross-ref>]. Compound <ce:bold>54</ce:bold> efficaciously inhibited granulocyte colony-stimulating factor (G-CSF)–induced STAT3 phosphorylation in 6 AML cell lines, with the IC<ce:inf loc="post">50</ce:inf> value of 4.1 μM in KG-1 cells and 8.3 μM in NB-4 cells, but did not alter the level of total STAT3 protein. Compound <ce:bold>54</ce:bold> also potently induced apoptosis in AML cell lines, with the EC<ce:inf loc="post">50</ce:inf> value of 6 μM in GDM-1 cells and 8 μM in Kasumi-1 cells via inhibition of STAT3 activity. Its inhibitory effect on the clonogenicity was also observed in primary AML cells. In addition, treatment of nude mice bearing UM-SCC-17B squamous carcinoma xenografts with <ce:bold>54</ce:bold> showed that it inhibited tumor growth at the dosage of 100 mg/kg/day. More importantly, compound <ce:bold>54</ce:bold> was well tolerated, and showed good oral bioavailability. Given its potential PK and PD characteristics, compound <ce:bold>54</ce:bold> is being tested in phase I clinical trial (NCT03195699) to determine its safety, adequate dose and anticancer activity in patients with advanced cancers.</ce:para>
                           <ce:para id="p0195" view="all">Compound <ce:bold>55</ce:bold> (OPB-31121, <ce:cross-ref id="crosref0830" refid="fig8">Fig. 8</ce:cross-ref>) is a JAK2/STAT3 signaling pathway inhibitor developed by Otsuka Pharmaceutical Co., Ltd, which displayed dramatically high binding affinity to the STAT3 SH2 domain with K<ce:inf loc="post">D</ce:inf> value of 10 nM determined by isothermal titration calorimetry (ITC) experiments [<ce:cross-ref id="crosref0835" refid="bib107">107</ce:cross-ref>]. While it is noteworthy that compound <ce:bold>55</ce:bold> occupies a distinct binding site within the STAT3 SH2 domain compared to the above descripted STAT3 SH2 domain inhibitors, confirmed by <ce:italic>in vitro</ce:italic> binding assays and competition assays. The unique binding mode of compound <ce:bold>55</ce:bold> with STAT3 also operates within the context of cellular biological activity. It was revealed that compound <ce:bold>55</ce:bold> completely inhibited the phosphorylation of Tyr705 at the doses of 5–10 nM in DU145 and LNCaP cell lines, and showed highly cytotoxic activity against LNCaP and DU145 cells with the IC<ce:inf loc="post">50</ce:inf> values of 18 nM and 25 nM, respectively. Based on its efficacy in preclinical models, Phase I/II clinical trials have been conducted in patients with advanced solid tumors. It demonstrated a favorable toxicity profile with Grade 1/2 treatment-related adverse events, but was characterized with poor PK profiles with high variability and low bioavailability. Making matters worse, maximum concentration (C<ce:inf loc="post">max</ce:inf>) of compound <ce:bold>55</ce:bold> after accumulation was over 100-fold lower than active concentrations in mouse tumor xenograft models, leading further clinical investigation of <ce:bold>55</ce:bold> being halted.</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec5.1.2" view="all">
                        <ce:label>5.1.2</ce:label>
                        <ce:section-title id="sectitle0110">Noncovalent STAT3 inhibitors targeting DNA-binding domain</ce:section-title>
                        <ce:para id="p0200" view="all">As another critical step in the STAT3 signaling pathway, dimerized STAT3 binding to specific DNA-response elements and thereby regulating the transcription of target genes is essential for cellular responses. Therefore, inhibition of STAT3 signaling pathway by targeting DNA-binding domain is considered another viable approach and efforts are made to develop potential inhibitors.</ce:para>
                        <ce:para id="p0205" view="all">By using drug repositioning strategy, Ding and coworkers identified compound <ce:bold>56</ce:bold> (Niclosamide, <ce:cross-ref id="crosref0840" refid="tbl4">Table 4</ce:cross-ref>
                           <ce:float-anchor refid="tbl4"/></ce:float-anchor>), an FDA-approved anthelmintic drug, which displayed signiﬁcant inhibitory effect on STAT3-induced luciferase activity in Hela cells with the IC<ce:inf loc="post">50</ce:inf> of 0.25 μM and suppressed Tyr705 phosphorylation level of STAT3 in Du145 cells without affecting the total STAT3 protein level [<ce:cross-ref id="crosref0845" refid="bib108">108</ce:cross-ref>]. Compound <ce:bold>56</ce:bold> dramatically inhibited the proliferation and colony formation of Du145 cells with IC<ce:inf loc="post">50</ce:inf> values of 0.7 and 0.1 μM, respectively, and induced G0/G1 phase arrest and apoptosis in Du145 dose dependently. An immunofluorescence assay showed that STAT3 nuclear translocation induced by EGF was successfully inhibited by treatment of compound <ce:bold>56</ce:bold>. Western blotting study revealed that compound <ce:bold>56</ce:bold> effectively inhibited the transcription function of STAT3 protein leading to decrease of the protein levels of downstream target genes, such as cyclin D1, c-Myc, and Bcl-XL. Mechanism of action studies revealed that compound <ce:bold>56</ce:bold> did not demonstrate inhibition against JAk1, JAK2, Src, EGFR, VEGFR, and PDGFR etc. Compound <ce:bold>56</ce:bold> was unable to bind to the SH2 domain in the FP assay. However, Reigan group revealed that compound <ce:bold>56</ce:bold> targeted the DNA-binding domain of STAT3 via a modified DNA-binding ELISA assay incorporating recombinant STAT3 protein, with an IC<ce:inf loc="post">50</ce:inf> value of 1.93 μM [<ce:cross-ref id="crosref0850" refid="bib109">109</ce:cross-ref>].</ce:para>
                        <ce:para id="p0210" view="all">In order to discover new molecules with ideal pharmacokinetic profile, a series of novel <ce:italic>O</ce:italic>-alkylamino tethered derivatives (compounds <ce:bold>57</ce:bold>–<ce:bold>61</ce:bold>, <ce:cross-ref id="crosref0855" refid="tbl4">Table 4</ce:cross-ref>) of compound <ce:bold>56</ce:bold> have been developed with remarkably enhanced aqueous solubility by Zhou group [<ce:cross-ref id="crosref0860" refid="bib110">110</ce:cross-ref>]. 2-Aminoethyl substituted compound <ce:bold>59</ce:bold> (HJC0152) displayed near 3000-times improvement in water solubility and exhibited similar inhibitory potency compared to compound <ce:bold>56</ce:bold>. Compound <ce:bold>59</ce:bold> also inhibited STAT3 promoter activity, inhibited cell cycle, and promoted apoptosis in MDA-MB-231 cells. Furthermore, compound <ce:bold>59</ce:bold> significantly suppressed MDA-MB-231 xenograft tumor growth <ce:italic>in vivo</ce:italic> at a dose of 25 mg/kg, which is even more efficacious than compound <ce:bold>56</ce:bold> at 75 mg/kg. In addition, compound <ce:bold>59</ce:bold> significantly suppressed human HNSCC tumor growth (derived from the SCC25 cell line) [<ce:cross-ref id="crosref0865" refid="bib111">111</ce:cross-ref>], glioblastoma tumor growth (established from U87 cell line) [<ce:cross-ref id="crosref0870" refid="bib112">112</ce:cross-ref>] and gastric cancer tumor growth (derived from the MKN45 cell line) [<ce:cross-ref id="crosref0875" refid="bib113">113</ce:cross-ref>] at a dose of 7.5 mg/kg, with no significant change in body weight. Incorporation of 4-piperidinyl to compound <ce:bold>56</ce:bold> led to dramatically improvement in cytotoxic activity against breast cancer cell lines MCF-7 and MDA-MB-231 for compound <ce:bold>57</ce:bold>. However, methylation of compound <ce:bold>57</ce:bold> or dimethylation of compound <ce:bold>59</ce:bold> resulted in remarkable loss of cytotoxic activities, maybe due to the abolished ability of hydrogen bond donor for compounds <ce:bold>58</ce:bold> and <ce:bold>60</ce:bold>. The <ce:italic>O</ce:italic>-alkylamino length also played an important role in modulating inhibitory activity of this series compounds verified by the lost activity of compound <ce:bold>61</ce:bold> compared to compound <ce:bold>59</ce:bold>.</ce:para>
                        <ce:para id="p0215" view="all">In order to discover small molecular compounds that selectively inhibit STAT3 DNA-binding activity, Zhang et al. performed structure-based virtual screening of approximately 200,000 compounds to the STAT3 DNA-binding domain, and successfully identiﬁed compound <ce:bold>62</ce:bold> (InS3-54, <ce:cross-ref id="crosref0880" refid="fig9">Fig. 9</ce:cross-ref>
                           <ce:float-anchor refid="fig9"/></ce:float-anchor>) [<ce:cross-ref id="crosref0885" refid="bib114">114</ce:cross-ref>]. Compound <ce:bold>62</ce:bold> inhibited STAT3 DNA-binding activity in a dose-dependent manner with an IC<ce:inf loc="post">50</ce:inf> of 20 μM in the EMSA assay and inhibited STAT3-dependent luciferase reporter expression in MDA-MB-231 cells with an IC<ce:inf loc="post">50</ce:inf> of 13.8 μM in the luciferase assay. The growth and survival of cancer cells harboring constitutively active STAT3 (A549, H1299, MDA-MB-231, and MDAMB-468) were sensitive to treatment of compound <ce:bold>62</ce:bold> with IC<ce:inf loc="post">50</ce:inf> of 3.2–5.4 μM in the cytotoxicity assay. In addition, compound <ce:bold>62</ce:bold> inhibited migration of both A549 and MDA-MB231 cells in dose- and time-dependent manners. However, <ce:bold>62</ce:bold> had no eﬀect on the level of total STAT3 or basal level of Tyr705-phosphorylated STAT3, and had no inhibition on IL-6 stimulated phosphorylation of STAT3, indicating that it unlikely bond to the SH2 domain. Furthermore, quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis of mRNAs confirmed that the expression of STAT3 downstream target genes (cyclin D1, survivin, VEGF, MMP2, MMP-9, and Twist) were all decreased following compound <ce:bold>62</ce:bold> treatment in both A549 and MDA-MB-231 cell lines. In addition, Wells group [<ce:cross-ref id="crosref0890" refid="bib115">115</ce:cross-ref>] developed a new FP assay to screen molecules that prevent the STAT3 DNA-binding using a STAT3<ce:sup loc="post">127−688</ce:sup> protein and a Bodipy-DNA conjugate as the fluorescent probe, and validated that compound <ce:bold>62</ce:bold> was able to inhibit the STAT3: DNA association with the IC<ce:inf loc="post">50</ce:inf> value of 21.3 μM. Nevertheless, it is still necessary to note that the higher activity of <ce:bold>62</ce:bold> in inhibiting cancer cell survival than inhibiting DNA binding and luciferase reporter expression may arise from its potential oﬀ-target eﬀect, which needs to be validated.</ce:para>
                        <ce:para id="p0220" view="all">In an effort to discover STAT3 inhibitors targeting the DNA binding domain with improved potency and specificity, Zhang and coworkers performed an extensive structure and activity-guided optimization of compound <ce:bold>62</ce:bold> and identified compound <ce:bold>63</ce:bold> (A18) with improved specificity and potency [<ce:cross-ref id="crosref0895" refid="bib116">116</ce:cross-ref>]. The specificity of compound <ce:bold>63</ce:bold> was confirmed in colony-formation assay and it was revealed that compound <ce:bold>63</ce:bold> reduced colony-formation efficiency of hematopoietic progenitor cells from STAT3<ce:sup loc="post">+/+</ce:sup> mice, but did not appear to have any significant effect on the colony-formation of hematopoietic progenitor cells from STAT3<ce:sup loc="post">−/−</ce:sup> mice. However, compound <ce:bold>62</ce:bold> not only reduced the proliferative activity of STAT3<ce:sup loc="post">+/+</ce:sup> hematopoietic progenitor cells, but also reduced the colony formation of the cells from STAT3<ce:sup loc="post">−/−</ce:sup>mice. EMSA assay demonstrated that compound <ce:bold>63</ce:bold> inhibited the DNA-binding activity of STAT3 in a dose-dependent manner, but did not affect the DNA-binding activity of STAT1. Compound <ce:bold>63</ce:bold> was also more effective than compound <ce:bold>62</ce:bold> in inhibiting cancer cell survival (A549, MCF10A1, and MDA-MB-231). Further pharmacological investigation revealed that compound <ce:bold>63</ce:bold> enabled to inhibit cancer cell (A549 and MDA-MB-231) migration and invasion and decrease the expression of STAT3 downstream target genes (cyclin D1, surviving, matrix metalloproteinase-9, and VEGF) in A549 and MDA-MB-231 cell lines, and inhibit the binding of STAT3 to its target sequence on chromatin DNA <ce:italic>in situ</ce:italic>. Compound <ce:bold>63</ce:bold> also significantly suppressed xenograft tumor growth of A549 at a dose of 200 mg/kg, with little adverse effect on mouse body weight.</ce:para>
                        <ce:para id="p0225" view="all">Ligand-based virtual screening of the Specs chemical library in combination with 3D shape- and electrostatic-based drug design approach by Huang and coworkers lead to the identification of a new STAT3 inhibitor, compound <ce:bold>64</ce:bold>, based on the pharmacophore of compound <ce:bold>62</ce:bold> and <ce:bold>63</ce:bold> [<ce:cross-ref id="crosref0900" refid="bib117">117</ce:cross-ref>]. Compound <ce:bold>64</ce:bold> showed inhibitory activity on survival of H1299 cells with an IC<ce:inf loc="post">50</ce:inf> of 8.1 ± 4.1 μM and inhibited STAT3 binding to the DNA domain with a k<ce:inf loc="post">i</ce:inf> value of 3.92 μM in microscale thermophoresis assay. Compound <ce:bold>64</ce:bold> also enabled to suppress survival of cisplatin-resistant ovarian cancer cell (SKOV3/DDP) with an IC<ce:inf loc="post">50</ce:inf> of 14.7 ± 2.4 μM compared to the IC<ce:inf loc="post">50</ce:inf> of 3.7 ± 0.7 μM for ovarian cancer cell (SKOV3) and induced apoptosis in SKOV3/DDP cells. Of particular note is that compound <ce:bold>64</ce:bold> possess unsaturated ketone which may react with cysteine residues of STAT3, while it is not discussed whether it can covalently modify STAT3 in the publication.</ce:para>
                     </ce:section>
                     <ce:section id="sec5.1.3" view="all">
                        <ce:label>5.1.3</ce:label>
                        <ce:section-title id="sectitle0115">Other noncovalent STAT3 inhibitors</ce:section-title>
                        <ce:para id="p0230" view="all">Compound <ce:bold>65</ce:bold> (<ce:cross-ref id="crosref0905" refid="fig9">Fig. 9</ce:cross-ref>) was identified to be an inhibitor of IL-6/STAT3 signaling pathway by Li group [<ce:cross-ref id="crosref0910" refid="bib118">118</ce:cross-ref>] via virtual screening, which displayed inhibitory effect on STAT3-induced luciferase activity in HepG2 cell with an IC<ce:inf loc="post">50</ce:inf> of 3.567 μM. Compound <ce:bold>65</ce:bold> showed above 6-fold selectivity over IFN-γ/STAT1 signaling pathway, but did not demonstrate inhibitory activity toward TNF-α/NF-KB signaling. Taking compound <ce:bold>65</ce:bold> as a potential lead structure, Li discovered a better inhibitor, compound <ce:bold>66</ce:bold> (<ce:cross-ref id="crosref0915" refid="fig9">Fig. 9</ce:cross-ref>), whose inhibitory activity was enhanced 3-times compared with compound <ce:bold>65</ce:bold>, with an IC<ce:inf loc="post">50</ce:inf> of 1.16 μM. It also inhibited cell viability of MDA-MB-468 with an IC<ce:inf loc="post">50</ce:inf> of 16.06 μM. However, the binding site of compound <ce:bold>66</ce:bold> is still needed to be verified.</ce:para>
                        <ce:para id="p0235" view="all">A benzyloxyphenyl scaffold <ce:bold>67</ce:bold> (<ce:cross-ref id="crosref0920" refid="tbl5">Table 5</ce:cross-ref>
                           <ce:float-anchor refid="tbl5"/></ce:float-anchor>) was identified by Li et al. [<ce:cross-ref id="crosref0925" refid="bib119">119</ce:cross-ref>] as novel STAT3 inhibitor through virtual screening, which displayed inhibitory activity on STAT3 transcription with an IC<ce:inf loc="post">50</ce:inf> of 26.68 μM in the luciferase assay and inhibited cell viability of MDA-MB-468 with an IC<ce:inf loc="post">50</ce:inf> value of 18.83 μM as determined using MTT assay. Removing the chlorine atom at C-5 improved the luciferase inhibitory activity from 26.68 μM to 7.71 μM (<ce:bold>67</ce:bold> vs <ce:bold>68</ce:bold>). Incorporation of a fluorine atom (compound <ce:bold>70</ce:bold>) to C-5 position of <ce:bold>68</ce:bold> was tolerated while the bromine atom (compound <ce:bold>71</ce:bold>) was detrimental to the inhibitory activity. Replacement of hydroxyl group within compound <ce:bold>67</ce:bold> by sulfonamide led to compound <ce:bold>72</ce:bold> with slightly reduced IC<ce:inf loc="post">50</ce:inf> value of 35.67 μM for luciferase activity. Moving the chlorine from C-5 to C-3 (compound <ce:bold>69</ce:bold>) resulted in a significant enhanced luciferase activity with an IC<ce:inf loc="post">50</ce:inf> value of 1.38 μM.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec5.2" view="all">
                     <ce:label>5.2</ce:label>
                     <ce:section-title id="sectitle0120">Covalent STAT3 inhibitors</ce:section-title>
                     <ce:para id="p0240" view="all">As exemplified in <ce:cross-ref id="crosref0930" refid="fig3">Fig. 3</ce:cross-ref>, compound <ce:bold>9</ce:bold> was identiﬁed from the NCI chemical libraries by taking advantage of structure-based virtual screening into the STAT3 SH2 domain, and was proposed to show its inhibitory efficacy <ce:italic>in vivo</ce:italic> as a result of covalent modification of STAT3 and/or other off-targets. STAT3 consists of twelve cysteine residues (Cys108, 251, 259, 328, 367, 418, 426, 468, 542, 550, 687, and 712) with distinct potential reactivities toward electrophiles. Cys251, 328 and 550 are buried in the interior of STAT3 and are not solvent exposed. Cys108, 259, 418, 426, and 712 are exposed to solvent. Cys468 is solvent exposed in the absence of STAT3 specific DNA binding partner, whereas Cys367, 542, and 687 are less exposed residues.<ce:sup loc="post">76</ce:sup> Therefore, multiple chemical biology approaches were employed by Gunning and coworkers to explore its potential reactivity toward STAT3 and elucidate its mechanism of action (MOA).<ce:sup loc="post">76</ce:sup> An HPLC-based assay revealed that compound <ce:bold>9</ce:bold> reacted rapidly with glutathione, a nucleophile including cysteine, via S<ce:inf loc="post">N</ce:inf>2 nucleophilic substitution reaction mechanism. Incubation of STAT3 with compound <ce:bold>9</ce:bold> and thereby LC-MS/MS analysis revealed that compound <ce:bold>9</ce:bold> covalently modified Cys108, Cys259, Cys367, Cys542, Cys687 of STAT3, all of which are solvent exposed. A DANSYL fluorescent tagged compound <ce:bold>9</ce:bold> induced a time dependent increase in fluorescent signal of the STAT3 protein, labeled three STAT subtypes (STAT1, STAT3 and STAT5) non-specifically, and alkylated multiple intracellular proteins in MDA-MB-231 cell lysates. These data demonstrated that compound <ce:bold>9</ce:bold> was not an optimal chemical probe for studying STAT3-related cell biology and needed more structural optimization to provide more specific covalent inhibitory effect on STAT3.</ce:para>
                     <ce:para id="p0245" view="all">Compound <ce:bold>73</ce:bold> (Stattic, <ce:cross-ref id="crosref0935" refid="fig10">Fig. 10</ce:cross-ref>
                        <ce:float-anchor refid="fig10"/></ce:float-anchor>) was identified as a STAT3 SH2 domain inhibitor via HTS of a diverse chemical library [<ce:cross-ref id="crosref0940" refid="bib120">120</ce:cross-ref>]. Compound <ce:bold>73</ce:bold> disrupted STAT3 dimerization with the IC<ce:inf loc="post">50</ce:inf> value of 5.1 μM in the FP assay and inhibited active STAT3 DNA binding activity at 10 μM in the EMSA assay. The breast cancer cell lines, MDA-MB-231 and MDA-MB-435s, were induced apoptosis after the treatment of compound <ce:bold>73</ce:bold> at 10 μM. While it was also revealed that compound <ce:bold>73</ce:bold> displayed its inhibitory effect on STAT3 SH2 domain in a time-, temperature-, and dithiothreitol-dependent manner, indicating its covalent irreversible interaction with STAT3. Saturation of the double bond of the vinyl sulfone moiety afforded compound <ce:bold>74</ce:bold> (<ce:cross-ref id="crosref0945" refid="fig10">Fig. 10</ce:cross-ref>) and led to loss of activity in the FP assay, supporting the Michael addition reaction between compound <ce:bold>73</ce:bold> and nucleophilic residues (such as cysteine) of STAT3. Since there are twelve cysteine residues present in STAT3, mass spectrometry methods were developed to investigate the reaction sites of STAT3 with compound <ce:bold>73</ce:bold>. Buettner et al. observed that a mass increase of 1690 Da for phosphorylated STAT3 after treatment with compound <ce:bold>73</ce:bold> [<ce:cross-ref id="crosref0950" refid="bib121">121</ce:cross-ref>]. The mass difference indicated that eight equivalents of compound <ce:bold>73</ce:bold> were incorporated to one equivalent of phosphorylated STAT3 protein. A similar research was conducted to research the alkylation reaction between compound <ce:bold>73</ce:bold> and un-phosphorylated STAT3βtc by Heidelberger et al. [<ce:cross-ref id="crosref0955" refid="bib122">122</ce:cross-ref>] It was revealed that nine compound <ce:bold>73</ce:bold> molecules were added to one inactivated STAT3βtc covalently and four or five of the nine modified residues were confirmed as cysteines. Furthermore, Cys468 and Cys542 were confirmed not to react with compound <ce:bold>73</ce:bold>, indicating that a degree of reaction selectivity between cysteine residues of STAT3. As a control, bovine serum albumin (BSA) including cysteines was also alkylated by compound <ce:bold>73</ce:bold>, indicating that the molecular lacked selectivity over other proteins.</ce:para>
                     <ce:para id="p0250" view="all">To identify novel potent STAT3 inhibitors with new scaffolds and improved drug-like properties, Zhou et el. designed a series of novel diversified analogues of compound <ce:bold>73</ce:bold> based on the privileged fragments from the reported representative STAT3 inhibitors [<ce:cross-ref id="crosref0960" refid="bib123">123</ce:cross-ref>]. Structural hybridization of 2-phenylquinoline-4-caboxylic acid amide of compound <ce:bold>42</ce:bold> and benzo[b]thiophene 1,1-dioxide (BTP) of compound <ce:bold>73</ce:bold> generated compound <ce:bold>75</ce:bold> (<ce:cross-ref id="crosref0965" refid="fig9">Fig. 9</ce:cross-ref>), while compound <ce:bold>76</ce:bold> (<ce:cross-ref id="crosref0970" refid="fig10">Fig. 10</ce:cross-ref>) was achieved by condensation of 5-chloro-2-hydroxybenzoic acid with 6-amino substituted BTP. Compound <ce:bold>75</ce:bold> significantly inhibited STAT3 promoter activity in MDA-MB-231 cells at 5 μM using cell-based transient transfection assay. Furthermore, compound <ce:bold>75</ce:bold> inhibited the growth of breast cancer (MCF-7 and MDA-MB-231) and pancreatic cancer (AsPC1 and Panc-1) cell lines with lower IC<ce:inf loc="post">50</ce:inf> values (0.10–1.25 μM) than that of compound <ce:bold>73</ce:bold> (1.32–3.60 μM, <ce:cross-ref id="crosref0975" refid="tbl6">Table 6</ce:cross-ref>
                        <ce:float-anchor refid="tbl6"/></ce:float-anchor>), and suppressed the growth of MDA-MB-231 xenograft tumors <ce:italic>in vivo</ce:italic> at the dose of 50 mg/kg, without evidence of adverse toxicities observed. Compound <ce:bold>76</ce:bold> also exhibited significant cytotoxic activity against the above cancer cells with the IC<ce:inf loc="post">50</ce:inf> values range in 0.91–2.34 μM (<ce:cross-ref id="crosref0980" refid="tbl6">Table 6</ce:cross-ref>). Introduction of 3-aminopropyl group to the hydroxy of compound <ce:bold>76</ce:bold> generated compound <ce:bold>77</ce:bold> (<ce:cross-ref id="crosref0985" refid="fig10">Fig. 10</ce:cross-ref>) and resulted in enhanced cytotoxic effects (IC<ce:inf loc="post">50</ce:inf> = 0.04–1.97 μM, <ce:cross-ref id="crosref0990" refid="tbl6">Table 6</ce:cross-ref>) and drug-like properties [<ce:cross-ref id="crosref0995" refid="bib124">124</ce:cross-ref>].</ce:para>
                     <ce:para id="p0255" view="all">Using structure-based drug design approach, Kong et al. discovered new BTP derivatives by introducing substituted phenylamine to C-6 or C-7 position of BTP scaffold [<ce:cross-ref id="crosref1000" refid="bib125">125</ce:cross-ref>]. Comprehensive SAR study revealed that C7-substituted BTP derivatives were more potent than C6-substituted ones. Among them, the most potent compound <ce:bold>78</ce:bold> (<ce:cross-ref id="crosref1005" refid="fig10">Fig. 10</ce:cross-ref>) exhibited remarkable cytotoxic activity against four cancer cell line (MDA-MB-231, A549, MCF-7, and HCT116) with IC<ce:inf loc="post">50</ce:inf> values of 0.68, 0.36, 0.75, and 0.33 μM, respectively. Compound <ce:bold>78</ce:bold> effectively downregulated the overexpressed and IL-6 induced phosphorylation of STAT3, blocked STAT3 mediated DNA binding activity in the EMSA assay, induced apoptosis in MDA-MB-231 cells dose dependently, and induced significant antitumor responses <ce:italic>in vivo</ce:italic>. Compound <ce:bold>79</ce:bold> (<ce:cross-ref id="crosref1010" refid="fig10">Fig. 10</ce:cross-ref>) was designed by incorporation of piperidine through amide bond linkage to the C2 position of BTP, which exhibited a remarkable inhibitory effect on STAT3-induced luciferase activity in HeLa cells [<ce:cross-ref id="crosref1015" refid="bib126">126</ce:cross-ref>]. It also inhibited phosphorylation of STAT3 in a dose-dependent manner, and induced the apoptosis in MDA-MB-435s and MCF-7 cells.</ce:para>
                     <ce:para id="p0260" view="all">Compound <ce:bold>80</ce:bold> (Galiellalactone, <ce:cross-ref id="crosref1020" refid="fig11">Fig. 11</ce:cross-ref>
                        <ce:float-anchor refid="fig11"/></ce:float-anchor>), a fungal metabolite, was identified to be a IL-6-dependent JAK/STAT3 signaling inhibitor, which inhibited STAT3 dimers binding to their transcriptional DNA elements with the IC<ce:inf loc="post">50</ce:inf> values of 250–500 nM, without affecting the Tyr705 and Ser727 phosphorylation of STAT3 [<ce:cross-ref id="crosref1025" refid="bib127">127</ce:cross-ref>]. It inhibited the growth of prostate cancer cells (PC-3 and DU145) expressing constitutively activated STAT3 at the dose of 10 μM, while did not induce apoptosis in LNCaP cells, which lacked STAT3 activity. Compound <ce:bold>80</ce:bold> also inhibited the expression of STAT3-regulated genes and proteins, such as Bcl-XL, Bcl-2, c-myc and cyclin D1 in DU145 cells [<ce:cross-ref id="crosref1030" refid="bib128">128</ce:cross-ref>]. Furthermore, compound <ce:bold>80</ce:bold> signiﬁcantly reduced the tumor growth in DU145 xenograft model.</ce:para>
                     <ce:para id="p0265" view="all">Since compound <ce:bold>80</ce:bold> includes a reactive α, β-unsaturated lactone functionality, it has the potential to covalently alkylate the cysteines within STAT3. Incubation of recombinant STAT3 protein with compound <ce:bold>80</ce:bold> and then mass spectrometry analysis demonstrated that three cysteines (Cys367, Cys468, Cys542) were covalently modified [<ce:cross-ref id="crosref1035" refid="bib129">129</ce:cross-ref>]. In addition, three more cysteines (Cys251, Cys259, and Cys687) were identified to be alkylated by compound <ce:bold>80</ce:bold> at higher concentrations. The binding characteristics of compound <ce:bold>80</ce:bold> to STAT3 were also investigated via wash-out experiments and it was revealed that compound <ce:bold>80</ce:bold> bond reversibly to STAT3 and maintained inhibitory activity even after the compound was removed. It is important to note that compound <ce:bold>80</ce:bold> was also reported to inhibit NF-kB and TGF-β signaling pathways and was lack of specificity for JAK/STAT3 signaling pathway.</ce:para>
                     <ce:para id="p0270" view="all">In order to discover potential STAT3 inhibitors that impressively inhibits STAT3-DNA interaction, Williams et al. discovered compound <ce:bold>81</ce:bold> (C48, <ce:cross-ref id="crosref1040" refid="fig11">Fig. 11</ce:cross-ref>) using virtual ligand screening (VLS) analysis [<ce:cross-ref id="crosref1045" refid="bib130">130</ce:cross-ref>]. Biochemical studies revealed that compound <ce:bold>81</ce:bold> inhibited STAT3 DNA-binding activity with an IC<ce:inf loc="post">50</ce:inf> value of 10–50 μM, without affecting the DNA-binding affinity of STAT1 even at concentration of 500 μM in EMSA. Cell-based assays demonstrated that compound <ce:bold>81</ce:bold> inhibited STAT3-induced gene expression in HeLa cells at concentrations of 3–10 μM and that MDA-MB-468 and MDA-MB-231 underwent apoptosis following incubation with 1–20 μM of compound <ce:bold>81</ce:bold>. Western blot analysis revealed that compound <ce:bold>81</ce:bold> inhibited STAT3 phosphorylation in MDA-MB-468 cells, with no effect on STAT3 upstream activators such as, JAK1 and JAK2. In addition, compound <ce:bold>81</ce:bold> displayed significant antitumor efficacy in MDA-MB-468 and C3L5 mouse xenograft models at the dose of 200 mg/kg.</ce:para>
                     <ce:para id="p0275" view="all">Given that the benzylic carbon (highlighted in red) of compound <ce:bold>81</ce:bold> is potentially reactive and susceptible to be attacked by cysteine residues, site-directed mutagenesis and mass spectrometry were used to determine its MOA [<ce:cross-ref id="crosref1050" refid="bib130">130</ce:cross-ref>]. It was found that Cys468 mutated to Ser468 resulted in the recovery of phosphorylation level of C468S mutant STAT3 and that no significant effect of compound <ce:bold>81</ce:bold> on DNA binding activity of C468S mutant STAT3 was observed. Incubation of phosphorylated STAT3 with compound <ce:bold>81</ce:bold> and subsequent LC-MS analysis revealed six residues of STAT3 being modified and one, among others, was confirmed to be Cys468, which locates at the DNA-binding interface.</ce:para>
                     <ce:para id="p0280" view="all">Compound <ce:bold>82</ce:bold> (Curcumin, <ce:cross-ref id="crosref1055" refid="fig11">Fig. 11</ce:cross-ref>) is isolated from turmeric and exerts anticancer effects through regulation of a series of intracellular signaling pathways and protein-protein interactions, including JAK2/STAT3 pathway [<ce:cross-ref id="crosref1060" refid="bib131">131</ce:cross-ref>]. However, the clinical use of compound <ce:bold>82</ce:bold> as an anticancer therapeutic agent has been limited due to its poor bioavailability and low potency. With the aim of improving its PK profile and anticancer efficacy, several novel analogues of compound <ce:bold>82</ce:bold> were developed. Li et al. displaced the two hydrogens on the middle carbon of <ce:bold>82</ce:bold> with spiro-cyclohexyl to prevent the transformation of diketone to enol form in solution and identified compound <ce:bold>83</ce:bold> (FLLL32, <ce:cross-ref id="crosref1065" refid="fig11">Fig. 11</ce:cross-ref>) [<ce:cross-ref id="crosref1070" refid="bib132">132</ce:cross-ref>], which displayed 25 times higher inhibitory activity targeting STAT3 SH2 domain than compound <ce:bold>82</ce:bold>. Kuppusamy et al. identified a new analogue <ce:bold>84</ce:bold> (<ce:cross-ref id="crosref1075" refid="fig11">Fig. 11</ce:cross-ref>) by substituting the β-diketone of <ce:bold>82</ce:bold> with a piperidone link and incorporating fluorine to the phenyl groups, which exhibited more potent anticancer efficacy <ce:italic>in vitro</ce:italic> than lead <ce:bold>82</ce:bold> [<ce:cross-ref id="crosref1080" refid="bib133">133</ce:cross-ref>]. Further optimization of <ce:bold>84</ce:bold> by incorporating N-hydroxy-pyrroline moiety to the piperidone N-terminus of <ce:bold>83</ce:bold> based on the protective nature of the N-hydroxyl group for healthy cells yielded compound <ce:bold>85</ce:bold> (<ce:cross-ref id="crosref1085" refid="fig11">Fig. 11</ce:cross-ref>), which displayed both anticancer and antioxidant properties [<ce:cross-ref id="crosref1090" refid="bib134">134</ce:cross-ref>].</ce:para>
                     <ce:para id="p0285" view="all">As compound <ce:bold>82</ce:bold>–<ce:bold>85</ce:bold> include the α, β-unsaturated carbonyl moiety, all of them have the potential to alkylate STAT3 covalently. Recently Surh et al. investigated the molecular mechanism of <ce:bold>82</ce:bold> in regulating STAT3 signaling and revealed that STAT3 was covalently modified by compound <ce:bold>82</ce:bold> [<ce:cross-ref id="crosref1095" refid="bib135">135</ce:cross-ref>]. And multiple chemical biological approaches demonstrated that compound <ce:bold>82</ce:bold> exerted its STAT3 inhibitory activity through direct modifying Cys259. It is noteworthy that curcumin and its analogues have been regarded as pan-assay interference compounds (PAINS) [<ce:cross-ref id="crosref1100" refid="bib136">136</ce:cross-ref>], which demonstrate nonspecific activities in multiple modes of assays and display false biological activities for intended targets. On the other hand, overwhelming evidences have indicated their poor PK/PD properties, such as bad chemical stability, undesirable physicochemical properties, and low bioavailability [<ce:cross-ref id="crosref1105" refid="bib137">137</ce:cross-ref>]. Hence, these unfavorable drug-like properties should be taken into consideration when curcumin analogues are utilized as STAT3 lead inhibitors for further drug evaluations and developments.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec6" view="all">
                  <ce:label>6</ce:label>
                  <ce:section-title id="sectitle0125">Perspective</ce:section-title>
                  <ce:para id="p0290" view="all">A large number of studies have shown that STAT3 is constitutively activated in the vast majority types of cancer [<ce:cross-ref id="crosref1110" refid="bib7">7</ce:cross-ref>]. Recent studies also reveal that STAT3 is directly involved in immune regulation in cancer cells. Direct inhibition of STAT3 activity has been validated as a promising approach for cancer therapy. Therefore, development of direct STAT3 inhibitors attracts more and more attentions [<ce:cross-ref id="crosref1115" refid="bib138">138</ce:cross-ref>]. In the past two decades, a great deal of direct STAT3 inhibitors with different MOA have been discovered [<ce:cross-ref id="crosref1120" refid="bib139">139</ce:cross-ref>], as we discussed in section <ce:cross-ref id="crosref1125" refid="sec5">5</ce:cross-ref> and briefly summarised in <ce:cross-ref id="crosref1130" refid="tbl7">Table 7</ce:cross-ref>
                     <ce:float-anchor refid="tbl7"/></ce:float-anchor>. It can be easily concluded that most of potent STAT3 inhibitors, especially those entering into the clinical trial or under preclinical studies (<ce:cross-ref id="crosref1135" refid="tbl8">Table 8</ce:cross-ref>
                     <ce:float-anchor refid="tbl8"/></ce:float-anchor>), such as STA-21, C188-9, OPB-31121 and its analogue OPB-51602 (structure not disclosed) [<ce:cross-ref id="crosref1140" refid="bib140">140</ce:cross-ref>], target SH2 domain to inhibit STAT3 phosphorylation, dimerization and nuclear translocation. This is in accordance with the important function of SH2 domain in the STAT3 signal transduction pathway. Nonetheless, it is noteworthy that these direct STAT3 inhibitors, except OPB-31121 and OPB-51602, demonstrate moderate inhibitory potency in cell-based assays, possibly due to the fact that dimerization of activated STAT3 proteins belongs to the protein-protein interactions (PPIs). The binding interfaces of PPIs, such as the pY-peptide binding site within the STAT3 SH2 domain generally spread over large, relatively flat surfaces and lack of well-defined, deep binding pockets, making them difficult to bind with small molecules. In addition, these above-mentioned direct STAT3 inhibitors are also characterized with low aqueous solubility, low cell permeability and poor oral bioavailability, which may hinder their drug developments and clinical studies. Taken together, new strategies are needed to provide more potent STAT3 inhibitors with excellent drug-like properties.</ce:para>
                  <ce:para id="p0295" view="all">Recently, targeted covalent inhibitors (TCI) [<ce:cross-ref id="crosref1145" refid="bib141">141</ce:cross-ref>,<ce:cross-ref id="crosref1150" refid="bib142">142</ce:cross-ref>] has emerged as a potentially more efficient strategy to block PPIs [<ce:cross-ref id="crosref1155" refid="bib143">143</ce:cross-ref>], as covalent modification of a nucleophilic residue (such as cysteine residue) located at or in the immediate vicinity of PPIs can overcome the above disadvantages of extensive interfaces in the protein binding groove, and provide high-affinity inhibitors with longer residence time and sustained inhibitory activity compared to noncovalent ones. Actually, STAT3 is sensitive toward chemical modification as evidenced by the reported covalent inhibitors that we summarized in section <ce:cross-ref id="crosref1160" refid="sec5.2">5.2</ce:cross-ref>. However, most of them are identified via HTS or molecular modeling and virtual screening, alkylate several cysteines of STAT3, and lack specificity for STAT3. These features of above STAT3 covalent inhibitors induce potential risks and challenges associated with off-target toxicity concerns. Therefore, development of covalent STAT3 inhibitors to alkylate unique and non-conserved cysteine residue maybe a promising approach to discover potential anticancer therapeutics. As we discussed in section <ce:cross-ref id="crosref1165" refid="sec5.1">5.1</ce:cross-ref>, plenty of specific non-covalent STAT3 inhibitors have been identified, which can be used as the starting point for the following structure-based covalent inhibitor discovery. Incorporation of electrophiles to these noncovalent congeners to chemically modify unique and non-conserved cysteine, such as Cys687 locating in the SH2 domain, and Cys712 residing in the dimerization interface, may provide specific covalent STAT3 inhibitors with improved potency and acceptable safety profiles.</ce:para>
                  <ce:para id="p0300" view="all">On the other hand, proteolysis targeting chimera (PROTAC) technology has emerged and refined over the past two decades as a powerful strategy to provide a more complete and lasting inactivation of target protein signaling via degradation of target protein of interest (POI) [<ce:cross-refs id="crosrefs0060" refid="bib144 bib145 bib146 bib147 bib148 bib149 bib150 bib151 bib152 bib153 bib154 bib155 bib156">144–156</ce:cross-refs>]. The PROTACs are bifunctional molecules with one side capable of engaging an E3 ubiquitin ligase, and the other side binding to POI. Unlike the classical noncovalent inhibitors, which directly bind to POI and block signaling relying on occupancy driven approaches, PROTACs play their roles via recruiting an E3 ligase to tag the POI for ubiquitination and subsequent degradation through the proteasome, through an event driven MOA. Therefore, binding affinity is no longer the most critical factor to be considered when it comes to development of potential PROTACs for POI [<ce:cross-ref id="crosref1170" refid="bib144">144</ce:cross-ref>]. As previous studies have revealed that STAT3 can be ubiquitin by E3 ligase and degraded by proteasome [<ce:cross-ref id="crosref1175" refid="bib157">157</ce:cross-ref>], it should be another promising approach to develop PROTACs for STAT3 based on the reported selective noncovalent inhibitors. It is noteworthy that Wang group [<ce:cross-ref id="crosref1180" refid="bib158">158</ce:cross-ref>] reported the first STAT3 PROTAC during the peer review process of this manuscript.</ce:para>
                  <ce:para id="p0305" view="all">Furthermore, as we described in section <ce:cross-ref id="crosref1185" refid="sec3">3</ce:cross-ref>, several different types of STAT3 mutations have been detected in clinic cancer patients, which show increased phosphorylation and transcriptional activity of STAT3, compared to wild type STAT3. Making matters worse, these mutations, especially the ones in SH2 domains, such as Y640F which change the binding pocket for dimerization in our computer simulation, may promote cancers to become resistant to the specific STAT3 inhibitors targeting SH2 domain which are developed so far. Therefore, besides that it is urgent to develop specific inhibitors of wild type STAT3 to be approved for clinical application in cancer patients, identification of potent and specific inhibitors to combat STAT3 mutations is also an unmet medical need. Fortunately, both TCI and PROTACs have the advantage of combating acquired drug resistance to targeted cancer therapies. Taken together, targeting STAT3 to develop TCI and PROTACs may not only provide potent and specific small molecule inhibitors, but also enable to delay and overcome acquired drug resistance in human cancers, thereby improving therapeutic response in cancers.</ce:para>
               </ce:section>
               <ce:section id="sec7" view="all">
                  <ce:section-title id="sectitle0130">Declaration of competing interestCOI</ce:section-title>
                  <ce:para id="p0310" view="all">The authors declare no competing financial interest.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0135">Acknowledgements</ce:section-title>
               <ce:para id="p0315" view="all">This work was suppoted by <ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100001809" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Natural Science Foundation of China</ce:grant-sponsor> (<ce:grant-number refid="gs1">21977128</ce:grant-number> and <ce:grant-number refid="gs1">81973359</ce:grant-number>) and <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100003453" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Guangdong Natural Science Fund</ce:grant-sponsor> (<ce:grant-number refid="gs2">2018A030313300</ce:grant-number>). Supporting grants from <ce:grant-sponsor id="gs3" sponsor-id="https://doi.org/10.13039/501100002402" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">SYSU</ce:grant-sponsor> startup funding (<ce:grant-number refid="gs3">36000-18831205</ce:grant-number> and <ce:grant-number refid="gs3">36000-18831113</ce:grant-number>), <ce:grant-sponsor id="gs4" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Guangdong Provincial Key Laboratory of Construction Foundation</ce:grant-sponsor> (No. <ce:grant-number refid="gs4">2017B030314030</ce:grant-number>), <ce:grant-sponsor id="gs5" sponsor-id="https://doi.org/10.13039/501100013061" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Jilin Province Science and Technology Development</ce:grant-sponsor> Project (<ce:grant-number refid="gs5">20190304046YY</ce:grant-number>), <ce:grant-sponsor id="gs6" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Major Special Projects for the Creation and Manufacture of New Drugs</ce:grant-sponsor> (<ce:grant-number refid="gs6">2018ZX09301031-001</ce:grant-number>) and <ce:grant-sponsor id="gs7" sponsor-id="https://doi.org/10.13039/100012541" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Guangdong Innovative and Entrepreneurial Research Team Program</ce:grant-sponsor> (No. <ce:grant-number refid="gs7">2016ZT06Y337</ce:grant-number>) are also appreciated.</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="all">
                  <ce:section-title id="sectitle0140">Abbreviations</ce:section-title>
                  <ce:para id="p0320" view="all">
                     <ce:def-list id="dlist0010">
                        <ce:def-term id="d0010">STAT3</ce:def-term>
                        <ce:def-description id="defdis0010">
                           <ce:para id="p0325" view="all">Signal Transducer and Activator of Transcription 3</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0015">JAK</ce:def-term>
                        <ce:def-description id="defdis0015">
                           <ce:para id="p0330" view="all">Janus kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0020">APRF</ce:def-term>
                        <ce:def-description id="defdis0020">
                           <ce:para id="p0335" view="all">acute-phase response factor</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0025">ETC</ce:def-term>
                        <ce:def-description id="defdis0025">
                           <ce:para id="p0340" view="all">electron transport chain</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0030">SOCS</ce:def-term>
                        <ce:def-description id="defdis0030">
                           <ce:para id="p0345" view="all">suppressors of cytokine signaling</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0035">PTPs</ce:def-term>
                        <ce:def-description id="defdis0035">
                           <ce:para id="p0350" view="all">protein tyrosine phosphatases</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0040">VEGF</ce:def-term>
                        <ce:def-description id="defdis0040">
                           <ce:para id="p0355" view="all">vascular endothelial growth factor</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0045">MMP-2</ce:def-term>
                        <ce:def-description id="defdis0045">
                           <ce:para id="p0360" view="all">matrix metalloproteinase-2</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0050">HNSCC</ce:def-term>
                        <ce:def-description id="defdis0050">
                           <ce:para id="p0365" view="all">head and neck squamous cell carcinoma</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0055">ALCL</ce:def-term>
                        <ce:def-description id="defdis0055">
                           <ce:para id="p0370" view="all">anaplastic large T cell lymphoma</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0060">EPO</ce:def-term>
                        <ce:def-description id="defdis0060">
                           <ce:para id="p0375" view="all">erythropoietin</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0065">DLBCL</ce:def-term>
                        <ce:def-description id="defdis0065">
                           <ce:para id="p0380" view="all">diffuse large B cell lymphoma</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0070">T-LGL</ce:def-term>
                        <ce:def-description id="defdis0070">
                           <ce:para id="p0385" view="all">T-cell large granular leukemia</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0075">CLPD-NK</ce:def-term>
                        <ce:def-description id="defdis0075">
                           <ce:para id="p0390" view="all">chronic lymphoproliferative disorders of NK cells</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0080">Th1</ce:def-term>
                        <ce:def-description id="defdis0080">
                           <ce:para id="p0395" view="all">T helper 1</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0085">DCs</ce:def-term>
                        <ce:def-description id="defdis0085">
                           <ce:para id="p0400" view="all">Dendritic cells</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0090">CCL5</ce:def-term>
                        <ce:def-description id="defdis0090">
                           <ce:para id="p0405" view="all">CC-chemokine ligand 5</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0095">CXCL-10</ce:def-term>
                        <ce:def-description id="defdis0095">
                           <ce:para id="p0410" view="all">CXC-chemokine ligand 10</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0100">PD-L1</ce:def-term>
                        <ce:def-description id="defdis0100">
                           <ce:para id="p0415" view="all">programmed death ligand 1</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0105">PD-1</ce:def-term>
                        <ce:def-description id="defdis0105">
                           <ce:para id="p0420" view="all">programmed cell death protein 1</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0110">ALK</ce:def-term>
                        <ce:def-description id="defdis0110">
                           <ce:para id="p0425" view="all">anaplastic lymphoma kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0115">LMP1</ce:def-term>
                        <ce:def-description id="defdis0115">
                           <ce:para id="p0430" view="all">latent membrane protein-1</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0120">JAKs</ce:def-term>
                        <ce:def-description id="defdis0120">
                           <ce:para id="p0435" view="all">Janus kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0125">pTyr705</ce:def-term>
                        <ce:def-description id="defdis0125">
                           <ce:para id="p0440" view="all">phosphorylated tyrosine 705</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0130">HTS</ce:def-term>
                        <ce:def-description id="defdis0130">
                           <ce:para id="p0445" view="all">high throughput screening</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0135">Cmax</ce:def-term>
                        <ce:def-description id="defdis0135">
                           <ce:para id="p0450" view="all">maximum concentration</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0140">RT-PCR</ce:def-term>
                        <ce:def-description id="defdis0140">
                           <ce:para id="p0455" view="all">reverse transcription polymerase chain reaction</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0145">EMSA</ce:def-term>
                        <ce:def-description id="defdis0145">
                           <ce:para id="p0460" view="all">electrophoretic mobility shift assay</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0150">PK</ce:def-term>
                        <ce:def-description id="defdis0150">
                           <ce:para id="p0465" view="all">pharmacokinetic</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0155">BBB</ce:def-term>
                        <ce:def-description id="defdis0155">
                           <ce:para id="p0470" view="all">blood brain barrier</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0160">SAR</ce:def-term>
                        <ce:def-description id="defdis0160">
                           <ce:para id="p0475" view="all">structure–activity relationship</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0165">SPR</ce:def-term>
                        <ce:def-description id="defdis0165">
                           <ce:para id="p0480" view="all">surface plasmon resonance</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0170">FP</ce:def-term>
                        <ce:def-description id="defdis0170">
                           <ce:para id="p0485" view="all">Fluorescence polarization</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0175">PK</ce:def-term>
                        <ce:def-description id="defdis0175">
                           <ce:para id="p0490" view="all">pharmacokinetic</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0180">FAK</ce:def-term>
                        <ce:def-description id="defdis0180">
                           <ce:para id="p0495" view="all">Focal adhesion kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0185">FRET</ce:def-term>
                        <ce:def-description id="defdis0185">
                           <ce:para id="p0500" view="all">Fluorescence resonance energy transfer</ce:para>
                        </ce:def-description>
                     </ce:def-list>
                  </ce:para>
                  <ce:para id="p0505" view="all">
                     <ce:def-list id="dlist0015">
                        <ce:section-title id="sectitle0145">Chip chromatin immunoprecipitation</ce:section-title>
                        <ce:def-term id="d0190">QSAR</ce:def-term>
                        <ce:def-description id="defdis0190">
                           <ce:para id="p0510" view="all">quantitative structure activity relationship</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0195">MST</ce:def-term>
                        <ce:def-description id="defdis0195">
                           <ce:para id="p0515" view="all">MicroScale Thermophoresis</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0200">G-CSF</ce:def-term>
                        <ce:def-description id="defdis0200">
                           <ce:para id="p0520" view="all">granulocyte colony-stimulating factor</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0205">ITC</ce:def-term>
                        <ce:def-description id="defdis0205">
                           <ce:para id="p0525" view="all">isothermal titration calorimetry</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0210">BSA</ce:def-term>
                        <ce:def-description id="defdis0210">
                           <ce:para id="p0530" view="all">bovine serum albumin</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0215">BTP</ce:def-term>
                        <ce:def-description id="defdis0215">
                           <ce:para id="p0535" view="all">benzo[b]thiophene 1,1-dioxide</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0220">VLS</ce:def-term>
                        <ce:def-description id="defdis0220">
                           <ce:para id="p0540" view="all">virtual ligand screening</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0225">MOA</ce:def-term>
                        <ce:def-description id="defdis0225">
                           <ce:para id="p0545" view="all">mechanism of action</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0230">TCI</ce:def-term>
                        <ce:def-description id="defdis0230">
                           <ce:para id="p0550" view="all">targeted covalent inhibitors</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0235">PROTAC</ce:def-term>
                        <ce:def-description id="defdis0235">
                           <ce:para id="p0555" view="all">proteolysis targeting chimera</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0240">POI</ce:def-term>
                        <ce:def-description id="defdis0240">
                           <ce:para id="p0560" view="all">protein of interest</ce:para>
                        </ce:def-description>
                     </ce:def-list>
                  </ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0150">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Hillmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Watowich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 signaling in immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cytokine Growth Factor Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>15</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">Hillmer, E. J.; Zhang, H.; Li, H. S.; Watowich, S. S. STAT3 signaling in immunity. Cytokine Growth Factor Rev. 2016, 31, 1-15.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kujawski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Herrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Investig.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>118</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3367</sb:first-page>
                              <sb:last-page>3377</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">Kujawski, M.; Kortylewski, M.; Lee, H.; Herrmann, A.; Kay, H.; Yu, H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 2008, 118, 3367-3377.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Miklossy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Hilliard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic modulators of STAT signalling for human diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>611</sb:first-page>
                              <sb:last-page>629</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">Miklossy, G.; Hilliard, T. S.; Turkson, J. Therapeutic modulators of STAT signalling for human diseases. Nat. Rev. Drug Discov. 2013, 12, 611-629.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Banerjee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Resat</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive activation of STAT3 in breast cancer cells: a review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>138</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2570</sb:first-page>
                              <sb:last-page>2578</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">Banerjee, K.; Resat, H. Constitutive activation of STAT3 in breast cancer cells: A review. Int. J. Cancer 2016, 138, 2570-2578.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Waldmann</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: inspired by functional and structural genomics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell. Endocrinol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>451</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>66</sb:first-page>
                              <sb:last-page>70</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">Waldmann, T. A. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics. Mol. Cell Endocrinol. 2017, 451, 66-70.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>O’Keefe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Grandis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the IL-6/JAK/STAT3 signalling axis in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>234</sb:first-page>
                              <sb:last-page>248</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">Johnson, D. E.; O’Keefe, R.A.; Grandis, J. R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 2018, 15, 234-248.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The STATs of cancer--new molecular targets come of age</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>97</sb:first-page>
                              <sb:last-page>105</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">Yu, H.; Jove, R. The STATs of cancer--new molecular targets come of age. Nat. Rev. Cancer 2004, 4, 97-105.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcription factors as targets for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>740</sb:first-page>
                              <sb:last-page>749</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">Darnell, J. E. Jr. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002, 2, 740-749.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of Stat3 in suppressing anti-tumor immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>798</sb:first-page>
                              <sb:last-page>809</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">Yu, H.; Pardoll, D.; Jove, R. Role of Stat3 in suppressing anti-tumor immunity. Nat. Rev. Cancer 2009, 9, 798-809.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Villarino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kanno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Ferdinand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>O’Shea</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms of Jak/STAT signaling in immunity and disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>194</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>21</sb:first-page>
                              <sb:last-page>27</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">Villarino, A. V.; Kanno, Y.; Ferdinand, J. R.; O’Shea, J. J. Mechanisms of Jak/STAT signaling in immunity and disease. J. Immunol. 2015, 194, 21-27.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Herrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Buettner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Revisiting STAT3 signaling in cancer: new and unexpected biological functions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>736</sb:first-page>
                              <sb:last-page>746</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">Yu, H.; Lee, H.; Herrmann, A.; Buettner, R.; Jove, R. Revisiting STAT3 signaling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 2014, 14, 736-746.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Pilati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zucman-Rossi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mutations leading to constitutive active gp130/JAK1/STAT3 pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cytokine Growth Factor Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>499</sb:first-page>
                              <sb:last-page>506</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">Pilati, C.; Zucman-Rossi, J. Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. Cytokine Growth Factor Rev. 2015, 26, 499-506.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Shahmarvand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Nagy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shahryari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Ohgami</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mutations in the signal transducer and activator of transcription family of genes in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>109</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>926</sb:first-page>
                              <sb:last-page>933</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">Shahmarvand, N.; Nagy, A.; Shahryari, J.; Ohgami, R. S. Mutations in the signal transducer and activator of transcription family of genes in cancer. Cancer Sci. 2018, 109, 926-933.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Aigner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Just</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Stoiber</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 isoforms: alternative fates in cancer?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cytokine</sb:maintitle>
                                 </sb:title>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <ce:doi>10.1016/j.cyto.2018.07.014</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">Aigner, P.; Just, V.; Stoiber, D. STAT3 isoforms: Alternative fates in cancer? Cytokine 2018, doi.org/10.1016/j.cyto.2018.07.014.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Functional importance of Stat3 tetramerization in activation of the alpha 2-macroglobulin gene</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>276</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>33576</sb:first-page>
                              <sb:last-page>33581</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">Zhang X, Darnell, J. E. Jr. Functional importance of Stat3 tetramerization in activation of the alpha 2-macroglobulin gene. J. Biol. Chem. 2001, 276, 33576-33581.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lerner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Henriksen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3-dependent enhanceosome assembly and disassembly: synergy with GR for full transcriptional increase of the alpha 2-macroglobulin gene</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Genes Dev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2564</sb:first-page>
                              <sb:last-page>2577</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">Lerner, L.; Henriksen, M. A.; Zhang, X.; Darnell, J. E. Jr. STAT3-dependent enhanceosome assembly and disassembly: synergy with GR for full transcriptional increase of the alpha 2-macroglobulin gene. Genes Dev. 2003, 17, 2564-2577.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.X.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.T.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ata Ur Rasheed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Rochman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Cui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.L.</ce:given-name>
                                 <ce:surname>Kelsall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ahmed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Leonard</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Critical role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunity</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>586</sb:first-page>
                              <sb:last-page>599</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">Lin, J. X.; Li, P.; Liu, D.; Jin, H. T.; He, J.; Ata Ur Rasheed, M.; Rochman, Y.; Wang, L.; Cui, K.; Liu, C.; Kelsall, B. L.; Ahmed, R.; Leonard, W. J. Critical role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity 2012, 36, 586-599.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>De Simone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Franze</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ronchetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Colantoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Fantini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Di Fusco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Sica</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sileri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.T.</ce:given-name>
                                 <ce:surname>MacDonald</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Pallone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Monteleone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Stolfi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Th17-type cytokines, IL-6 and TNF-alpha synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3493</sb:first-page>
                              <sb:last-page>3503</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">De Simone, V.; Franze, E.; Ronchetti, G.; Colantoni, A.; Fantini, M. C.; Di Fusco, D.; Sica, G. S.; Sileri, P.; MacDonald, T. T.; Pallone, F.; Monteleone, G.; Stolfi, C. Th17-type cytokines, IL-6 and TNF-alpha synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene 2015, 34, 3493-3503.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.H.</ce:given-name>
                                 <ce:surname>van Boxel-Dezaire</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Cheon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Stark</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>110</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>16975</sb:first-page>
                              <sb:last-page>16980</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">Wang, Y.; van Boxel-Dezaire, A. H.; Cheon, H.; Yang, J.; Stark, G. R. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 16975-16980.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Coppo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Dusanter-Fourt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Millot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Nogueira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dugray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Bonnet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Mitjavila-Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Le Pesteur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Guilhot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Vainchenker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Sainteny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Turhan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4102</sb:first-page>
                              <sb:last-page>4110</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">Coppo, P.; Dusanter-Fourt, I.; Millot, G.; Nogueira, M. M.; Dugray, A.; Bonnet, M. L.; Mitjavila-Garcia, M. T.; Le Pesteur, D.; Guilhot, F.; Vainchenker, W.; Sainteny, F.; Turhan, A. G. Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene 2003, 22, 4102-4110.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Bowman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Minton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Muro-Cacho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.E.</ce:given-name>
                                 <ce:surname>Cox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Falcone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fairclough</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Parsons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Laudano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gazit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Levitzki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kraker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2499</sb:first-page>
                              <sb:last-page>2513</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">Garcia, R.; Bowman, T. L.; Niu, G.; Yu, H.; Minton, S.; Muro-Cacho, C. A.; Cox, C. E.; Falcone, R.; Fairclough, R.; Parsons, S.; Laudano, A.; Gazit, A., Levitzki, A.; Kraker, A.; Jove R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20, 2499-2513.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Braunstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Brutsaert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Schindler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs dimerize in the absence of phosphorylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>278</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>34133</sb:first-page>
                              <sb:last-page>34140</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">Braunstein, J.; Brutsaert, S.; Olson, R.; Schindler, C. STATs dimerize in the absence of phosphorylation. J. Biol. Chem. 2003, 278, 34133-34140.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.L.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Guan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Chatterjee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.E.</ce:given-name>
                                 <ce:surname>Chin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat3 dimerization regulated by reversible acetylation of a single lysine residue</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>307</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>269</sb:first-page>
                              <sb:last-page>273</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">Yuan, Z. L.; Guan, Y. J.; Chatterjee, D.; Chin, Y. E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005, 307, 269−273.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Delgoffe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Vignali</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT heterodimers in immunity: a mixed message or a unique signal?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>JAK-STAT</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:article-number>e23060</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">Delgoffe, G. M.; Vignali, D. A. STAT heterodimers in immunity: A mixed message or a unique signal? JAKSTAT. 2013, 2, e23060.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Herrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Hoon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Forman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Riggs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>109</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7765</sb:first-page>
                              <sb:last-page>7769</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">Lee, H.; Zhang, P.; Herrmann, A.; Yang, C.; Xin, H.; Wang, Z.; Hoon, D. S.; Forman, S. J.; Jove, R.; Riggs, A. D.; Yu, H., Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 7765-7769.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wingelhofer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Neubauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Valent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Constantinescu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Muller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Moriggl</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1713</sb:first-page>
                              <sb:last-page>1726</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">Wingelhofer, B.; Neubauer, H. A.; Valent, P.; Han, X.; Constantinescu, S. N.; Gunning, P. T.; Muller, M.; Moriggl, R. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia 2018, 32, 1713-1726.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Rincon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mitochondrial Stat3, the need for design thinking</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Biol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>532</sb:first-page>
                              <sb:last-page>544</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">Yang, R.; Rincon, M. Mitochondrial Stat3, the need for design thinking. Int. J. Biol. Sci. 2016, 12, 532-544.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Beldi-Ferchiou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Skouri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ben Ali</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Safra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Abdelkefi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ladeb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Mrad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ben Othman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ben Ahmed</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:article-number>e0174835</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">Beldi-Ferchiou, A.; Skouri, N.; Ben Ali, C.; Safra, I.; Abdelkefi, A.; Ladeb, S.; Mrad, K.; Ben Othman, T.; Ben Ahmed, M. Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma. PLoS One 2017, 12, e0174835.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Watson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.R.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>71</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>840</sb:first-page>
                              <sb:last-page>844</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">Watson, C. J.; Miller, W. R. Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br. J. Cancer 1995, 71, 840-844.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>McDaniel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.E.</ce:given-name>
                                 <ce:surname>Varley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Gertz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Savic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Bailey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Shevde</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Ramaker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.N.</ce:given-name>
                                 <ce:surname>Lasseigne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Kirby</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Newberry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.C.</ce:given-name>
                                 <ce:surname>Partridge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Boone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Levy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Oliver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Sexton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.E.</ce:given-name>
                                 <ce:surname>Grizzle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Forero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Buchsbaum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Cooper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Myers</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Genomic regulation of invasion by STAT3 in triple negative breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8226</sb:first-page>
                              <sb:last-page>8238</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">McDaniel, J. M.; Varley, K. E.; Gertz, J.; Savic, D. S.; Roberts, B. S.; Bailey, S. K.; Shevde, L. A.; Ramaker, R. C.; Lasseigne, B. N.; Kirby, M. K.; Newberry, K. M.; Partridge, E. C.; Jones, A. L.; Boone, B.; Levy, S. E.; Oliver, P. G.; Sexton, K. C.; Grizzle, W. E.; Forero, A.; Buchsbaum, D. J.; Cooper, S. J.; Myers, R. M. Genomic regulation of invasion by STAT3 in triple negative breast cancer. Oncotarget 2017, 8, 8226-8238.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Bowman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Minton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Muro-Cacho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.E.</ce:given-name>
                                 <ce:surname>Cox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Falcone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fairclough</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Parsons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Laudano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gazit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Levitzki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kraker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2499</sb:first-page>
                              <sb:last-page>2513</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">Garcia, R.; Bowman, T. L.; Niu, G.; Yu, H.; Minton, S.; Muro-Cacho, C. A.; Cox, C. E.; Falcone, R.; Fairclough, R.; Parsons, S.; Laudano, A.; Gazit, A.; Levitzki, A.; Kraker, A.; Jove, R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20, 2499-2513.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhuang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Scolyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>McCarthy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.D.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Thompson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Hersey</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mod. Pathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>416</sb:first-page>
                              <sb:last-page>426</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">Zhuang, L.; Lee, C. S.; Scolyer, R. A.; McCarthy, S. W.; Zhang, X. D.; Thompson, J. F.; Hersey, P. Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod. Pathol. 2007, 20, 416-426.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Wright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Haura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sinibaldi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Coppola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Heller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Ellis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Karras</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2000</sb:first-page>
                              <sb:last-page>2008</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">Niu, G.; Wright, K. L.; Huang, M.; Song, L.; Haura, E.; Turkson, J.; Zhang, S.; Wang, T.; Sinibaldi, D.; Coppola, D.; Heller, R.; Ellis, L. M.; Karras, J.; Bromberg, J.; Pardoll, D.; Jove, R.; Yu, H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21, 2000-2008.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Masuda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Suzui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Yasumatu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nakashima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kuratomi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Azuma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Tomita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Komiyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.B.</ce:given-name>
                                 <ce:surname>Weinstein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive activation of signal transducers and activators of transcription 3 correlates with Cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3351</sb:first-page>
                              <sb:last-page>3355</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">Masuda, M.; Suzui, M.; Yasumatu, R.; Nakashima, T.; Kuratomi, Y.; Azuma, K.; Tomita, K.; Komiyama, S.; Weinstein, I. B. Constitutive activation of signal transducers and activators of transcription 3 correlates with Cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002, 62, 3351-3355.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Sriuranpong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.I.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Amornphimoltham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Nelkin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Gutkind</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine-paracrine stimulation of the interleukin 6-gp130 cytokine system</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>63</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2948</sb:first-page>
                              <sb:last-page>2956</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">Sriuranpong, V.; Park, J. I.; Amornphimoltham, P.; Patel, V.; Nelkin, B. D.; Gutkind, J. S. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine-paracrine stimulation of the interleukin 6-gp130 cytokine system. Cancer Res. 2003, 63, 2948-2956.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Don-Doncow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Marginean</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Coleman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Nelson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ehrnstrom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Krzyzanowska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Morrissey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hellsten</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bjartell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expression of STAT3 in prostate cancer metastases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. Urol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>71</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>313</sb:first-page>
                              <sb:last-page>316</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">Don-Doncow, N.; Marginean, F.; Coleman, I.; Nelson, P. S.; Ehrnstrom, R.; Krzyzanowska, A.; Morrissey, C.; Hellsten, R.; Bjartell, A. Expression of STAT3 in prostate cancer metastases. Eur. Urol. 2017, 71, 313-316.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ishii</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sasaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Iguchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kajiwara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kanda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hirokawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Arima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mizokami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Sugimura</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>The Prostate</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>78</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>849</sb:first-page>
                              <sb:last-page>856</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">Ishii, K.; Sasaki, T.; Iguchi, K.; Kajiwara, S.; Kato, M.; Kanda, H.; Hirokawa, Y.; Arima, K.; Mizokami, A.; Sugimura, Y., Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation. Prostate 2018, 78, 849-856.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Natesh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bhosale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Desai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chandrika</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Pujari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jagtap</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chugh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ranade</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Shastry</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oncostatin-M differentially regulates mesenchymal and proneural signature genes in gliomas via STAT3 signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neoplasia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>225</sb:first-page>
                              <sb:last-page>237</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">Natesh, K.; Bhosale, D.; Desai, A.; Chandrika, G.; Pujari, R.; Jagtap, J.; Chugh, A.; Ranade, D.; Shastry, P. Oncostatin-M differentially regulates mesenchymal and proneural signature genes in gliomas via STAT3 signaling. Neoplasia 2015, 17, 225-237.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Arora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Arfuso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Chng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sethi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of signal transducer and activator of transcription 3 (STAT3) and its targeted inhibition in hematological malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancers</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>327</sb:first-page>
                              <sb:last-page>343</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">Arora, L.; Kumar, A. P.; Arfuso, F.; Chng, W. J.; Sethi, G. The role of signal transducer and activator of transcription 3 (STAT3) and its targeted inhibition in hematological malignancies. Cancers 2018, 10, 327-343.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Baer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.W.</ce:given-name>
                                 <ce:surname>Block</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Baumann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wetzler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3173</sb:first-page>
                              <sb:last-page>3180</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">Xia, Z.; Baer, M.R.; Block, A. W.; Baumann, H.; Wetzler, M. Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res. 1998, 58, 3173-3180.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Watanabe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Naka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kishimoto</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Implication of SOCS-1 gene methylation in acute myeloid leukaemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Haematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>127</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>608</sb:first-page>
                              <sb:last-page>609</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">Watanabe, D.; Naka, T.; Kishimoto, T. Implication of SOCS-1 gene methylation in acute myeloid leukaemia. Br. J. Haematol. 2004, 127, 608-609.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcription factor STAT3 as a novel molecular target for cancer prevention</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancers (Basel)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>926</sb:first-page>
                              <sb:last-page>957</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">Xiong, A.; Yang, Z.; Shen, Y.; Zhou, J.; Shen, Q. Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers (Basel). 2014, 6, 926-957.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.Z.</ce:given-name>
                                 <ce:surname>Chai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Shanmugam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Arfuso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dharmarajan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.P.</ce:given-name>
                                 <ce:surname>Samy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.H.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.C.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Ahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Hui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sethi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting transcription factor STAT3 for cancer prevention and therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>162</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>86</sb:first-page>
                              <sb:last-page>97</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">Chai, E. Z.; Shanmugam, M. K.; Arfuso, F.; Dharmarajan, A.; Wang, C.; Kumar, A. P.; Samy, R. P.; Lim, L. H.; Wang, L.; Goh, B. C.; Ahn, K. S.; Hui, K. M.; Sethi G. Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacol. Ther. 2016, 162, 86-97.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Villalva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Martin-Lannerée</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Dkhissi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wager</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Le Corf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Tourani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Dusanter-Fourt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Turhan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Karayan-Tapon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>128</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>826</sb:first-page>
                              <sb:last-page>838</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">Villalva, C.; Martin-Lanneree, S.; Cortes, U.; Dkhissi, F.; Wager, M.; Le Corf, A.; Tourani, J. M.; Dusanter-Fourt, I.; Turhan, A. G.; Karayan-Tapon, L. STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy? Int. J. Cancer 2011, 128, 826-838.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Marotta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Almendro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Marusyk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Shipitsin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schemme</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Walker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bloushtain-Qimron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Choudhury</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Maruyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gönen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Mulvey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.O.</ce:given-name>
                                 <ce:surname>Bessarabova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Huh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Silver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.E.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Anderson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Richardson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nikolskaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nikolsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.S.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Root</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Hahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Frank</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Polyak</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Investig.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>121</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2723</sb:first-page>
                              <sb:last-page>2735</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">Marotta, L. L.; Almendro, V.; Marusyk, A.; Shipitsin, M.; Schemme, J.; Walker, S. R.; Bloushtain-Qimron, N.; Kim, J. J.; Choudhury, S. A.; Maruyama, R.; Wu, Z.; Gonen, M.; Mulvey, L. A.; Bessarabova, M. O.; Huh, S. J.; Silver, S. J.; Kim, S. Y.; Park, S. Y.; Lee, H. E.; Anderson, K. S.; Richardson, A. L.; Nikolskaya, T.; Nikolsky, Y.; Liu, X. S.; Root, D. E.; Hahn, W. C.; Frank, D. A.; Polyak, K. The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 2011, 121, 2723-2735.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>Koskela</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Eldfors</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ellonen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>van Adrichem</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kuusanmäki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.I.</ce:given-name>
                                 <ce:surname>Andersson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lagström</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Clemente</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Jalkanen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Majumder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Almusa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Edgren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lepistö</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Mattila</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Guinta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Koistinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kuittinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Penttinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Parsons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Knowles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Saarela</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Wennerberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Kallioniemi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Porkka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Loughran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Heckman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Maciejewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mustjoki</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Somatic STAT3 mutations in large granular lymphocytic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>366</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1905</sb:first-page>
                              <sb:last-page>1913</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">Koskela, H. L.; Eldfors, S.; Ellonen, P.; van Adrichem, A. J.; Kuusanmaki, H.; Andersson, E. I.; Lagstrom, S.; Clemente, M. J.; Olson, T.; Jalkanen, S. E.; Majumder, M. M.; Almusa, H.; Edgren, H.; Lepisto, M.; Mattila, P.; Guinta, K.; Koistinen, P.; Kuittinen, T.; Penttinen, K.; Parsons, A.; Knowles, J.; Saarela, J.; Wennerberg, K.; Kallioniemi, O.; Porkka, K.; Loughran, T. P .; Heckman, C. A.; Maciejewski, J. P.; Mustjoki, S. Somatic STAT3 mutations in large granular lymphocytic leukemia. N. Engl. J. Med. 2012, 366,1905-1913.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Andersson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kuusanmaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bortoluzzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lagstrom</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Parsons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Rajala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>van Adrichem</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Eldfors</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Clemente</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Laasonen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ellonen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Heckman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Loughran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Maciejewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mustjoki</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1204</sb:first-page>
                              <sb:last-page>1208</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">Andersson, E.; Kuusanmaki, H.; Bortoluzzi, S.; Lagstrom, S.; Parsons, A.; Rajala, H.; van Adrichem, A.; Eldfors, S.; Olson, T.; Clemente, M. J.; Laasonen, A.; Ellonen, P.; Heckman, C.; Loughran, T. P.; Maciejewski, J. P.; Mustjoki, S. Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. Leukemia 2016, 30, 1204-1208.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Couronne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Scourzic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Pilati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Della Valle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Duffourd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Solary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Vainchenker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Merlio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Beylot-Barry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Damm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Stern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Gaulard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lamant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Delabesse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Merle-Beral</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Nguyen-Khac</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Fontenay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Tilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Bastard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zucman-Rossi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.A.</ce:given-name>
                                 <ce:surname>Bernard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Mercher</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Haematologica</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>98</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1748</sb:first-page>
                              <sb:last-page>1752</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">Couronne, L.; Scourzic, L.; Pilati, C.; Della Valle, V.; Duffourd, Y.; Solary, E.; Vainchenker, W.; Merlio, J. P.; Beylot-Barry, M.; Damm, F.; Stern, M. H.; Gaulard, P.; Lamant, L.; Delabesse, E.; Merle-Beral, H.; Nguyen-Khac, F.; Fontenay, M.; Tilly, H.; Bastard, C.; Zucman-Rossi, J.; Bernard, O. A.; Mercher, T. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica 2013, 98, 1748-1752.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dutta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>Hutchison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Mohi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 mutations are not sufficient to induce large granular lymphocytic leukaemia in mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Haematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>180</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>911</sb:first-page>
                              <sb:last-page>915</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">Dutta, A.; Yan, D.; Hutchison, R. E.; Mohi, G. STAT3 mutations are not sufficient to induce large granular lymphocytic leukaemia in mice. Br. J. Haematol. 2018, 180, 911-915.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Ohgami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Monabati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Zehnder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Arbe</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 mutations are present in aggressive B-cell</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Haematologica</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>99</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>105</sb:first-page>
                              <sb:last-page>107</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0270">Ohgami, R. S.; Ma, L.; Monabati, A.; Zehnder, J. L.; Arbe, D. A. STAT3 mutations are present in aggressive B-cell. Haematologica 2014, 99, 105-107.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Takeda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.E.</ce:given-name>
                                 <ce:surname>Clausen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kaisho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tsujimura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Terada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Förster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Akira</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunity</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>39</sb:first-page>
                              <sb:last-page>49</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">Takeda, K.; Clausen, B E.; Kaisho, T.; Tsujimura, T.; Terada, N.; Forster, I.; Akira, S. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999, 10, 39-49.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kujawski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pilon-Thomas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Mule</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Kerr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1314</sb:first-page>
                              <sb:last-page>1321</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">Kortylewski, M.; Kujawski, M.; Wang, T.; Wei, S.; Zhang, S.; Pilon-Thomas, S.; Niu, G.; Kay, H.; Mule, J.; Kerr, W. G.; Jove, R.; Pardoll, D.; Yu, H. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 2005, 11, 1314-1321.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Constantino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Gomes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Falcao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Neves</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Cruz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dendritic cell-based immunotherapy: a basic review and recent advances</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunol. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>65</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>798</sb:first-page>
                              <sb:last-page>810</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">Constantino, J.; Gomes, C.; Falcao, A.; Neves, B. M.; Cruz, M. T. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol. Res. 2017, 65, 798-810.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Burdelya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Shain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bhattacharya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Gabrilovich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Heller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Coppola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Dalton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>48</sb:first-page>
                              <sb:last-page>54</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">Wang, T.; Niu, G.; Kortylewski, M.; Burdelya, L.; Shain, K.; Zhang, S.; Bhattacharya, R.; Gabrilovich, D.; Heller, R.; Coppola, D.; Dalton, W.; Jove, R.; Pardoll, D.; Yu, H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 2004, 10, 48-54.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Priceman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 in CD8+ T cells inhibits their tumor accumulation by downregulating CXCR3/CXCL10 axis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Immunol. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>864</sb:first-page>
                              <sb:last-page>870</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0295">Yue, C.; Shen, S.; Deng, J.; Priceman, S. J.; Li, W.; Huang, A.; Yu, H. STAT3 in CD8+ T cells inhibits their tumor accumulation by downregulating CXCR3/CXCL10 axis. Cancer Immunol. Res. 2015, 3, 864-870.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nairismägi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Laurensia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Pang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kizhakeyil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wijaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nagarajan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Chia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Cheah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Rao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.K.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Iqbal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Grigoropoulos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Chng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Teh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.K.</ce:given-name>
                                 <ce:surname>Verma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer-T-cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>132</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1146</sb:first-page>
                              <sb:last-page>1158</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0300">Song, T. L.; Nairismagi, M.; Laurensia, Y.; Lim, J.; Tan, J.; Li, Z.; Pang, W.; Kizhakeyil, A.; Wijaya, G.; Huang, D.; Nagarajan, S.; Chia, B. K.; Cheah, D.; Liu, Y.; Zhang, F.; Rao, H.; Tang, T.; Wong, E. K.; Bei, J.; Iqbal, J.; Grigoropoulos, N.; Ng, S.; Chng, W.; Teh, B.; Tan, S.; Verma, N. K.; Fan, H.; Lim, S.; Ong, C. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer-T-cell lymphoma. Blood 2018, 132, 1146-1158.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Atsaves</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Tsesmetzis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Chioureas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Leventaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Drakos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Panaretakis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Grander</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Medeiros</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Young</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.Z.</ce:given-name>
                                 <ce:surname>Rassidakis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1633</sb:first-page>
                              <sb:last-page>1637</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0305">Atsaves, V.; Tsesmetzis, N.; Chioureas, D.; Kis, L.; Leventaki, V.; Drakos, E.; Panaretakis, T.; Grander, D.; Medeiros, L. J.; Young, K. H.; Rassidakis, G. Z. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia 2017, 31, 1633-1637.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Marzec</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Goradia</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>105</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>20852</sb:first-page>
                              <sb:last-page>20857</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0310">Marzec, M.; Zhang, Q.; Goradia, A. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 20852-20857.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>12189</sb:first-page>
                              <sb:last-page>12202</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0315">Fang, W.; Zhang, J.; Hong, S. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget 2014, 5, 12189-12202.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U.M.</ce:given-name>
                                 <ce:surname>Litzenburger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Opitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Sahm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Rauschenbach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Trump</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Winter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ochs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lutz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Anastasov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Lehmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Höfer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>von Deimling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Platten</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive Ido expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1038</sb:first-page>
                              <sb:last-page>1051</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0320">Litzenburger, U. M.; Opitz, C. A.; Sahm, F.; Rauschenbach, K. J.; Trump, S.; Winter, M.; Ott, M.; Ochs, K.; Lutz, C.; Liu, X.; Anastasov, N.; Lehmann, I.; Hofer, T.; von Deimling, A.; Wick, W.; Platten, M. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget. 2014, 5, 1038-1051.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Zerdes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wallerius</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.G.</ce:given-name>
                                 <ce:surname>Sifakis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wallmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Betts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bartish</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Tsesmetzis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.P.</ce:given-name>
                                 <ce:surname>Tobin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Coucoravas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bergh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.Z.</ce:given-name>
                                 <ce:surname>Rassidakis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Rolny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Foukakis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 activity promotes programmed-death ligand 1 expression and suppresses immune responses in breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancers (Basel)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>pii: E1479</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0325">Zerdes, I.; Wallerius, M.; Sifakis, E. G.; Wallmann, T.; Betts, S.; Bartish, M.; Tsesmetzis, N.; Tobin, N. P.; Coucoravas, C.; Bergh, J.; Rassidakis, G. Z.; Rolny, C.; Foukakis, T. STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer. Cancers (Basel). 2019, 11, pii: E1479.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref62">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Debnath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Neamati</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6645</sb:first-page>
                              <sb:last-page>6668</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0330">Debnath, B.; Xu, S.; Neamati, N. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. J. Med. Chem. 2012, 55, 6645-6668.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Furtek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Backos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Matheson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Reigan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Strategies and approaches of targeting STAT3 for cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>308</sb:first-page>
                              <sb:last-page>318</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0335">Furtek, S. L.; Backos, D. S.; Matheson, C. J.; Reigan, P. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem. Biol. 2016, 11, 308-318.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref64">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Mandal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>McMurray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-affinity relationships of glutamine mimics incorporated into phosphopeptides targeted to the SH2 domain of signal transducer and activator of transcription 3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6126</sb:first-page>
                              <sb:last-page>6141</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0340">Mandal, P. K.; Ren, Z.; Chen, X.; Xiong, C.; McMurray, J. S. Structure-affinity relationships of glutamine mimics incorporated into phosphopeptides targeted to the SH2 domain of signal transducer and activator of transcription 3. J. Med. Chem. 2009, 52, 6126-6141.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref65">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Coleman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Mandal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Cameron</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Dyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Muranjan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Campbell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>McMurray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>48</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6661</sb:first-page>
                              <sb:last-page>6670</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0345">Coleman, D. R.; Ren, Z.; Mandal, P. K.; Cameron, A. G.; Dyer, G. A.; Muranjan, S.; Campbell, M.; Chen, X.; McMurray, J. S. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. J. Med. Chem. 2005, 48, 6661-6670.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>[66]</ce:label>
                     <sb:reference id="sref66">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Mandal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Limbrick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Coleman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Dyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Birtwistle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Briggs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>McMurray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Conformationally constrained peptido-mimetic inhibitors of signal transducer and activator of transcription 3: evaluation and molecular modeling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2429</sb:first-page>
                              <sb:last-page>2442</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0350">Mandal, P. K.; Limbrick, D.; Coleman, D. R.; Dyer, G. A.; Ren, Z.; Birtwistle, J. S.; Xiong, C.; Chen, X.; Briggs, J. M.; McMurray, J. S. Conformationally constrained peptido-mimetic inhibitors of signal transducer and activator of transcription 3: Evaluation and molecular modeling. J. Med. Chem. 2009, 52, 2429-2442.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>[67]</ce:label>
                     <sb:reference id="sref67">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Mandal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ramesh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Birtwistle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Kaluarachchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Bast</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.S.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>McMurray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3549</sb:first-page>
                              <sb:last-page>3563</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0355">Mandal, P. K.; Gao, F.; Lu, Z.; Ren, Z.; Ramesh, R.; Birtwistle, J. S.; Kaluarachchi, K. K.; Chen, X.; Bast, R. C. Jr.; Liao, W. S.; McMurray, J. S. Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J. Med. Chem. 2011, 54, 3549-3563.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib68">
                     <ce:label>[68]</ce:label>
                     <sb:reference id="sref68">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Mandal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Morlacchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Knight</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Link</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Nurieva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dhanik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kavraki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.B.</ce:given-name>
                                 <ce:surname>Corry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Ladbury</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>McMurray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the Src homology 2 (SH2) domain of signal transducer and activator of transcription 6 (STAT6) with cell-permeable, phosphatase-stable phosphopeptide mimics potently inhibits Tyr641 phosphorylation and transcriptional activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8970</sb:first-page>
                              <sb:last-page>8984</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0360">Mandal, P. K.; Morlacchi, P.; Knight, J. M.; Link, T. M.; Lee, G. R.; Nurieva, R.; Singh, D.; Dhanik, A.; Kavraki, L.; Corry, D. B.; Ladbury, J. E.; McMurray, J. S. Targeting the Src homology 2 (SH2) domain of signal transducer and activator of transcription 6 (STAT6) with cell-permeable, phosphatase-stable phosphopeptide mimics potently inhibits Tyr641 phosphorylation and transcriptional activity. J. Med. Chem. 2015, 58, 8970-8984.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib69">
                     <ce:label>[69]</ce:label>
                     <sb:reference id="sref69">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Gomez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Nikolovska-Coleska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and evaluation of peptidomimetics containing Freidinger lactams as STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1733</sb:first-page>
                              <sb:last-page>1736</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0365">Gomez, C.; Bai, L.; Zhang, J.; Nikolovska-Coleska, Z.; Chen, J.; Yi, H.; Wang, S. Design, synthesis, and evaluation of peptidomimetics containing Freidinger lactams as STAT3 inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 1733−1736.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib70">
                     <ce:label>[70]</ce:label>
                     <sb:reference id="sref70">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bernard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Nikolovska-Coleska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Gomez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of conformationally constrained, cell-permeable STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>85</sb:first-page>
                              <sb:last-page>89</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0370">Chen, J.; Bai, L.; Bernard, D.; Nikolovska-Coleska, Z.; Gomez, C.; Zhang, J.; Yi, H.; Wang, S. Structure-based design of conformationally constrained, cell-permeable STAT3 inhibitors. ACS Med. Chem. Lett. 2010, 1. 85-89.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib71">
                     <ce:label>[71]</ce:label>
                     <sb:reference id="sref71">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Miklossy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Hilliard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic modulators of STAT signaling for human diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>611</sb:first-page>
                              <sb:last-page>629</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0375">Miklossy, G.; Hilliard, T. S.; Turkson, J. Therapeutic modulators of STAT signaling for human diseases. Nat. Rev. Drug Discov. 2013, 12, 611-629.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib72">
                     <ce:label>[72]</ce:label>
                     <sb:reference id="sref72">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ryan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Haura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Laudano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Hamilton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>276</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>45443</sb:first-page>
                              <sb:last-page>45455</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0380">Turkson, J.; Ryan, D.; Kim, J. S.; Zhang, Y.; Chen, Z.; Haura, E.; Laudano, A.; Sebti, S.; Hamilton, A. D.; Jove, R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 2001, 276, 45443-45455.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib73">
                     <ce:label>[73]</ce:label>
                     <sb:reference id="sref73">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Glenn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Haura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Hamilton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>261</sb:first-page>
                              <sb:last-page>269</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0385">Turkson, J.; Kim, J. S.; Zhang, S.; Yuan, J.; Huang, M.; Glenn, M.; Haura, E.; Sebti, S.; Hamilton, A. D.; Jove, R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther. 2004, 3, 261-269.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib74">
                     <ce:label>[74]</ce:label>
                     <sb:reference id="sref74">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>Glenn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Siddiquee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.P.</ce:given-name>
                                 <ce:surname>Katt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Masson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Hamilton</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chembiochem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2800</sb:first-page>
                              <sb:last-page>2803</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0390">Gunning, P. T.; Glenn, M. P.; Siddiquee, K. A.; Katt, W. P.; Masson, E.; Sebti, S. M.; Turkson, J.; Hamilton, A. D. Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chembiochem 2008, 9, 2800-2803.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib75">
                     <ce:label>[75]</ce:label>
                     <sb:reference id="sref75">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Siddiquee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Guida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Blaskovich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Greedy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Yip</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>McLaughlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective chemical probe inhibitor of Stat3, identiﬁed through structure-based virtual screening, induces antitumor activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7391</sb:first-page>
                              <sb:last-page>7396</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0395">Siddiquee, K.; Zhang, S.; Guida, W. C.; Blaskovich, M. A.; Greedy, B.; Lawrence, H. R.; Yip, M. L.; Jove, R.; McLaughlin, M. M.; Lawrence, N. J.; Sebti, S. M.; Turkson, J. Selective chemical probe inhibitor of Stat3, identiﬁed through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 7391−7396.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib76">
                     <ce:label>[76]</ce:label>
                     <sb:reference id="sref76">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Resetca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Wilson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>20669</sb:first-page>
                              <sb:last-page>20679</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0400">Ball, D. P.; Lewis, A. M.; Williams, D.; Resetca, D.; Wilson, D. J.; Gunning, P. T. Signal transducer and activator of transcription 3 (STAT3) inhibitor, S3I-201, acts as a potent and non-selective alkylating agent. Oncotarget 2016, 7, 20669-20679.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib77">
                     <ce:label>[77]</ce:label>
                     <sb:reference id="sref77">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sharmeen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Shahani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Schimmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent <ce:italic>in vitro</ce:italic> and tumor cell activities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chembiochem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1959</sb:first-page>
                              <sb:last-page>1964</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0405">Fletcher, S.; Singh, J.; Zhang, X.; Yue, P.; Page, B. D.; Sharmeen, S.; Shahani, V. M.; Zhao, W.; Schimmer, A. D.; Turkson, J.; Gunning, P. T. Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem. 2009, 10, 1959-1964.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib78">
                     <ce:label>[78]</ce:label>
                     <sb:reference id="sref78">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel small-molecule disrupts Stat3 SH2 domain phosphotyrosine interactions and Stat3-dependent tumor processes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>79</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1398</sb:first-page>
                              <sb:last-page>1409</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0410">Zhang, X.; Yue, P.; Fletcher, S.; Zhao, W.; Gunning, P. T.; Turkson, J. A novel small-molecule disrupts Stat3 SH2 domain phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem. Pharmacol. 2010, 79, 1398−1409.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib79">
                     <ce:label>[79]</ce:label>
                     <sb:reference id="sref79">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sharmeen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Datti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Wrana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Trudel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Schimmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identiﬁcation of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5605</sb:first-page>
                              <sb:last-page>5609</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0415">Page, B. D.; Fletcher, S.; Yue, P.; Li, Z.; Zhang, X.; Sharmeen, S.; Datti, A.; Wrana, J. L.; Trudel, S.; Schimmer, A. D.; Turkson, J.; Gunning, P. T. Identiﬁcation of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg. Med. Chem. Lett. 2011, 21, 5605−5609.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib80">
                     <ce:label>[80]</ce:label>
                     <sb:reference id="sref80">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Namanja</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Paladino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Orally bioavailable small-molecule inhibitor of transcription factor Stat3 egresses human breast and lung cancer xenografts</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>109</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9623</sb:first-page>
                              <sb:last-page>9628</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0420">Zhang, X.; Yue, P.; Page, B. D.; Li, T.; Zhao, W.; Namanja, A. T.; Paladino, D.; Zhao, J.; Chen, Y.; Gunning, P. T.; Turkson, J. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 egresses human breast and lung cancer xenografts. Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 9623−9628.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib81">
                     <ce:label>[81]</ce:label>
                     <sb:reference id="sref81">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Haftchenary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Luchman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.O.</ce:given-name>
                                 <ce:surname>Jouk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Veloso</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.R.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Dawson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Grinshtein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Shahani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kerman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Kaplan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Griffin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Aman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Al-Awar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Weiss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potent targeting of the STAT3 protein in brain cancer stem cells: a promising route for treating glioblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1102</sb:first-page>
                              <sb:last-page>1107</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0425">Haftchenary, S.; Luchman, H. A.; Jouk, A. O.; Veloso, A. J.; Page, B. D.; Cheng, X. R.; Dawson, S. S.; Grinshtein, N.; Shahani, V. M.; Kerman, K.; Kaplan, D. R.; Griffin, C.; Aman, A. M.; Al-Awar, R.; Weiss, S.; Gunning, P. T. Potent targeting of the STAT3 protein in brain cancer stem cells: a promising route for treating glioblastoma. ACS Med. Chem. Lett. 2013, 4, 1102-1107.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib82">
                     <ce:label>[82]</ce:label>
                     <sb:reference id="sref82">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Lopez-Tapia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Paladino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Namanja</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hilliard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Tius</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Hydroxamic acid and benzoic acid-based STAT3 inhibitors suppress human glioma and breast cancer phenotypes <ce:italic>in Vitro</ce:italic> and <ce:italic>in Vivo</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>76</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>652</sb:first-page>
                              <sb:last-page>663</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0430">Yue, P.; Lopez-Tapia, F.; Paladino, D.; Li, Y.; Chen, C. H.; Namanja, A. T.; Hilliard, T.; Chen, Y.; Tius, M. A.; Turkson, J. Hydroxamic acid and benzoic acid-based STAT3 inhibitors suppress human glioma and breast cancer phenotypes In Vitro and In Vivo. Cancer Res. 2016, 76, 652-663.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib83">
                     <ce:label>[83]</ce:label>
                     <sb:reference id="sref83">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Khoury</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Laister</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Vellozo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Manzoli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Minden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1047</sb:first-page>
                              <sb:last-page>1055</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0435">Page, B. D.; Khoury, H.; Laister, R. C.; Fletcher, S.; Vellozo, M.; Manzoli, A.; Yue, P.; Turkson, J.; Minden, M. D.; Gunning, P. T. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J. Med. Chem. 2012, 55,1047-1055.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib84">
                     <ce:label>[84]</ce:label>
                     <sb:reference id="sref84">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Croucher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Haftchenary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.H.</ce:given-name>
                                 <ce:surname>Jimenez-Zepeda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Atkinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Spagnuolo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.L.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Colaguori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Schimmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Trudel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7190</sb:first-page>
                              <sb:last-page>7200</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0440">Page, B. D.; Croucher, D. C.; Li, Z. H.; Haftchenary, S.; Jimenez-Zepeda, V. H.; Atkinson, J.; Spagnuolo, P. A.; Wong, Y. L.; Colaguori, R.; Lewis, A. M.; Schimmer, A. D.; Trudel, S.; Gunning, P. T. Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma. J. Med. Chem. 2013, 56,7190-7200.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib85">
                     <ce:label>[85]</ce:label>
                     <sb:reference id="sref85">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Lopez-Tapia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Brotherton-Pleiss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Murakami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Costa Araujo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Reis Dos Santos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Ichinotsubo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Rabkin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Shah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lantz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Tius</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Linker variation and structure-activity relationship analyses of carboxylic acid-based small molecule STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>250</sb:first-page>
                              <sb:last-page>255</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0445">Lopez-Tapia, F.; Brotherton-Pleiss, C.; Yue, P.; Murakami, H.; Costa Araujo, A. C.; Reis Dos Santos, B.; Ichinotsubo, E.; Rabkin, A.; Shah, R.; Lantz, M.; Chen, S.; Tius, M. A.; Turkson, J. Linker variation and structure-activity relationship analyses of carboxylic acid-based small molecule STAT3 inhibitors. ACS Med. Chem. Lett. 2018, 9, 250-255.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib86">
                     <ce:label>[86]</ce:label>
                     <sb:reference id="sref86">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A low-molecular weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4700</sb:first-page>
                              <sb:last-page>4705</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0450">Song, H., Wang, R., Wang, S., Lin, J. A low-molecular weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 4700−4705.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib87">
                     <ce:label>[87]</ce:label>
                     <sb:reference id="sref87">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bhasin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Cisek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Pandharkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Regan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Pandit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and studies of small molecule STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>391</sb:first-page>
                              <sb:last-page>395</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0455">Bhasin, D.; Cisek, K.; Pandharkar, T.; Regan, N.; Li, C.; Pandit, B.; Lin, J.; Li, P. K. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg. Med. Chem. Lett. 2008. 18, 391−395.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib88">
                     <ce:label>[88]</ce:label>
                     <sb:reference id="sref88">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Hutzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>DeAngelis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Foust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sobo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Friedman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bhasin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neoplasia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>39</sb:first-page>
                              <sb:last-page>50</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0460">Lin, L.; Hutzen, B.; Li, P. K.; Ball, S.; Zuo, M.; DeAngelis, S.; Foust, E.; Sobo, M.; Friedman, L.; Bhasin, D.; Cen, L.; Li, C.; Lin, J. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. Neoplasia 2010, 12, 39−50.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib89">
                     <ce:label>[89]</ce:label>
                     <sb:reference id="sref89">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4402</sb:first-page>
                              <sb:last-page>4412</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0465">Yu, W.; Xiao, H.; Lin, J.; Li, C. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. J. Med. Chem. 2013, 56, 4402-4412.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib90">
                     <ce:label>[90]</ce:label>
                     <sb:reference id="sref90">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Berg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A high-throughput ﬂuorescence polarization assay for signal transducer and activator of transcription 3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anal. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>330</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>114</sb:first-page>
                              <sb:last-page>118</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0470">Schust, J.; Berg, T. A high-throughput ﬂuorescence polarization assay for signal transducer and activator of transcription 3. Anal. Biochem. 2004, 330,114-118.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib91">
                     <ce:label>[91]</ce:label>
                     <sb:reference id="sref91">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.1</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2718</sb:first-page>
                              <sb:last-page>2731</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0475">Yu W, Li C1, Zhang W, Xia Y, Li S, Lin, J. Y.; Yu, K.; Liu, M.; Yang, L.; Luo, J.; Chen, Y.; Sun, H.; Kong, L. Discovery of an orally selective inhibitor of signal transducer and activator of transcription 3 using advanced multiple ligand simultaneous docking. J. Med. Chem. 2017, 60, 2718-2731.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib92">
                     <ce:label>[92]</ce:label>
                     <sb:reference id="sref92">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1251</sb:first-page>
                              <sb:last-page>1258</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0480">Zhang, Y.; Jin, Z.; Zhou, H.; Ou, X.; Xu, Y.; Li, H.; Liu, C.; Li, B. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin. Cancer Med. 2016, 5, 1251-1258.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib93">
                     <ce:label>[93]</ce:label>
                     <sb:reference id="sref93">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Hubbard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A. Napabucasin</ce:given-name>
                                 <ce:surname>Grothey</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An update on the first-in-class cancer stemness inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>77</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1091</sb:first-page>
                              <sb:last-page>1103</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0485">Hubbard, J. M.; Grothey, A. Napabucasin: An update on the first-in-class cancer stemness inhibitor. Drugs 2017, 77, 1091-1103.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib94">
                     <ce:label>[94]</ce:label>
                     <sb:reference id="sref94">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Thakur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Trivedi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Rastogi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Mishra</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10194</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0490">Thakur, R.; Trivedi, R.; Rastogi, N.; Singh, M.; Mishra, D. P. Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer. Sci. Rep. 2015, 5, 10194.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib95">
                     <ce:label>[95]</ce:label>
                     <sb:reference id="sref95">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Qiu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.K.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.W.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.F.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.H.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of new shikonin derivatives as STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>146</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>74</sb:first-page>
                              <sb:last-page>86</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0495">Qiu, H. Y.; Fu, J. Y.; Yang, M. K.; Han, H. W.; Wang, P. F.; Zhang, Y. H.; Lin, H. Y.; Tang, C. Y.; Qi, J. L.; Yang, R. W.; Wang, X. M.; Zhu, H. L.; Yang, Y. H. Identification of new shikonin derivatives as STAT3 inhibitors. Biochem. Pharmacol. 2017, 146, 74-86.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib96">
                     <ce:label>[96]</ce:label>
                     <sb:reference id="sref96">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Fowler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Meurer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Honarvar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kirkland</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A review of the genotoxic potential of 1,4-naphthoquinone</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mutat. Res. Genet. Toxicol. Environ. Mutagen.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>834</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6</sb:first-page>
                              <sb:last-page>17</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0500">Fowler, P.; Meurer, K.; Honarvar, N.; Kirkland, D. A review of the genotoxic potential of 1,4-naphthoquinone. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 2018, 834, 6-17.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib97">
                     <ce:label>[97]</ce:label>
                     <sb:reference id="sref97">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Jou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5592</sb:first-page>
                              <sb:last-page>5596</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0505">Li, H.; Liu, A.; Zhao, Z.; Xu, Y.; Lin, J.; Jou, D.; Li, C. Fragment based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). J. Med. Chem. 2011, 54, 5592−5596.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib98">
                     <ce:label>[98]</ce:label>
                     <sb:reference id="sref98">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>151</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>752</sb:first-page>
                              <sb:last-page>764</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0510">Guo, J.; Yu, W.; Cai, G.; Zhang, W.; Li, S.; Zhu, J.; Song, D.; Kong, L. Discovery of new benzensulfonamide derivatives as tripedal STAT3 inhibitors. Eur. J. Med. Chem. 2018, 151, 752-764.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib99">
                     <ce:label>[99]</ce:label>
                     <sb:reference id="sref99">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Pallandre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Borg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Rognan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Boibessot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Luzet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yesylevskyy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ramseyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pudlo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>103</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>163</sb:first-page>
                              <sb:last-page>174</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0515">Pallandre, J. R.; Borg, C.; Rognan, D.; Boibessot, T.; Luzet, V.; Yesylevskyy, S.; Ramseyer, C.; Pudlo, M. Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors. Eur. J. Med. Chem. 2015, 103, 163-174.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib100">
                     <ce:label>[100]</ce:label>
                     <sb:reference id="sref100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Matsuno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Masuda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Uehara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Muroya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yokotagawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Furuya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Okawara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>O tsuka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ogo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ashizawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Oshita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ishii</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Akiyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Asai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of a new series of STAT3 inhibitors by virtual screening</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>371</sb:first-page>
                              <sb:last-page>375</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0520">Matsuno, K.; Masuda, Y.; Uehara, Y.; Sato, H.; Muroya, A.; Takahashi, O.; Yokotagawa, T.; Furuya, T.; Okawara, T.; O tsuka, M.; Ogo, N.; Ashizawa, T.; Oshita, C.; Tai, S.; Ishii, H.; Akiyama, Y.; Asai, A. Identification of a new series of STAT3 inhibitors by virtual screening. ACS Med. Chem. Lett. 2010, 1, 371-375.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib101">
                     <ce:label>[101]</ce:label>
                     <sb:reference id="sref101">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1381</sb:first-page>
                              <sb:last-page>1387</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0525">Liu, A.; Liu, Y.; Xu, Z.; Yu, W.; Wang, H.; Li, C.; Lin, J. Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells. Cancer Sci. 2011, 102, 1381-1387.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib102">
                     <ce:label>[102]</ce:label>
                     <sb:reference id="sref102">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Daka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Karunaratne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Csatary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and evaluation of XZH-5 analogues as STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1348</sb:first-page>
                              <sb:last-page>1355</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0530">Daka, P.; Liu, A.; Karunaratne, C.; Csatary, E.; Williams, C.; Xiao, H.; Lin, J.; Xu, Z.; Page, R. C.; Wang, H. Design, synthesis and evaluation of XZH-5 analogues as STAT3 inhibitors. Bioorg. Med. Chem. 2015, 23, 1348-1355.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib103">
                     <ce:label>[103]</ce:label>
                     <sb:reference id="sref103">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Shahani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Haftchenary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Lukkarila</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Nona</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of purine-scaffold small-molecule inhibitors of Stat3 activation by QSAR studies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>79</sb:first-page>
                              <sb:last-page>84</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0535">Shahani, V. M.; Yue, P.; Haftchenary, S.; Zhao, W.; Lukkarila, J. L.; Zhang, X.; Ball, D.; Nona, C.; Gunning, P. T.; Turkson, J. Identification of purine-scaffold small-molecule inhibitors of Stat3 activation by QSAR studies. ACS Med. Chem. Lett. 2011, 2, 79-84.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib104">
                     <ce:label>[104]</ce:label>
                     <sb:reference id="sref104">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Kasembeli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Tweardy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Tweardy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemical probes that competitively and selectively inhibit Stat3 activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4783</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0540">Xu, X.; Kasembeli, M. M.; Jiang, X.; Tweardy, B. J.; Tweardy, D. J. Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS One 2009, 4, 4783.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib105">
                     <ce:label>[105]</ce:label>
                     <sb:reference id="sref105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Bharadwaj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.K.</ce:given-name>
                                 <ce:surname>Eckols</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Kasembeli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Adachi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Mo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Tweardy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>26307</sb:first-page>
                              <sb:last-page>26330</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0545">Bharadwaj, U.; Eckols, T. K.; Xu, X.; Kasembeli, M. M.; Chen, Y.; Adachi, M.; Song, Y.; Mo, Q.; Lai, S. Y.; Tweardy, D. J. Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma. Oncotarget 2016, 7, 26307-26330.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib106">
                     <ce:label>[106]</ce:label>
                     <sb:reference id="sref106">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Redell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Ruiz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Alonzo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.B.</ce:given-name>
                                 <ce:surname>Gerbing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Tweardy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>117</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>5701-5109</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0550">Redell, M. S.; Ruiz, M. J.; Alonzo, T. A.; Gerbing, R. B.; Tweardy, D. J. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 2011, 117, 5701-5109.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib107">
                     <ce:label>[107]</ce:label>
                     <sb:reference id="sref107">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Brambilla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Genini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Laurini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Merulla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Perez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Fermeglia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Carbone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pricl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.V.</ce:given-name>
                                 <ce:surname>Catapano</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Hitting the right spot: mechanism of action of OPB-31121, a novel and potent inhibitor of the signal transducer and activator of transcription 3 (STAT3)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1194</sb:first-page>
                              <sb:last-page>1206</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0555">Brambilla, L.; Genini, D.; Laurini, E.; Merulla, J.; Perez, L.; Fermeglia, M.; Carbone, G. M.; Pricl, S.; Catapano, C. V. Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the signal transducer and activator of transcription 3 (STAT3). Mol. Oncol. 2015, 9, 1194-1206.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib108">
                     <ce:label>[108]</ce:label>
                     <sb:reference id="sref108">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>454</sb:first-page>
                              <sb:last-page>459</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0560">Ren, X.; Duan, L.; He, Q.; Zhang, Z.; Zhou, Y.; Wu, D.; Pan, J.; Pei, D.; Ding, K. Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. ACS Med. Chem. Lett. 2010, 1, 454−459.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib109">
                     <ce:label>[109]</ce:label>
                     <sb:reference id="sref109">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Furtek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Matheson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Backos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Reigan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>77998</sb:first-page>
                              <sb:last-page>78008</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0565">Furtek, S. L.; Matheson, C. J.; Backos, D. S.; Reigan, P. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors. Oncotarget 2016, 7, 77998-78008.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib110">
                     <ce:label>[110]</ce:label>
                     <sb:reference id="sref110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Terry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of O-alkylamino tethered niclosamide derivatives as potent and orally bioavailable anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>180</sb:first-page>
                              <sb:last-page>185</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0570">Chen, H.; Yang, Z.; Ding, C.; Chu, L.; Zhang, Y.; Terry, K.; Liu, H.; Shen, Q.; Zhou, J. Discovery of O-alkylamino tethered niclosamide derivatives as potent and orally bioavailable anticancer agents. ACS Med. Chem. Lett. 2013, 4, 180-185.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib111">
                     <ce:label>[111]</ce:label>
                     <sb:reference id="sref111">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Jing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Qu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Qiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Suppression of the growth and invasion of human head and neck squamous cell carcinomas via regulating STAT3 signaling and the miR-21/β-catenin axis with HJC0152</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>578</sb:first-page>
                              <sb:last-page>590</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0575">Wang, Y.; Wang, S.; Wu, Y.; Ren, Y.; Li, Z.; Yao, X.; Zhang, C.; Ye, N.; Jing, C.; Dong, J.; Zhang, K.; Sun, S.; Zhao, M.; Guo, W.; Qu, X.; Qiao, Y.; Chen, H.; Kong, L.; Jin, R.; Wang, X.; Zhang, L.; Zhou, J.; Shen, Q.; Zhou, X. Suppression of the growth and invasion of human head and neck squamous cell carcinomas via regulating STAT3 signaling and the miR-21/β-catenin axis with HJC0152. Mol.Cancer Ther. 2017, 16, 578-590.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib112">
                     <ce:label>[112]</ce:label>
                     <sb:reference id="sref112">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Jing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel STAT3 inhibitor, HJC0152, exerts potent antitumor activity in glioblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Am. J. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>699</sb:first-page>
                              <sb:last-page>713</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0580">Li, Z.; Zhu, T.; Xu, Y.; Wu, C.; Chen, J.; Ren, Y.; Kong, L.; Sun, S.; Guo, W.; Wang, Y.; Jing, C.; Dong, J.; Zhou, J.; Zhang, L.; Shen, Q.; Zhou, X. A novel STAT3 inhibitor, HJC0152, exerts potent antitumor activity in glioblastoma. Am. J. Cancer Res. 2019, 1, 699-713.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib113">
                     <ce:label>[113]</ce:label>
                     <sb:reference id="sref113">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Teng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Manag. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6857</sb:first-page>
                              <sb:last-page>6867</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0585">Jiang, X.; Wu, M.; Xu, Z.; Wang, H.; Wang, H.; Yu, X.; Li, Z.; Teng, L. HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer. Cancer Manag. Res. 2018, 12, 6857-6867.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib114">
                     <ce:label>[114]</ce:label>
                     <sb:reference id="sref114">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1188</sb:first-page>
                              <sb:last-page>1196</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0590">Huang, W.; Dong, Z.; Wang, F.; Peng, H.; Liu, J. Y.; Zhang, J. T. A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion. ACS Chem. Biol. 2014, 9, 1188-1196.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib115">
                     <ce:label>[115]</ce:label>
                     <sb:reference id="sref115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.C.</ce:given-name>
                                 <ce:surname>Shih</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.N.</ce:given-name>
                                 <ce:surname>Parkinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Wilderspin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wells</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A high-throughput fluorescence polarization assay for discovering inhibitors targeting the DNA-binding domain of signal transducer and activator of transcription 3 (STAT3)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>32690</sb:first-page>
                              <sb:last-page>32701</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0595">Shih, P. C.; Yang, Y.; Parkinson, G. N.; Wilderspin, A.; Wells, G. A high-throughput fluorescence polarization assay for discovering inhibitors targeting the DNA-binding domain of signal transducer and activator of transcription 3 (STAT3). Oncotarget 2018, 9, 32690-32701.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib116">
                     <ce:label>[116]</ce:label>
                     <sb:reference id="sref116">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Hangoc</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Pollok</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sandusky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.Y.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.E.</ce:given-name>
                                 <ce:surname>Broxmeyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>802</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0600">Huang, W.; Dong, Z.; Chen, Y.; Wang, F.; Wang, C. J.; Peng, H.; He, Y.; Hangoc, G.; Pollok, K.; Sandusky, G.; Fu, X. Y.; Broxmeyer, H. E.; Zhang, Z. Y.; Liu, J. Y.; Zhang, J. T. Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo. Oncogene. 2016, 35, 802.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib117">
                     <ce:label>[117]</ce:label>
                     <sb:reference id="sref117">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.W.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.M.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Cui</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>157</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>887</sb:first-page>
                              <sb:last-page>897</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0605">Huang, W.; Liu, Y.; Wang, J.; Yuan, X.; Jin, H. W.; Zhang, L. R.; Zhang, J. T.; Liu, Z. M.; Cui, J. R. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis. Eur. J. Med. Chem. 2018, 157, 887-897.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib118">
                     <ce:label>[118]</ce:label>
                     <sb:reference id="sref118">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>301</sb:first-page>
                              <sb:last-page>310</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0610">Zhang, M.; Zhu, W.; Li, Y. Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening. Eur. J. Med. Chem. 2013, 62, 301-310.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib119">
                     <ce:label>[119]</ce:label>
                     <sb:reference id="sref119">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis and biological evaluation of benzyloxyphenyl-methylaminophenol derivatives as STAT3 signaling pathway inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2549</sb:first-page>
                              <sb:last-page>2558</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0615">Gao, D.; Xiao, Q.; Zhang, M.; Li, Y. Design, synthesis and biological evaluation of benzyloxyphenyl-methylaminophenol derivatives as STAT3 signaling pathway inhibitors. Bioorg. Med. Chem. 2016, 24, 2549-2558.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib120">
                     <ce:label>[120]</ce:label>
                     <sb:reference id="sref120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sperl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hollis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.U.</ce:given-name>
                                 <ce:surname>Mayer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Berg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stattic: a small molecule inhibitor of STAT3 activation and dimerization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1235</sb:first-page>
                              <sb:last-page>1242</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0620">Schust, J.; Sperl, B.; Hollis, A.; Mayer, T. U.; Berg, T. Stattic: a small molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 2006, 13, 1235-1242.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib121">
                     <ce:label>[121]</ce:label>
                     <sb:reference id="sref121">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Buettner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Corzano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Rashid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Senthil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hedvat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Schroeder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Herrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yakushijin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Yakushijin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Vaidehi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Gugiu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.D.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Yip</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Horne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>432</sb:first-page>
                              <sb:last-page>443</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0625">Buettner, R.; Corzano, R.; Rashid, R.; Lin, J.; Senthil, M.; Hedvat, M.; Schroeder, A.; Mao, A.; Herrmann, A.; Yim, J.; Li, H.; Yuan, Y. C.; Yakushijin, K,; Yakushijin, F.; Vaidehi, N.; Moore, R.; Gugiu, G.; Lee, T. D.; Yip, R.; Chen, Y.; Jove, R.; Horne, D.; Williams, J. C. Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development. ACS Chem. Biol. 2011, 6, 432-443.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib122">
                     <ce:label>[122]</ce:label>
                     <sb:reference id="sref122">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Heidelberger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Zinzalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Antonow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Essex</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.P.</ce:given-name>
                                 <ce:surname>Basu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Palmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Husby</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Jackson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Rahman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>Wilderspin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zloh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Thurston</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Investigation of the protein alkylation sites of the STAT3:STAT3 inhibitor Stattic by mass spectrometry</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4719</sb:first-page>
                              <sb:last-page>4722</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0630">Heidelberger, S.; Zinzalla, G.; Antonow, D.; Essex, S.; Basu, B. P.; Palmer, J.; Husby, J.; Jackson, P. J.; Rahman, K. M.; Wilderspin, A. F.; Zloh, M.; Thurston, D. E. Investigation of the protein alkylation sites of the STAT3:STAT3 inhibitor Stattic by mass spectrometry. Bioorg. Med. Chem. Lett. 2013, 23, 4719-4722.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib123">
                     <ce:label>[123]</ce:label>
                     <sb:reference id="sref123">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Terry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>498</sb:first-page>
                              <sb:last-page>507</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0635">Chen, H.; Yang, Z.; Ding, C.; Chu, L.; Zhang, Y.; Terry, K.; Liu, H.; Shen, Q.; Zhou, J. Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. Eur. J. Med. Chem. 2013, 62, 498-507.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib124">
                     <ce:label>[124]</ce:label>
                     <sb:reference id="sref124">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wild</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Flores</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>82</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>195</sb:first-page>
                              <sb:last-page>203</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0640">Chen, H.; Yang, Z.; Ding, C.; Xiong, A.; Wild, C.; Wang, L.; Ye, N.; Cai, G.; Flores, R. M.; Ding, Y.; Shen, Q.; Zhou, J. Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3). Eur. J. Med. Chem. 2014, 82,195-203.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib125">
                     <ce:label>[125]</ce:label>
                     <sb:reference id="sref125">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>125</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>538</sb:first-page>
                              <sb:last-page>550</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0645">Zhang, W.; Ma, T.; Li, S.; Yang, Y.; Guo, J.; Yu, W.; Kong, L. Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules. Eur. J. Med. Chem. 2017, 125, 538-550.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib126">
                     <ce:label>[126]</ce:label>
                     <sb:reference id="sref126">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Qiao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel 2-carbonylbenzo[b]thiophene 1,1-dioxide derivatives as potent inhibitors of STAT3 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1010</sb:first-page>
                              <sb:last-page>1014</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0650">Ji, P.; Xu, X.; Ma, S.; Fan, J.; Zhou, Q.; Mao, X.; Qiao, C. Novel 2-carbonylbenzo[b]thiophene 1,1-dioxide derivatives as potent inhibitors of STAT3 signaling pathway. ACS Med. Chem. Lett. 2015, 6, 1010-1014.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib127">
                     <ce:label>[127]</ce:label>
                     <sb:reference id="sref127">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Weidler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rether</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Anke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Erkel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of interleukin-6 signaling by galiellalactone</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>FEBS Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>484</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>6</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0655">Weidler, M.; Rether, J.; Anke, T.; Erkel, G. Inhibition of interleukin-6 signaling by galiellalactone. FEBS Lett. 2000, 484, 1-6.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib128">
                     <ce:label>[128]</ce:label>
                     <sb:reference id="sref128">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hellsten</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Johansson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dahlman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Dizeyi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Sterner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bjartell</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>The Prostate</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>68</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>269</sb:first-page>
                              <sb:last-page>280</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0660">Hellsten, R.; Johansson, M.; Dahlman, A.; Dizeyi, N.; Sterner, O.; Bjartell, A. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. Prostate 2008, 68, 269-280.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib129">
                     <ce:label>[129]</ce:label>
                     <sb:reference id="sref129">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Don-Doncow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Escobar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Johansson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kjellström</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Munoz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Sterner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bjartell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hellsten</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>289</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>15969</sb:first-page>
                              <sb:last-page>15978</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0665">Don-Doncow, N.; Escobar, Z.; Johansson, M.; Kjellstrom, S.; Garcia, V.; Munoz, E.; Sterner, O.; Bjartell, A.; Hellsten, R. Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells. J. Biol. Chem. 2014, 289, 15969-15978.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib130">
                     <ce:label>[130]</ce:label>
                     <sb:reference id="sref130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Buettner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Corzano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Rashid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Senthil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hedvat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Schroeder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Herrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yakushijin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Yakushijin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Vaidehi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Gugiu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.D.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Yip</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Horne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>432</sb:first-page>
                              <sb:last-page>443</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0670">Buettner, R.; Corzano, R.; Rashid, R.; Lin, J.; Senthil, M.; Hedvat, M.; Schroeder, A.; Mao, A.; Herrmann, A.; Yim, J.; Li, H.; Yuan, Y. C.; Yakushijin, K.; Yakushijin, F.; Vaidehi, N.; Moore, R.; Gugiu, G.; Lee, T. D.; Yip, R.; Chen, Y.; Jove, R.; Horne, D.; Williams, J. C. Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development. ACS Chem. Biol. 2011, 6, 432-443.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib131">
                     <ce:label>[131]</ce:label>
                     <sb:reference id="sref131">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Weissenberger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Priester</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Bernreuther</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rakel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Glatzel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Seifert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kögel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1,2/STAT3 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5781</sb:first-page>
                              <sb:last-page>5795</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0675">Weissenberger, J.; Priester, M.; Bernreuther, C.; Rakel, S.; Glatzel, M.; Seifert, V; Kogel, D. Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1,2/STAT3 signaling pathway. Clin. Cancer Res. 2010, 16, 5781-5795.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib132">
                     <ce:label>[132]</ce:label>
                     <sb:reference id="sref132">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Deangelis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Foust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Fuchs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.B.</ce:given-name>
                                 <ce:surname>Schwartz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.B.</ce:given-name>
                                 <ce:surname>Lesinski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Benson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hoyt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>217</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0680">Lin, L.; Deangelis, S.; Foust, E.; Fuchs, J.; Li, C.; Li, P. K.; Schwartz, E. B.; Lesinski, G. B.; Benson, D.; Lu, J.; Hoyt, D.; Lin, J. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol. Cancer 2010, 9, 217.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib133">
                     <ce:label>[133]</ce:label>
                     <sb:reference id="sref133">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Selvendiran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bratasz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Kuppusamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ahmed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ravi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Trigg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Rivera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kálai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hideg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kuppusamy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1169</sb:first-page>
                              <sb:last-page>1179</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0685">Selvendiran, K.; Tong, L.; Bratasz, A.; Kuppusamy, M. L.; Ahmed, S.; Ravi, Y.; Trigg, N. J.; Rivera, B. K.; Kalai, T.; Hideg, K.; Kuppusamy, P. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol. Cancer Ther. 2010, 9, 1169-1179.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib134">
                     <ce:label>[134]</ce:label>
                     <sb:reference id="sref134">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Selvendiran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ahmed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dayton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Kuppusamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Rivera</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kálai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hideg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kuppusamy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Biol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>837</sb:first-page>
                              <sb:last-page>845</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0690">Selvendiran, K.; Ahmed, S.; Dayton, A.; Kuppusamy, M. L.; Rivera, B. K.; Kalai, T.; Hideg, K.; Kuppusamy, P. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biol. Ther. 2011, 12, 837-845.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib135">
                     <ce:label>[135]</ce:label>
                     <sb:reference id="sref135">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.I.</ce:given-name>
                                 <ce:surname>Hahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.Y.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bandu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.P.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.K.</ce:given-name>
                                 <ce:surname>Na</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.N.</ce:given-name>
                                 <ce:surname>Cha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Surh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin interacts directly with the Cysteine 259 residue of STAT3 and induces apoptosis in H-Ras transformed human mammary epithelial cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6409</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0695">Hahn, Y. I.; Kim, S. J.; Choi, B. Y.; Cho, K. C.; Bandu, R.; Kim, K. P.; Kim, D. H.; Kim, W.; Park, J. S.; Han, B. W.; Lee, J.; Na, H. K.; Cha, Y. N.; Surh, Y. J. Curcumin interacts directly with the Cysteine 259 residue of STAT3 and induces apoptosis in H-Ras transformed human mammary epithelial cells. Sci. Rep. 2018, 8, 6409.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib136">
                     <ce:label>[136]</ce:label>
                     <sb:reference id="sref136">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Dahlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.M.</ce:given-name>
                                 <ce:surname>Nissink</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Strasser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Francis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Higgins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pains in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2091</sb:first-page>
                              <sb:last-page>2113</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0700">Dahlin, J. L.; Nissink, J. W. M.; Strasser, J. M.; Francis, S.; Higgins, L. A.; Zhou, H. Pains in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. J. Med. Chem. 2015, 58, 2091-2113.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib137">
                     <ce:label>[137]</ce:label>
                     <sb:reference id="sref137">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Nelson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Dahlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bisson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.F.</ce:given-name>
                                 <ce:surname>Pauli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Walters</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The essential medicinal chemistry of curcumin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1620</sb:first-page>
                              <sb:last-page>1637</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0705">Nelson, K. M.; Dahlin, J. L.; Bisson, J.; Graham, J.; Pauli, G. F.; Walters, M. A. The Essential Medicinal Chemistry of Curcumin. J. Med. Chem. 2017, 60, 1620-1637.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib138">
                     <ce:label>[138]</ce:label>
                     <sb:reference id="sref138">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.L.A.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Hirpara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pervaiz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Q.</ce:given-name>
                                 <ce:surname>Eu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sethi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.C.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Do STAT3 inhibitors have potential in the future for cancer therapy?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Investig. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>883</sb:first-page>
                              <sb:last-page>887</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0710">Wong, A. L. A.; Hirpara, J. L.; Pervaiz, S.; Eu, J. Q.; Sethi, G.; Goh, B. C. Do STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin. Investig. Drugs 2017, 26, 883-887.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib139">
                     <ce:label>[139]</ce:label>
                     <sb:reference id="sref139">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Beebe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>191</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>74</sb:first-page>
                              <sb:last-page>91</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0715">Beebe， J. D.; Liu, J. Y.; Zhang, J. T. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? Pharmacol. Ther. 2018, 191, 74-91.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib140">
                     <ce:label>[140]</ce:label>
                     <sb:reference id="sref140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ogura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Uchida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Terui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Hayakawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kobayashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Taniwaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Takamatsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Naoe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Tobinai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Munakata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yamauchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kageyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yuasa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Motoyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tsunoda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hatake</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>106</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>896</sb:first-page>
                              <sb:last-page>901</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0720">Ogura, M.; Uchida, T.; Terui, Y.; Hayakawa, F.; Kobayashi, Y.; Taniwaki, M.; Takamatsu, Y.; Naoe, T.; Tobinai, K.; Munakata, W.; Yamauchi, T.; Kageyama, A.; Yuasa, M.; Motoyama, M.; Tsunoda, T.; Hatake, K. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Sci. 2015, 106, 896-901.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib141">
                     <ce:label>[141]</ce:label>
                     <sb:reference id="sref141">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Way</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>40</sb:first-page>
                              <sb:last-page>46</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0725">Way, J. C. Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs. Curr. Opin. Chem. Biol. 2000, 4, 40-46.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib142">
                     <ce:label>[142]</ce:label>
                     <sb:reference id="sref142">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Lonsdale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Ward</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of targeted covalent inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Soc. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3816</sb:first-page>
                              <sb:last-page>3830</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0730">Lonsdale, R.; Ward, R. A. Structure-based design of targeted covalent inhibitors. Chem Soc Rev. 2018, 47, 3816-3830.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib143">
                     <ce:label>[143]</ce:label>
                     <sb:reference id="sref143">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Petter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Baillie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Whitty</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The resurgence of covalent drugs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>307</sb:first-page>
                              <sb:last-page>317</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0735">Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 2011, 10, 307-317.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib144">
                     <ce:label>[144]</ce:label>
                     <sb:reference id="sref144">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Crews</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Induced protein degradation: an emerging drug discovery paradigm</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>101</sb:first-page>
                              <sb:last-page>114</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0740">Lai, A. C.; Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 2017, 16, 101-114.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib145">
                     <ce:label>[145]</ce:label>
                     <sb:reference id="sref145">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Schiedel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Herp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hammelmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Swyter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lehotzky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Robaa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Oláh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ovádi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Sippl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jung</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chemically induced degradation of Sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on Sirtuin rearranging ligands (SirReals)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>482</sb:first-page>
                              <sb:last-page>491</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0745">Schiedel, M.; Herp, D.; Hammelmann, S.; Swyter, S.; Lehotzky, A.; Robaa, D.; Olah, J.; Ovadi, J.; Sippl, W.; Jung, M. Chemically induced degradation of Sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on Sirtuin rearranging ligands (SirReals). J. Med. Chem. 2018, 61, 482-491.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib146">
                     <ce:label>[146]</ce:label>
                     <sb:reference id="sref146">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Miao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.F.</ce:given-name>
                                 <ce:surname>Hayes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Chinnaswamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Delproposto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Stuckey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1420</sb:first-page>
                              <sb:last-page>1442</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0750">Hu, J.; Hu, B.; Wang, M.; Xu, F.; Miao, B.; Yang, C. Y.; Wang, M.; Liu, Z.; Hayes, D. F.; Chinnaswamy, K.; Delproposto, J.; Stuckey, J.; Wang, S. Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER). J. Med. Chem. 2019, 62, 1420-1442.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib147">
                     <ce:label>[147]</ce:label>
                     <sb:reference id="sref147">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Qin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Xiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Fernandez-Salas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Chinnaswamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Delproposto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Stuckey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>941</sb:first-page>
                              <sb:last-page>964</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0755">Han, X.; Wang, C.; Qin, C.; Xiang, W.; Fernandez-Salas, E.; Yang, C. Y.; Wang, M.; Zhao, L.; Xu, T.; Chinnaswamy, K.; Delproposto, J.; Stuckey, J.; Wang, S. Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer. J. Med. Chem. 2019, 62, 941-964.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib148">
                     <ce:label>[148]</ce:label>
                     <sb:reference id="sref148">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Churcher</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>444</sb:first-page>
                              <sb:last-page>452</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0760">Churcher, I. Protac-induced protein degradation in drug discovery: Breaking the rules or just making new ones? J. Med. Chem. 2018, 61, 444-452.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib149">
                     <ce:label>[149]</ce:label>
                     <sb:reference id="sref149">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Qin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Fernandez-Salas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>McEachern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Przybranowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Stuckey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Meagher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.N.</ce:given-name>
                                 <ce:surname>Ziazadeh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Xiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6685</sb:first-page>
                              <sb:last-page>6704</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0765">Qin, C.; Hu, Y.; Zhou, B.; Fernandez-Salas, E.; Yang, C. Y.; Liu, L.; McEachern, D.; Przybranowski, S.; Wang, M.; Stuckey, J.; Meagher, J.; Bai, L.; Chen, Z.; Lin, M.; Yang, J.; Ziazadeh, D. N.; Xu, F.; Hu, J.; Xiang, W.; Huang, L.; Li, S.; Wen, B.; Sun, D.; Wang, S. Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression. J. Med. Chem. 2018, 61, 6685-6704.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib150">
                     <ce:label>[150]</ce:label>
                     <sb:reference id="sref150">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Fernandez-Salas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>McEachern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Przybranowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>462</sb:first-page>
                              <sb:last-page>481</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0770">Zhou, B.; Hu, J.; Xu, F.; Chen, Z.; Bai, L.; Fernandez-Salas, E.; Lin, M.; Liu, L.; Yang, C. Y.; Zhao, Y.; McEachern, D.; Przybranowski, S.; Wen, B.; Sun, D.; Wang, S. Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J. Med. Chem. 2018, 61, 462-481.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib151">
                     <ce:label>[151]</ce:label>
                     <sb:reference id="sref151">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.P.</ce:given-name>
                                 <ce:surname>Wurz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.J.</ce:given-name>
                                 <ce:surname>Cee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeted degradation of MDM2 as a new approach to improve the efficacy of MDM2-p53 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>445</sb:first-page>
                              <sb:last-page>447</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0775">Wurz, R. P.; Cee, V. J. Targeted degradation of MDM2 as a new approach to improve the efficacy of MDM2-p53 inhibitors. J. Med. Chem. 2019, 62, 445-447.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib152">
                     <ce:label>[152]</ce:label>
                     <sb:reference id="sref152">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.P.</ce:given-name>
                                 <ce:surname>Wurz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Dellamaggiore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Dou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Javier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Lo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>McCarter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mohl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sastri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Lipford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.J.</ce:given-name>
                                 <ce:surname>Cee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A "click chemistry platform" for the rapid synthesis of bispecific molecules for inducing protein degradation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>453</sb:first-page>
                              <sb:last-page>461</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0780">Wurz, R. P.; Dellamaggiore, K.; Dou, H.; Javier, N.; Lo, M. C.; McCarter, J. D.; Mohl, D.; Sastri, C.; Lipford, J. R.; Cee, V. J. A "click chemistry platform" for the rapid synthesis of bispecific molecules for inducing protein degradation. J. Med. Chem. 2018, 61, 453-461.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib153">
                     <ce:label>[153]</ce:label>
                     <sb:reference id="sref153">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Zoppi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Hughes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Maniaci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Testa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Gmaschitz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wieshofer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Koegl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Riching</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Daniels</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Spallarossa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ciulli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von hippel-lindau (VHL) based dual degrader probe of BRD9 and BRD7</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>699</sb:first-page>
                              <sb:last-page>726</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0785">Zoppi, V.; Hughes, S. J.; Maniaci, C.; Testa, A.; Gmaschitz, T.; Wieshofer, C.; Koegl, M.; Riching, K. M.; Daniels, D. L.; Spallarossa, A.; Ciulli, A. Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von hippel-lindau (VHL) based dual degrader probe of BRD9 and BRD7. J. Med. Chem. 2019, 62, 699-726.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib154">
                     <ce:label>[154]</ce:label>
                     <sb:reference id="sref154">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Aguilar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>McEachern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Przybranowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>62</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>448</sb:first-page>
                              <sb:last-page>466</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0790">Li, Y.; Yang, J.; Aguilar, A.; McEachern, D.; Przybranowski, S.; Liu, L.; Yang, C. Y.; Wang, M.; Han, X.; Wang, S. Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression. J. Med. Chem. 2019, 62, 448-466.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib155">
                     <ce:label>[155]</ce:label>
                     <sb:reference id="sref155">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Crew</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Raina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Qian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Vigil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.V.</ce:given-name>
                                 <ce:surname>Serebrenik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Hamman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Morgan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ferraro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Siu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.K.</ce:given-name>
                                 <ce:surname>Neklesa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Winkler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.G.</ce:given-name>
                                 <ce:surname>Coleman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Crews</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification and characterization of von hippel-lindau-recruiting proteolysis targeting chimeras (PROTACs) of TANK-binding kinase 1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>583</sb:first-page>
                              <sb:last-page>598</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0795">Crew, A. P.; Raina, K. Dong, H.; Qian, Y.; Wang, J.; Vigil, D.; Serebrenik, Y. V.; Hamman, B. D.; Morgan, A.; Ferraro, C.; Siu, K.; Neklesa, T. K.; Winkler, J. D.; Coleman, K. G.; Crews, C. M. Identification and characterization of von hippel-lindau-recruiting proteolysis targeting chimeras (PROTACs) of TANK-binding kinase 1. J. Med. Chem. 2018, 61, 583-598.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib156">
                     <ce:label>[156]</ce:label>
                     <sb:reference id="sref156">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Proteolysis targeting chimera (PROTAC): a paradigm-shifting approach in small molecule drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Top. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1354</sb:first-page>
                              <sb:last-page>1356</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0800">Wang, P.; Zhou, J. Proteolysis targeting chimera (PROTAC): a paradigm-shifting approach in small molecule drug discovery. Curr. Top. Med. Chem. 2018, 18, 1354-1356.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib157">
                     <ce:label>[157]</ce:label>
                     <sb:reference id="sref157">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Murase</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signal transducer and activator of transcription 3 (STAT3) degradation by proteasome controls a developmental switch in neurotrophin dependence</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>288</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>20151</sb:first-page>
                              <sb:last-page>20161</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0805">Murase, S. Signal transducer and activator of transcription 3 (STAT3) degradation by proteasome controls a developmental switch in neurotrophin dependence. J. Biol. Chem. 2013, 288, 20151-20161.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib158">
                     <ce:label>[158]</ce:label>
                     <sb:reference id="sref158">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Chinnaswamy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>McEachern</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Meagher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Stuckey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3<ce:italic>6</ce:italic>
                                 </sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>498</sb:first-page>
                              <sb:last-page>511</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0810">Bai, L.; Zhou, H.; Xu, R.; Zhao, Y.; Chinnaswamy, K.; McEachern, D.; Chen, J.; Yang, C. Y.; Liu, Z.; Wang, M.; Liu, L.; Jiang, H.; Wen, B.; Kumar, P.; Meagher, J. L.; Sun, D.; Stuckey, J. A.; Wang, S. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell. 2019. 36, 498-511.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>